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GENERAL INTRODUCTION AND 
OUTLINE OF THE THESIS
CHAPTER 1
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1 BACKGROUND
Aldosterone was discovered only 65 years ago. Sylvia Simpson Tait, her husband James 
Tait and colleague Helen Grundy discovered the steroidal hormone in fractioned 
bovine adrenal extract and published their empirical work in Nature in 1952. They 
first described aldosterone as electrocortin, because of  its strong sodium-retaining 
properties. (1) 
Indeed, aldosterone plays a major role in salt and body fluid handling, completing 
the renin-angiotensin-aldosterone system (RAAS) (Figure 1). Aldosterone is mainly 
produced in the adrenal cortex, with angiotensin II (Ang II) and plasma potassium 
levels being the most important regulators of  its production. Binding of  aldosterone 
to the mineralocorticoid receptor (MR) in the distal convoluted tubule of  the nephron 
results in sodium reabsorption and potassium excretion, thereby increasing blood 
pressure levels.
FIGURE 1. The regulatory effects of the RAAS on blood pressure
From Wikimedia Commons, the free media repository
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PRIMARY ALDOSTERONISM 
Jerome W. Conn was the first who characterized the pathophysiological condition 
of  autonomous adrenal aldosterone overproduction. Conn’s syndrome refers to the 
condition of  aldosterone excess due to a (unilateral) aldosterone producing adenoma 
(APA). Bilateral adrenal hyperplasia (BAH) represents the other major subtype of  
primary aldosteronism (PA). Most patients with PA present with hypertension and/or 
hypokalemia, due to the effects of  aldosterone in the kidney. 
Importantly, patients with PA have a higher risk of  future cardiovascular events 
including myocardial infarction, stroke and atrial fibrillation, in comparison to age- and 
sex-matched patients with essential hypertension (EHT) and similar blood pressure 
levels. (2) Similarly, left ventricular hypertrophy (LVH) and heart failure are also more 
prevalent in patients with PA than in patients with EHT. (2) The increased susceptibility 
to these cardiovascular complications is beyond the risk that is imposed by the high 
blood pressure itself  and suggests direct toxic effects of  aldosterone. Indeed, preclinical 
data demonstrate that aldosterone has detrimental effects on the cardiovascular system, 
such as promoting oxidative stress, fibrosis and apoptosis, and increasing infarct size 
(IS) in animal models of  ischemia and reperfusion (IR). (3-8)
The increased cardiovascular risk in patients with PA highlights the importance of  early 
diagnosis and treatment of  PA. It is important to realize though, that there is a reported 
delay in the diagnosis of  PA of  approximately 8 years. (9) This delay can be explained 
by several factors: 
Firstly, patients with a newly diagnosed hypertension are not routinely screened for PA 
in primary care. Case detection of  PA is advised in selected subgroups of  patients. (10) 
Screening for PA is recommended in therapy resistant hypertension, which is defined 
by an uncontrolled blood pressure despite 3 antihypertensive drugs including 1 diuretic, 
or in the presence of  hypokalemia. (10, 11) In patients with a true resistant hypertension, 
the time needed to optimize medical treatment delays screening for secondary causes 
of  hypertension. 
Secondly, hypokalemia is present in only 37-56% of  the patients with PA. (12, 13) The 
absence of  biochemical features leads to a large proportion of  unidentified PA 
cases. Furthermore, hypokalemia may be masked when medical treatment contains 
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an MR antagonist, which is currently the add-on drug of  choice in therapy resistant 
hypertension. (11) 
Lastly, we speculate that unawareness of  the disease contributes to the delay in 
diagnosis of  PA. (14) PA was previously considered to be a rare disease. In contrast, PA 
is now recognized as the most common cause of  secondary hypertension. In primary 
care hypertensive population prevalence rates of  PA of  3-12 % are reported, versus 
1-30 % in referral centres. (15, 16) Prevalence rates not only depend on the health care 
centre (primary care versus referral centres) studied, but also on the population studied: 
PA is more prevalent in specific patient groups, i.e. patients with severe or resistant 
hypertension and patients with sleep apnea and hypertension. (10)
The delay in diagnosis automatically leads to a delay in the specific treatment of  
PA, which differs from the standard antihypertensive treatment in EHT patients. 
The first choice of  treatment in patients with unilateral aldosterone overproduction 
is laparoscopic removal of  the culprit adrenal gland, whereas patients with bilateral 
aldosterone overproduction or patients who cannot undergo or do not desire surgery 
are pharmacologically treated with the MR antagonists spironolactone or eplerenone. 
In patients with PA, both adrenalectomy and medical treatment with MR antagonists 
reduce the blood pressure to a level observed in patients with EHT who are treated with 
standard antihypertensive treatment. (17) A longer duration of  hypertension however, 
lowers the chance of  blood pressure normalization after adrenalectomy. (18, 19) Hence, 
early diagnosis and treatment of  PA are essential.
In recent years, more attention has been paid to the quality of  life in patients with PA. 
Patients with PA have an impaired quality of  life and compared to patients with EHT, 
they are more prone to psychological problems. (20-22) After surgical or pharmacological 
treatment, the quality of  life scores in patients with PA improve. (20) These findings again 
subscribe the relevance of  early diagnoses and treatment of  PA.
DIAGNOSIS OF PRIMARY ALDOSTERONISM
The Radboud university medical center (Radboudumc) serves as a tertiary referral 
centre for patients with PA. Concordant with the current international guideline, the 
level of  circulating aldosterone and the aldosterone-to-renin-ratio (ARR) are used to 
detect possible cases of  PA. (10) When the baseline aldosterone concentration is <0.42 
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nmol/L and the ARR <0.09 nmol/mU, PA is currently considered to be excluded, 
according to the reference values of  the clinical chemistry laboratory. Patients with 
a plasma aldosterone concentration of  >0.42 nmol/L and ARR >0.09 nmol/mU at 
baseline undergo subsequent testing to confirm or exclude PA. 
To date, no confirmatory test is identified as the gold standard. (10) In our centre, we 
perform a salt loading test (SLT) by the intravenous infusion of  2 L saline in 4 hours. This 
test relies on the principle that expansion of  the effective circulating volume suppresses 
the RAAS system. A lack of  aldosterone suppression in response to salt loading is thus 
indicative of  autonomous aldosterone overproduction, that escapes normal feedback 
mechanisms. The diagnosis of  PA is confirmed when the aldosterone concentration 
exceeds 0.28 nmol/L after salt infusion. The SLT is considered negative when the 
aldosterone concentration is suppressed to <0.14 nmol/L after salt infusion. Patients 
with an aldosterone concentration of  0.14 to 0.28 nmol/L after SLT are discussed in 
our local adrenal working group that assigns such patients to either a PA or EHT group, 
based on a number of  clinical characteristics, including hypokalemia, plasma renin level 
and use of  potassium suppletion. 
Several conditions and drugs affect the interpretation of  ARR results. (10) For instance, 
hypokalemia may lead to a false negative ARR since it suppresses aldosterone production, 
whereas renal dysfunction may lead to a false positive ARR result. It is important to 
correct for hypokalemia and withdraw drugs that interfere with the RAAS before 
evaluation of  PA, since these drugs may either falsely elevate ARR results or mask PA. (10) 
Complete cessation of  antihypertensive drugs is often undesirable in patients evaluated 
for PA and high blood pressure levels. Concordant with international guidelines and 
our local protocol, treatment with the calcium-channel blockers (preferably the non-
dihydropyridine calcium channel blockers diltiazem and verapamil), doxazosin and 
hydralazine is allowed during evaluation for PA, since these drugs have a minimal effect 
on aldosterone and renin measurement. (10)
When the diagnosis of  PA is established, the current guideline recommends adrenal 
imaging with sequential adrenal venous sampling (AVS) in patients with PA who are 
candidates for surgical treatment. (10) Radiologists use computed tomography (CT) 
to visualize adrenal masses (uni- or bilateral) and to distinguish between benign and 
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malignant tumors. When AVS is followed, CT is helpful to localize the right adrenal vein 
which may facilitate cannulation during AVS. 
AVS of  the right and left adrenal vein is performed during cosyntropin infusion. AVS 
is determined successful when the adrenal vein to peripheral vein cortisol ratio exceeds 
3. Criteria for a unilateral aldosterone overproduction are met when the left versus right 
(or vice versa) aldosterone-cortisol-ratio is ≥4.0 and the ratio of  the contralateral site is 
≤1.0, as an indication for contralateral suppression.
Although the current guideline considers AVS to be the gold standard to dinstinguish 
between uni- and bilateral autonomous aldosterone overproduction, recent observations 
from a prospective diagnostic management study performed in our centre, the 
SPARTACUS study, do not necessarily advocate AVS. (10, 23) In this study, there were no 
differences in the intensity of  the antihypertensive treatment, the number of  patients 
in whom target blood pressure was reached, biochemical cure and the quality of  life 
between the patients who were treated based on AVS, compared to treatment based on 
CT, after a follow up period of  1 year. (23) 
ADRENALECTOMY VERSUS MINERALOCORTICOID RECEPTOR 
ANTAGONISTS
As described above, both adrenalectomy and pharmacological treatment with MR 
antagonists effectively reduce blood pressure levels in patients with PA to a similar level 
observed in medically treated patients with EHT. (17) A recent review showed a superior 
role of  adrenalectomy over medical treatment concerning blood pressure lowering and 
restoration of  plasma potassium levels in PA. (24) It is important to realize though that 
randomized studies comparing adrenalectomy with medical treatment in PA patients 
with an APA are lacking. Also, medical treatment is the preferred treatment option in 
PA patients with BAH since bilateral adrenalectomy results in life-long dependency on 
hormonal substitution and risk of  Addison’s crisis. 
In 33-86 % of  the adrenalectomized patients, the target blood pressure of  <140/<90 
mmHg is reached without the use of  any antihypertensive medication. (17, 21, 25, 26) 
The elimination of  chronic antihypertensive drug use in approximately half  of  the 
adrenalectomized patients makes adrenalectomy a cost-saving option in PA patients. (27) 
Laparoscopic adrenalectomy is a safe and minimally invasive procedure, whilst MR 
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antagonists can have undesirable side effects. (28, 29) Spironolactone and eplerenone 
are steroidal MR antagonists that competitively inhibit aldosterone at the level of  
the MR. Spironolactone also binds to other steroid receptors leading to mastodynia 
or gynecomastia, impotence, loss of  libido, or menstrual irregularities. The selective 
MR antagonist eplerenone displays lower affinity for the progesterone and androgen 
receptor and therefore, it has less progestagenic or antiandrogenic side effects. However, 
eplerenone is less potent than spironolactone regarding blood pressure lowering, and 
should be taken twice daily because of  its shorter half-life. 
The increased risk of  cardiovascular complications in patients with PA, in comparison 
to patients with EHT with similar blood pressure levels, implies treatment goals in 
PA beyond blood pressure normalization. One might assume favourable effects of  
adrenalectomy over and above pharmacological treatment regarding target organ 
damage and quality of  life, since adrenalectomy normalizes aldosterone secretion. 
Furthermore, MR antagonists do not counteract potential MR-independent effects of  
aldosterone on the cardiovascular system. (30, 31)
Indeed, although both adrenalectomy and treatment with MR antagonists significantly 
improve the quality of  life scores in patients with PA, the improvement during medical 
treatment is slower and to a lesser extent than the improvement after surgical treatment. 
(20) The superiority of  adrenalectomy over medical treatment concerning improvement 
of  quality of  life in patients with PA has been confirmed in a post-hoc analysis of  the 
SPARTACUS study, that was recently performed in our centre. (23, 32) 
Regarding cardiovascular damage however, adrenalectomy and medical treatment with 
MR antagonists reduce LV mass and the prevalence of  LVH to a similar extent after an 
averaged follow up period of  4 years. (33) After a 1 year follow up however, significant 
reductions in LV mass are achieved in adrenalectomized patients, but not in medically 
treated PA patients. (34, 35) In patients with PA who are cured after adrenalectomy versus 
patients with PA who are medically treated, there is no difference in cardiovascular 
outcomes compromising myocardial infarction, stroke, any type of  revascularization 
procedure, and sustained arrhythmias, after a mean follow up period of  7.4 years. (36) 
It is an interesting observation that in patients with PA, treatment with competitive 
MR antagonists is non-inferior to adrenalectomy regarding LV mass regression and 
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cardiovascular outcomes after long-term (4 years) but not after short-term (1 year) 
follow up. 
MR-dependent effects of  aldosterone on LVH and other cardiovascular outcome 
measures are likely to benefit from treatment with MR antagonists also after short-term 
follow up. Therefore, one might assume that the toxic effects of  aldosterone on the 
above mentioned cardiovascular outcomes are not fully blocked by MR antagonists, or 
that these effects are MR-independent. 
In addition, in preclinical models MR antagonists confer cardioprotection even when 
there is no endogenous aldosterone present, suggesting inverse agonism of  these ligands 
on MR-receptors or beneficial pleiotropic actions of  these drugs. (8) In Langendorff  
isolated perfused heart models and murine models using adrenalectomized animals, 
administration of  MR antagonists reduces IS in the setting of  simulated IR. (37-41) In 
large studies in patients with systolic heart failure, spironolactone and eplerenone reduce 
morbidity and mortality, but the underlying mechanism is not fully understood. (42-44)
OUTLINE OF THE THESIS
It follows that several important knowledge gaps remain, which prevent optimal 
diagnosis and treatment of  patients with PA. 
Firstly, it is known that with the current diagnostic strategy, patients with PA are at 
higher risk of  cardiovascular events than patients with EHT. To develop novel 
diagnostic strategies leading to earlier diagnosis, it is essential to know whether there is 
more profound cardiovascular damage compared to patients with EHT already at an 
early stage of  their disease. We screened patients with a newly diagnosed hypertension 
from a Dutch primary care cohort for PA. Subsequently, we assessed cardiovascular 
and renal damage in the patients diagnosed with PA in comparison to matched controls 
diagnosed with EHT. We described the results of  this explorative study in chapter 2.1. 
Secondly, patients with PA are at an increased risk for cardiovascular complications 
such as myocardial infarction and stroke. In preclinical models, aldosterone increases 
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myocardial IR injury and administration of  MR antagonists protects against IR injury. It 
is currently unknown whether patients with PA are more susceptible to IR than patients 
with EHT, which would provide yet another mechanism that explains the higher 
cardiovascular risk in these patients. In chapter 2.2, we hypothesized that patients with 
PA are more susceptible to endothelial IR than control patients with EHT. To test this 
hypothesis, we used brachial flow mediated dilation (FMD) before and after simulated 
forearm IR as a well-validated read out for IR injury. (45, 46)
Thirdly, we aimed to identify novel mechanisms that are active in patients with PA which 
contribute to the increased cardiovascular risk. We first aimed to translate preclinical 
findings of  recently proposed mechanisms of  direct adverse effects of  aldosterone on 
the cardiovascular system to humans. Preclinical studies have reported that aldosterone 
can stimulate galectin-3 expression and secretion in various cell types relevant for the 
cardiovascular system via MR activation, and that Gal-3 mediates the pro-fibrotic 
effects of  aldosterone. (47-50) We hypothesized that plasma Gal-3 concentrations are 
higher in patients with PA in comparison to patients with EHT, and that Gal-3 levels 
return to normal after adrenalectomy. The results of  this study are described in chapter 
2.3. Subsequently, we aimed to study the endogenous purine nucleotide adenosine 
in patients with PA. The adenosine concentration rapidly increases in situations of  
impending tissue danger, such as during ischemia, and adenosine receptor stimulation 
elicits various protective cardiovascular effects. In chapter 2.2, we describe the circulating 
adenosine concentration in patients with PA and EHT. 
In the final part, we focussed on the protective effects of  MR antagonists. First, we 
provided an overview of  the literature on the cardioprotective effects of  MR antagonists 
in chapter 3.1. MR antagonists consistently reduce IS in animal models of  IR and 
attenuate cardiac remodeling in animal models with permanent arterial occlusion. 
Cardioprotection is also conferred in the absence of  endogenous aldosterone. (8) These 
findings suggest inhibition of  spontaneously active MRs (inverse agonism) or beneficial 
off-target effects of  MR antagonists (pleiotropic actions) and these may contribute 
to the well documented benefits of  spironolactone and eplerenone in humans in vivo: 
treatment with these MR antagonists improves morbidity and mortality in patients 
with systolic heart failure, and treatment with MR antagonists is non-inferior to 
permanent removal of  aldosterone excess by adrenalectomy concerning target organ 
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damage. (34, 36, 42-44, 51) These observations indicate that it is highly relevant to unravel 
underlying pathways of  the cardioprotective effects of  MR antagonists, apart from 
aldosterone antagonism. In chapter 3.2, we hypothesized that eplerenone treatment 
increases extracellular levels of  adenosine, since endogenous adenosine has been shown 
to be crucial for the cardioprotective effects of  MR antagonists in preclinical models of  
myocardial infarction. (40) Finally, we investigated for the first time in human myocardial 
tissue whether eplerenone limits IR injury. We described the results of  our study in 
chapter 3.3.
METHODS AND TECHNIQUES APPLIED
IN-VIVO TECHNIQUES
PULSE WAVE ANALYSIS AND PULSE WAVE VELOCITY 
We analyzed the pulse wave of  the right radial artery using applanation tonometry 
(SphygmoCor, AtCor Medical, Australia). The SphygmoCor software automatically 
generates the central aortic blood pressure and other central hemodynamic indices, 
like the augmentation index (AIx), from a 10 second recording of  the radial pulse, 
after calibration for peripheral blood pressure (Figure 2). Although current guidelines 
on the diagnosis and treatment of  hypertension are based on brachial blood pressure 
levels, assessment of  central blood pressure may be superior in the identification and 
management of  patients with an increased cardiovascular risk. (52) Indeed, target organs 
such as the heart and large vessels, are directly exposed to central blood pressure and 
not brachial blood pressure. When compared to brachial blood pressure, central blood 
pressure is more strongly associated with target organ damage and cardiovascular 
mortality. (53-55) AIx is a good predictor of  future cardiovascular events and all-cause 
mortality. (56) 
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Pulse wave velocity (PWV) is the velocity at which the pulse wave, generated during each 
cardiac cycle, propagates through the arterial tree. PWV depends on the compliance of  
the arterial system and it is therefore a marker of  arterial stiffness. Stiffening of  the 
arteries is reflected in higher PWV’s with a PWV of  >10 m/s being considered as 
an indicator of  subclinical target organ damage. (57) Arterial stiffness, as a reflection 
of  structural changes in aortic media and adventitia resulting from arteriolosclerosis, 
is a strong predictor for future cardiovascular events, independent from traditional 
cardiovascular risk factors. (58-60) 
For the assessment of  the aortic PWV, we measured the pressure waves at the sites 
of  the right carotid artery and the right femoral artery by applanation tonometry 
(SphygmoCor, AtCor Medical, Australia). The SphygmoCor software automatically 
calculates the transit time as the delay between the R-spike in the electrocardiogram and 
the arrival of  the pressure waves at the recording sites. We estimated the travel distance 
by subtracting the distance from the carotid tonometer location to the sternal notch 
from the distance between the sternal notch to the femoral tonometer location. (61) 
FLOW-MEDIATED DILATION 
Ultrasound measurement of  the brachial artery flow-mediated dilation (FMD) is a 
non-invasive validated measure to indirectly assess endothelial function. Brachial artery 
FMD predicts future cardiovascular events: it has been estimated that per 1 % increase 
in brachial FMD the risk for future cardiovascular events decreases by 13% (RR 0.87 
(0.83-0.91 95% CI)). (62) In healthy children and adolescents, the FMD is 7-9 % and 
this percentage declines with age to approximately 3.5 % in older male patients (68-79 
years). (63, 64)
We imaged the brachial artery in a darkened, temperature-controlled room using a 10-
MHz multifrequency linear-array probe attached to a high-resolution ultrasound machine 
(Terason T3000, Burlington, MA) according to recent international guidelines. (65) After 
1 minute of  baseline recordings of  diameter and blood flow velocity, a blood pressure 
cuff, positioned around the forearm, was inflated during 5 minutes at a pressure of  200 
mmHg. We captured changes in brachial artery diameter and blood flow velocity until 
3 minutes post-deflation and analyzed the recordings using computer-assisted software, 
utilizing edge-detection and wall-tracking. 
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The endothelial function is quantified by the percentage of  change in brachial artery 
diameter after the increase in shear stress. This FMD is a read-out for nitric oxide 
production. (66) The increase in shear stress is the result of  reactive hyperaemia, induced 
by the 5 minute occlusion of  the forearm circulation by a blood pressure cuff  applied 
distal from the site of  measurement. The experimental set up of  the FMD measurement 
is depicted in Figure 2. 
To assess endothelial IR injury, the measurement of  FMD was repeated after 20 
minutes of  ischemia and 20 minutes of  reperfusion of  the forearm, induced by a blood 
pressure cuff  positioned around the upper arm. The reduction in brachial FMD after 
IR compared to the baseline FMD is a well-validated measure to assess endothelial IR 
injury. (45, 46) 
FIGURE 2. Experimental set up of the measurement of 
brachial FMD measurement
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CAROTID INTIMA MEDIA THICKNESS AND CAROTID PLAQUE 
DETECTION 
The early process of  atherosclerosis starts with the infiltration of  the arterial intima-
media complex by lipids and inflammatory cells. Carotid intima-media thickness (cIMT) 
is a widely accepted non-invasive marker of  generalized subclinical atherosclerosis, since 
it consistently predicts future myocardial infarction and stroke. (67, 68) The added value of  
cIMT measurement to cardiovascular risk scores however, remains questionable. (57, 69, 70) 
In contrast to a recent systematic review in which measurement of  CIMT was of  added 
value in those at intermediate risk for cardiovascular disease, cIMT measurement did 
not improve on the Framingham Risk Score for prediction of  cardiovascular disease in a 
large study comparing the added value of  risk markers in >6800 patients at intermediate 
risk. (67, 71)
We measured the intima-media thickness at the common carotid artery far wall over 
a 1 cm segment caudally from the carotid bulb, in 3 different angles of  90, 120 and 
180 °, by high resolution B-mode ultrasound (Esaote Medical Systems, Italy). The 
integrated software of  the Esaote platform uses radio-frequency technology to provide 
6 measures, calculated as means from real-time values, obtained during 6 cardiac cycles. 
During carotid ultrasonography, the extracranial carotid arteries were scanned for the 
presence of  plaques. 
VENOUS OCCLUSION PLETHYSMOGRAPHY
Venous occlusion plethysmography is a well-validated technique used to measure the 
forearm blood flow (FBF) and the vasodilator response to drugs that are infused into the 
brachial artery. (72, 73) The major advantage of  this approach is that the concentration of  
the tested drug in the forearm vascular bed is sufficiently high to induce local (vascular) 
responses, while systemic concentrations are sufficiently low to avoid disturbances on 
systemic haemodynamics.
We measured the FBF in a temperature-controlled room with the healthy volunteers in 
the supine position. By repetitively in- and deflating an upper arm cuff  to a pressure 
of  approximately 40 mmHg, which is above the venous pressure but below arterial 
pressure, forearm volume will change: arterial inflow does not alter while venous return 
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is hindered during inflation, leading to substantial increases in forearm volume. The rate 
of  increase in forearm volume is detected by mercury-filled strain gauges, positioned 
around the proximal part of  the forearm. By excluding the hand circulation during the 
measurements, the increase in FBF during inflation of  the upper arm cuff  is linear and 
proportional to the arterial inflow of  the arm. The experimental set up is shown in 
Figure 3. 
FIGURE 3. Experimental set up of venous occlusion plethysmography
In chapter 3.2, we used venous occlusion plethysmography during dipyridamole 
administration into the brachial artery to indirectly assess extracellular adenosine 
formation. 
Adenosine is an endogenous purine nucleoside, which is formed by intra-, and 
extracellular degradation of  adenosine monophosphate by the enzyme 5’-nucleotidase 
(CD73). Degradation of  adenosine only occurs in the intracellular compartment. As 
a consequence, facilitated diffusion of  adenosine over the cellular membrane by the 
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equilibrative nucleoside transporter (ENT) is normally directed inwards. Stimulation of  
membrane-bound adenosine receptors (A1, A2A, A2B, and A3) induces various effects, 
including vasodilation, inhibition of  inflammation, and protection against IR-injury. 
Measurement of  circulating endogenous adenosine is extremely difficult, because the 
half  life of  adenosine in blood is very short due to rapid uptake and degradation by 
circulating erythrocytes and endothelial cells. (74, 75) This uptake occurs through facilitated 
diffusion by equilibrative nucleoside transporters (ENT). This facilitated diffusion is 
strongly inhibited by ENT-inhibitors such as dipyridamole. In the presence of  this 
drug, endogenous adenosine formation is sufficient to induce vasodilation. Therefore, 
we used the vasodilator effect of  the ENT inhibitor dipyridamole as a read-out for 
endogenous extracellular adenosine formation by the enzyme CD73, as previously 
described by our group and depicted in Figure 4. (76, 77)
FIGURE 4. Simplified schematic overview of the extracellular formation and transport of 
adenosine. Dipyridamole increases the extracellular adenosine concentration by inhibition 
of the ENT, resulting in local vasodilation and increased FBF. 
Abbreviations: AMP, adenosine monophosphate; ATP, adenosine triphosphate; AR, adenosine receptor; CD73 or ecto-
5’-nucleotidase; ENT, equilibrative nucleoside transporter; SAH, S-adenosyl-L-homocysteine
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EX-VIVO TECHNIQUES
CONTRACTILE FORCE OF ATRIAL TISSUE
We used human atrial trabeculae from patients undergoing cardiac surgery to study 
the effect of  MR antagonists on IR injury. During cardiac surgery with extracorporeal 
circulation, the cardiothoracic surgeon incises the right atrial appendage to insert the 
cannula of  the extracorporeal circulation. In patients who provided written informed 
consent, the right atrial appendage was dissected immediately after the introduction of  
this cannula and placed in a cold buffer solution. We used the experimental set up, as 
described by Speechly-Dick. (78, 79) (Figure 5)
From each atrial appendage, we isolated 2 trabeculae and suspended these vertically in 
an organ bath. We performed electrical field stimulation on both sides of  the trabeculae 
and measured contractile force, calculated from the maximal tension during contraction 
and the minimal tension during relaxation. We exposed the trabeculae to IR and used 
the recovery of  contractile force as a read-out parameter for IR injury. 
FIGURE 5. Experimental set up (organ bath) of the measurement of contractile 
force in human atrial tissue
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Both pharmacological and ischemic preconditioning have been shown to increase post-
ischemic recovery of  contractile force in this ex vivo model. (78-80) We studied the effect 
of  the MR antagonist eplerenone on IR injury in a paired fashion: per atrial appendage 
one trabecula was randomly assigned to superfusion with eplerenone and the other to 
vehicle.
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ABSTRACT
Background Patients with primary aldosteronism (PA) have a higher risk of  
cardiovascular complications compared to patients with essential hypertension (EHT) 
and similar blood pressure levels. It is unclear whether cardiovascular damage is already 
present at the time of  diagnosing hypertension. 
Objective The aim of  this exploratory study was to assess cardiovascular organ 
damage in patients who were screened for PA at the time of  diagnosing hypertension in 
primary care. 
Methods  We prospectively assessed cardiovascular damage in six patients with 
newly diagnosed PA and 24 matched patients with EHT at the time when hypertension 
was diagnosed in the primary care. We performed detailed cardiovascular assessment, 
including ankle-brachial index, echocardiography, flow-mediated vasodilation, carotid 
ultrasonography, central aortic blood pressure, pulse wave velocity, and urinary albumin-
to-creatinine ratio measurement. 
Results Two of  the six patients with PA versus none of  the patients with EHT 
(p=0.04) fulfilled the criteria of  concentric LVH (>115 g/m2 in men and >95 g/m2 
in women). After adjustment for gender, age and blood pressure, left ventricular mass 
index was higher in the patients with PA than in the patients with EHT. We did not 
observe differences in the other outcome measures between the patient groups. 
Conclusion At the time of  the diagnosis of  hypertension, patients with PA have a 
higher frequency of  LVH than patients with EHT. If  confirmed in larger studies, this 
finding suggests that early biochemical testing for PA, and specific treatment of  PA, 
might contribute to the prevention of  further progression of  cardiovascular damage 
due to inadequately treated PA. 
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INTRODUCTION
Primary aldosteronism (PA) is characterized by unilateral or bilateral autonomous 
overproduction of  aldosterone in the adrenal cortex. PA is the most common cause 
of  secondary hypertension, with prevalence rates varying from 3-12% in primary care 
versus 1-30 % in referral centres. (1, 2) 
According to the Endocrine Society guideline, the diagnosis of  PA should be considered 
in specific patients with hypertension. (3) However, in daily clinical primary care practice, 
this recommendation on testing for PA is commonly omitted, as general practitioners 
are generally not aware of  this guideline. (4) To complicate matters further, hypokalemia, 
previously considered to be a prerequisite for a diagnosis of  PA, is present in only less 
than 40% of  the PA patients. So, this biomarker has limited utility to incite appropriately 
testing for PA. (5) For these reasons the diagnosis of  PA has been reported to be delayed 
for up to eight years. (6)
The delay in a timely diagnosis of  PA is potentially harmful for patients for at least 
two reasons. First, treatment of  PA differs from usual antihypertensive treatment in 
patients with essential hypertension (EHT). Patients with PA require specific treatment: 
those with a unilateral aldosterone-producing adenoma are advised to undergo 
adrenalectomy, whereas those with bilateral aldosterone overproduction are treated 
with a mineralocorticoid receptor (MR) antagonist, such as spironolactone. (3) Second, 
patients with PA have a higher risk of  cardiovascular complications in comparison to 
patients with EHT with similar blood pressure levels. (7) This may be explained by a 
direct effect of  aldosterone unopposed by appropriate treatment during the long pre-
diagnostic phase, inducing cardiovascular organ damage well before diagnosis. The 
higher risk of  cardiovascular complications in patients with PA suggests the need for 
timely biochemical testing for PA in (newly diagnosed) hypertensive patients to prevent 
further development of  cardiovascular organ damage. 
In this explorative study in the primary care setting, we prospectively assessed 
cardiovascular and renal damage in patients in whom PA was detected at the time when 
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hypertension was diagnosed for the first time. A group of  newly diagnosed patients 
with EHT, matched for gender, age and blood pressure, served as a control group. 
METHODS
PATIENTS
We included all patients over 18 years with newly diagnosed never treated hypertension 
from 55 primary care centres in the Netherlands from August 1st 2013 to December 
31st 2015. In the context of  a previous study on the prevalence of  PA, the participating 
patients had plasma aldosterone and renin measured at the time of  diagnosing 
hypertension, and before starting antihypertensive treatment. This study has been 
described in detail elsewhere. (8) 
The diagnosis of  hypertension was made according to the current guideline by the 
European Society of  Hypertension. (9) In brief, hypertension was diagnosed: 1) if  the 
average office blood pressure of  at least two blood pressure measurements per day was 
≥140/90 mmHg on two or more different visits within six months, or 2) if  24-hour 
ambulatory blood pressure measurement (ABPM) was ≥130/80 mmHg. 
Patients with newly diagnosed hypertension were screened for PA by measurement of  
plasma aldosterone and renin. In case of  an aldosterone-to-renin ratio (ARR) of  >40 
pmol/mU and a plasma aldosterone concentration of  >400 pmol/L, an intravenous 
saline loading test (SLT; two litres NaCl 0.9% in four hours) was performed. Diagnosis 
of  PA was made when the aldosterone concentration exceeded 280 pmol/L after saline 
loading. Patients were considered to have EHT if  ARR values were ≤40 pmol/mU 
with a concomitant low baseline aldosterone level of  ≤400 pmol/L (ARRneg), or an 
aldosterone value of  ≤280 pmol/L after SLT (ARRposSLTneg). During biochemical 
testing, patients did not use medication that interfered with aldosterone and renin 
levels. (3) 
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We included all patients diagnosed with PA and applied the following exclusion criteria: 
age <18 years, hypertensive crisis, heart failure classes II-IV (defined by the New York 
Heart Association) (10), diabetes mellitus, estimated glomerular filtration rate of  <45 ml/
min/1.73m2, pregnancy or breast feeding, and severe comorbidity that would seriously 
interfere with study procedures. We applied similar exclusion criteria for the patients 
with EHT. We matched the patients with PA with the patients with EHT for gender, 
age and baseline blood pressure. For every patient with PA, we included four control 
patients with EHT: one ARRposSLTneg patient, and three ARRneg patients. This numeric 
relation corresponds to the ratio ARRpos/ARRneg that was found among patients with 
newly diagnosed EHT in primary care. (8)
This study was approved by the Ethics Committee of  the Radboud university medical 
center. All patients provided written informed consent before enrollment. The study was 
conducted in accordance with Good Clinical Practices, and the Declaration of  Helsinki, 
and was prospectively registered at ClinicalTrials.gov by number NCT01728493.
CLINICAL DATA
We collected the following clinical data: body mass index (BMI), medication use, 
smoking status (pack years (PY)), previous and family history of  cardiovascular disease, 
alcohol intake per day (units of  10 g), physical exercise (standard defined as 30 minutes/
day during five or more days/week), snoring (defined as light or heavy according to 
the patients’ judgement) or diagnosis of  obstructive sleep apnea syndrome (OSAS) 
and history of  gestational hypertension. We expressed the antihypertensive medication 
in daily defined doses (DDD), as defined by the World Health Organisation. (11) From 
August 1st 2013 to December 14th 2014, plasma aldosterone was measured using the 
Coat-A-Count aldosterone radioimmunoassay (RIA) from Siemens Medical Solutions 
Diagnostics (United States of  America). From December 15th 2014 to December 
31st 2015, plasma aldosterone was measured by the Active Aldosterone RIA kit from 
Beckman Coulter (Czech Republic). Plasma renin concentration was measured using 
the DSL-25100 active renin immunoradiometric assay (IRMA) from Diagnostic 
Systems Laboratories (United States of  America). Baseline plasma concentrations of  
creatinine, potassium, cholesterol, high-density lipoprotein cholesterol, low-density 
lipoprotein cholesterol and triglycerides were determined using standard assays in a 
central laboratory (SHO, Velp, the Netherlands). 
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STUDY PROTOCOL
In patients with PA and ARRposSLTneg patients with EHT, ankle brachial index (ABI) and 
urinary albumin-to-creatinine ratio (uACR) were performed during their admission for 
SLT. Echocardiography was carried out shortly after this. We performed measurements 
of  the other cardiovascular risk markers during a separate visit. In ARRneg patients 
with EHT, all measures were obtained during a single visit. We measured the brachial 
blood pressure in the supine position using a manual sphygmomanometer (Welch Allyn, 
Leiden, the Netherlands), in a quiet room after a period of  five minutes rest according 
to the guideline. (12) All patients abstained from caffeine, alcohol and products rich on 
vitamin C and/or flavonoids 24 hours before the measurements. We performed the 
measurements at least six hours after fasting. We asked the patients not to smoke six 
hours before the experiments and to refrain from exercise during 24 hours before the 
measurements. Patients took their medication after finishing all vascular measurements 
on the day of  the experiments. (13, 14) We assessed the following seven primary outcomes: 
ANKLE-BRACHIAL INDEX (ABI)
For the measurement of  the ABI we used the standardized technique as described by 
the American Heart Association. (15) In brief, we performed limb pressure measurements 
after at least five minutes of  rest in the supine position. All limb pressure measurements 
were done by Doppler (Dopplex D900, Huntleigh Healthcare Ltd, Cardiff, UK) in 
the following sequence: right brachial artery, right tibial posterior artery, right dorsal 
pedal artery, left tibial posterior artery, left dorsal pedal artery, and left brachial artery. 
When the pressure between both brachial arteries exceeded 10 mmHg, we performed a 
second measurement of  the right brachial artery and discarded the first measurement. 
We expressed the ABI as the highest lower-extremity blood pressure, divided by the 
highest blood pressure in both arms. 
ECHOCARDIOGRAPHY
Standard echocardiographic examinations were carried out with subjects in the partial 
left decubitus position using a commercially available instrument (GE Vivid E9, 
General Electric, Horten, Norway), equipped with the multifrequency 1.5-4.0 MHz M5S 
transducer. End-diastolic and end-systolic left ventricular internal diameters (LVIDd, 
LVIDs), interventricular septum and posterior wall thicknesses (PWT) were measured 
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from two dimensional parasternal long axis view, from which left ventricular mass 
index (LVMI) was calculated according to the American Society of  Echocardiography 
guidelines and normalized by body surface area. (16) Relative wall thickness (RWT) was 
calculated as 2 × PWT/LVIDd. A normal LVMI was defined as ≤115 g/m2 in men, and 
≤95 g/m2 in women. We defined eccentric hypertrophy as an increased LVMI (>115 g/
m2 in men, and >95 g/m2 in women) with a RWT <0.42, and concentric hypertrophy 
as an increased LVMI with a RWT >0.42. Furthermore, concentric remodeling was 
defined as a normal LVMI, but increased RWT (>0.42). (16)
Left ventricular (LV) filling, in casu diastolic LV function was assessed by the standard 
pulsed and tissue Doppler technique. (17) The following parameters were considered: the 
early diastolic mitral peak flow velocity (E), the late diastolic mitral peak flow velocity 
(A), their ratio (E/A ratio), and the average of  both maximal early diastolic tissue 
velocity of  the medial and lateral mitral annulus (E’) and the average E/E’.
FLOW-MEDIATED DILATION (FMD)
An experienced researcher of  the Department of  Physiology of  the Radboud university 
medical center measured brachial FMD in a darkened, temperature-controlled room of  
22.1 ± 0.4 °C using a 10-MHz multifrequency linear-array probe attached to a high-
resolution ultrasound machine (Terason T3000, Burlington, USA) according to the 
guideline of  Thijssen et al. (14) The researcher was blinded for the diagnosis. Briefly, 
a sphygmomanometer blood pressure cuff  was positioned around the forearm and 
the brachial artery was imaged proximally of  the antecubital fossa. After one minute 
of  baseline recordings of  diameter and blood flow velocity, the cuff  was inflated for 
five minutes, at a pressure of  200 mmHg or at least 50 mmHg above systolic blood 
pressure (SBP). We captured changes in brachial artery diameter and blood flow velocity 
30 seconds before cuff  deflation until three minutes post-deflation, and analyzed the 
recordings offline in a blinded fashion using computer-assisted software, utilizing edge-
detection and wall-tracking. We expressed the FMD as the % change in diameter ((peak 
diameter after deflation minus baseline diameter)/baseline diameter x 100%). 
CAROTID INTIMA-MEDIA THICKNESS (CIMT)
The cIMT was measured by high resolution B-mode ultrasound with a 7.5-MHz linear-
array transducer (Esaote Biomedica, Genoa, Italy). We measured the intima and media 
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of  the left and right common carotid artery far wall over a 1 cm segment caudally 
from the carotid bulb, in three different angles of  90, 120 and 180°. The integrated 
software of  the Esaote platform uses radio-frequency technology to provide six 
measures, calculated as means from real-time values, obtained during six cardiac cycles. 
The standard deviation (SD) of  these six mean measures was directly visible and the 
data were accepted if  the SD did not exceed 20 µm. We calculated the mean diameter 
and cIMT from 18 measures (six means times three angles) of  every patient for the left 
and right carotid artery. We thoroughly scanned the extracranial carotid arteries for the 
presence of  plaques. A plaque was defined as a focal wall thickening of  ≥50% compared 
to the surrounding vessel wall, or a local cIMT greater than 1.5 mm, according to the 
consensus statement from the American Society of  Echocardiography. (18)
CENTRAL AORTIC BLOOD PRESSURE AND PULSE WAVE VELOCITY 
(PWV)
With the patient in the supine position, we performed pulse wave analysis of  the right 
radial artery using applanation tonometry (SphygmoCor, AtCor Medical, Australia). 
The SphygmoCor software generates the central aortic blood pressure and AIx from 
a ten second recording after calibration for peripheral blood pressure. We discarded 
measurements that did not meet the quality control criteria of  the software. We 
recorded the median of  three valid central aortal blood pressure measurements. For the 
assessment of  the aortic PWV, we measured the pressure waves at the sites of  the right 
carotid artery and the right femoral artery. The SphygmoCor software automatically 
calculates the transit time as the delay between the R-spike in the electrocardiogram and 
the arrival of  the pressure waves at the recording sites. We estimated the travel distance 
by subtracting the distance from the carotid tonometer location to the sternal notch 
from the distance between the sternal notch to the femoral tonometer location. (19) In 
all patients we performed three measurements and recorded the median PWV. When 
the difference between the first and second PWV was ≤0.5 m/s, we did not perform a 
third measurement and recorded the mean PWV of  these two measurements. (20) The 
quality of  the pressure wave was directly analyzed by the Sphygmocor software. If  the 
SD was ≥10% of  the PWV measurement, we discarded the measurement and replaced 
it by a novel measurement, up to a maximum of  six attempts. 
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URINARY ALBUMIN-TO-CREATININE RATIO 
The uACR was measured in a single urine sample by the Department of  Clinical 
Chemistry of  the Radboud university medical center. Urinary albumin was measured 
using a nephelometric technology (BN II analyzer, Siemens, The Netherlands). Urinary 
creatinine was analyzed by Cobas 8000, (Roche Diagnostics, The Netherlands). 
STATISTICAL ANALYSIS
For the analysis of  the data, we used IBM SPSS Statistics 22. We expressed all values 
as mean ± SD. We considered a significance value of  <0.05 (two-sided). Differences 
between patients with PA and patients with EHT were compared using an independent 
t-test. Because of  the small sample size, we checked the robustness of  the independent 
t-test with bootstrapping. Differences in proportions were compared using the Fisher’s 
exact test (two-sided). For comparisons between more than two groups, we used a one-
way ANOVA. We compared each of  the single outcome measures between the patients 
with PA and EHT using a general linear model with correction for gender, age and 
blood pressure. Central aortic blood pressures were corrected only for gender and age, 
because the Sphygmocor software calculates the central blood pressure and AIx from 
the brachial blood pressure. 
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RESULTS
PATIENTS AND CLINICAL CHARACTERISTICS
Of  the patients with newly diagnosed hypertension, nine were diagnosed with PA. (8) Of  
these patients, three patients declined to participate in the present study. Therefore, we 
included six patients with PA and 24 matched control patients with EHT in our study. 
For an overview of  the selection of  our study population see Figure 1. 
Exclusion (n=3)
• No informed consent 
(n=3)
Patients with primary 
aldosteronism (n=9)
Patients with essential 
hypertension (n=386)
Eligible patients with primary 
aldosteronism (n=6)
Matched patients with essential 
hypertension (n=64)
Not matched (n=322)
ARRposSLTneg (n=15) ARRneg (n=49)
Exclusion (n=22)
• Exclusion criteria met 
(n=12)
• No informed consent 
(n=9)
• Died (n=1)
Not asked (n=9)
Exclusion (n=4)
• No informed consent 
(n=4)
Not asked (n=5)
Ankle-brachial index, echocardiography, flow-mediated dilation, carotid intima-media 
thickness, pulse wave velocity, central aortic blood pressure and urinary albumin-
creatinine ratio in patients with primary aldosteronism (n=6), ARRposSLTneg (n=6) and 
ARRneg (n=18)
FIGURE 1. Overview of the selection process of patients 
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In this total group of  30 patients, the diagnosis of  hypertension was based on office 
blood pressure measurements in 26 patients and on APBM in four patients. (9) Four 
patients with PA had bilateral aldosterone overproduction and one had a unilateral 
aldosterone-producing adenoma. In one patient laterality could not be determined, as 
this patient refused adrenal venous sampling and computed tomography. One of  the six 
patients with PA dropped out, because of  recently diagnosed breast cancer. We did not 
perform FMD, PWV and central aortic blood pressure in this patient. Due to technical 
problems, we excluded the results of  FMD in one patient with EHT. In two patients 
with EHT we did not obtain a valid PWV (SD >10% of  the mean PWV) due to obesity. 
There were no differences in baseline characteristics between the patients with PA 
and EHT regarding cardiovascular risk factors and laboratory screening, except for 
differences in plasma aldosterone, ARR, and potassium values (Table 1). None of  the 
patients had hypokalemia. 
In the PA and the ARRposSLTneg patients, ABI and uACR were assessed after a mean 
period of  one month after the diagnosis of  hypertension (Table 2). The patients 
with PA did not use any antihypertensive medication at that time and their SBP was 
significantly higher compared to ARRneg patients (Table 3A). During echocardiography, 
two patients with PA used antihypertensive medication. In the other four patients with 
PA, antihypertensive treatment started after echocardiography. Echocardiography 
was performed 3.7 ± 2.9, 6.3 ± 9.2 and 19.1 ± 7.2 months after the diagnosis of  
hypertension in PA, ARRposSLTneg patients (with EHT) and ARRneg patients (with EHT) 
respectively (p<0.01). During assessment of  FMD, cIMT, PWV, and central aortic blood 
pressure, blood pressure levels and DDD of  antihypertensive drugs were comparable 
between patients with PA and patients with EHT (Table 3B). The general practitioner 
had started antihypertensive drugs in 12 of  the 24 patients with EHT without reaching 
target blood pressure levels of  <140/90 mmHg (RR 151 ± 15/93 ± 10 mmHg). (9) The 
remaining 12 patients did not use antihypertensive agents and their blood pressure was 
164 ± 19/89 ± 6 mmHg. 
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TABLE 1. Baseline characteristics
PA
(n=6)
EHT
(n=24) p-value
Demographics
Male (%) 3 (50) 12 (50) 1.00
Age (mean ± SD) 55.8 ± 9.1 56.6 ± 8.3 0.85
Cardiovascular risk factors
BMI in kg/m2 (mean ± SD) 26.6 ± 2.9 28.4 ± 3.4 0.23
Units alcohol/day (mean ± SD) 1.0 ± 1.2 1.2 ± 1.8 0.73
Smoking 0.12
Current smoker (%) 1 (16.7) 0
Former smoker (%) 1 (16.7) 12 (50)
PY (mean ± SD)* 23 ± 30 21 ± 19 0.96
Daily exercise
less than standard (%) 2 (33.3) 6 (25.0) 0.21
1st degree family history 
CVD (%) 2 (33.3) 17 (70.8) 0.33
Unknown (%) 0 1 (4.2)
2nd degree family history 0.35
CVD (%) 0 9 (37.5)
Unknown (%) 0 2 (8.3)
Gestational hypertension (%) 1 (33.3) 6 (50.0) 1.00
Snoring 0.08
Light (%) 1 15
Heavy (%) 2 2
OSA syndrome (%) 1 0 0.20
Diagnosis
Reason of visit 0.19
Complaints (%) 4 (66.7) 7 (29.2)
High blood pressure at screening test (%) 2 (33.3) 8 ( (33.3)
At clinic for other reason (%) 0 9 (37.5)
SBP in mmHg (mean ± SD) 169 ± 9 164 ± 11 0.24
DBP in mmHg (mean ± SD) 104 ± 7 97 ± 9 0.07
Laboratory screening (mean ± SD)
Aldosterone in pmol/L 721 ± 90 338 ± 218 <0.01
Renin in pmol/L 0.6 ± 0.3 2.1 ± 3.5 0.05
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ARR in pmol/mU 104.9 ± 57.6 26.8 ± 22.7 0.02
Sodium in mmol/L 141 ± 3 142 ± 2 0.36
Potassium in mmol/L 4.1 ± 0.3 4.5 ± 0.3 0.03
MDRD in mL/min 78 ± 8 74 ± 13 0.29
Fasting glucose in mmol/L 5.4 ± 0.6 5.5 ± 0.7 0.88
Cholesterol in mmol/L 6.8 ± 1.2 5.9 ± 1.0 0.15
HDL in mmol/L 1.5 ± 0.5 1.5 ± 0.4 0.98
Triglycerides in mmol/L 2.8 ± 2.6 1.3 ± 0.6 0.22
LDL in mmol/L 4.6 ± 0.8 4.1 ± 0.9 0.23
* For current and former smokers
Abbrevations: ARR, aldosterone-to-renin ratio; CVD, cardiovascular diseases; BMI, body mass index; EHT, essential 
hypertension; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OSA syndrome, obstructive sleep apnea 
syndrome; PA, primary aldosteronism
TABLE 2. Duration in months from diagnosis to measurement of the primary outcomes
PA EHT
 
(n=6)
ARRposSLTneg
(n=6)
ARRneg 
(n=18)
ABI, uACR 1 1 18
Echocardiography 4 6 19
FMD, cIMT, central aortic blood pressure and PWV 19* 12 18
* n=5
Abbrevations: ABI, ankle-brachial index; ARR, aldosterone-to-renin ratio; cIMT, carotid intima media thickness; EHT, 
essential hypertension; FMD, flow-mediated dilation; PA, primary aldosteronism; PWV, pulse wave velocity; SLT, salt 
loading test; uACR, urinary albumin-to-creatinine ratio
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TABLE 3. Blood pressure and antihypertensive treatment during assessment of ABI, uACR 
and shortly before echocardiography (A), and during FMD, cIMT, PWV and central aortic 
blood pressure (B)
A
PA EHT p-value
 
(n=6)
ARRposSLTneg
(n=6)
ARRneg 
(n=18)
Peripheral blood pressure (mean ± SD)
Brachial SBP in mmHg 172 ± 15 172 ± 23 154 ± 10 0.01
Brachial DBP in mmHg 100 ± 10 91 ± 6 92 ± 7 0.05
Duration of hypertension 
in months (mean ± SD) 1.0 ± 0.9 1.0 ± 1.1 18.0 ± 7.1 <0.01
Medication use
Number of patients taking antihypertensive drugs (%) 0 1 (16.7) 11 (61.1) 0.01
Thiazides (%) 0 0 3 (16.7) 1.00
ACE inhibitors (%) 0 0 6 (33.3) 0.30
Angiotensin II receptor antagonists (%) 0 0 1 (5.6) 1.00
Calcium channel blockers (%) 0 1 (16.7) 2 (11.1) 1.00
B-blockers (%) 0 0 0
MR antagonists (%) 0 0 0
Statin use (%) 0 0 2 (11.1) 1.00
B
PA EHT p-value
 
(n=6)
ARRposSLTneg
(n=6)
ARRneg 
(n=18)
Peripheral blood pressure (mean ± SD)
Brachial SBP in mmHg 139 ± 17.6 156 ± 26 154 ± 10 0.14
Brachial DBP in mmHg 86 ± 14 88 ± 10 92 ± 7 0.41
Duration of hypertension in months (mean ± SD) 18.8 ± 7.4 12.3 ± 6.0 18.0 ± 7.1 0.20
Medication use
Number of patients taking antihypertensive drugs (%) 5 (83.3) 2 (33.3) 11 (61.1) 0.09
Thiazides (%) 0 1 (16.7) 3 (16.7) 1.00
ACE inhibitors (%) 0 1 (16.7) 6 (33.3) 0.30
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Angiotensin II receptor antagonists (%) 0 1 (16.7) 1 (5.6) 1.00
Calcium channel blockers (%) 2 (40.0) 2 (33.3) 2 (11.1) 0.27
B-blockers (%) 0 1 (16.7) 0 1.00
MR antagonists (%) 4 (80.0) 0 0 0.00
Statin use (%) 2 (40.0) 0 2 (11.1) 0.17
Abbrevations: ACE inhibitors, angiotensin converting enzyme inhibitors; ARR, aldosterone-to-renin ratio; EHT, essential 
hypertension; MR, mineralocorticoid receptor; PA, primary aldosteronism; SLT, salt loading test
PRIMARY OUTCOMES
The unadjusted primary outcome measures are presented in Table 4A. None of  the 
patients had eccentric LVH, whereas two female patients with PA had concentric LVH 
on echocardiography (p=0.03). Concentric remodelling was present in two patients with 
PA (33.3%) and five patients with EHT (20.8%; p=0.60). LVMI was higher among 
patients with PA, but the difference with patients with EHT was not significant in the 
unadjusted analysis. After correction for blood pressure, gender and age, LVMI was 
significantly higher in patients with PA compared to patients with EHT (90.50 ± 7.73 
versus 70.70 ± 3.61 g/m2, respectively; p=0.04). There was no increased frequency of  
diastolic dysfunction, atrial dilation and carotid plaques in patients with PA compared 
to control patients with EHT. 
The adjusted mean values of  the single outcome measures with correction for gender, 
age and baseline blood pressure are depicted in Table 4B. We did not observe differences 
in ABI, cIMT, FMD, central blood pressure, AIx, PWV, and uACR between patients 
with PA compared to patients with EHT (Table 4).
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TABLE 4. Unadjusted values for each of the primary outcome measures (A) and primary 
outcome measures adjusted for gender, age, and systolic blood pressure (B)
A
PA EHT p-value
ABI (mean ± SD)
Left ABI 1.1 ± 0.0 1.1 ± 0.1 0.76
Right ABI 1.1 ± 0.1 1.1 ± 0.1 0.53
Echocardiography
Concentric hypertrophy (%) 2 (33.3) 0 (0) 0.03
Concentric remodeling (%) 2 (33.3) 5 (20.8) 0.60
LVMI (mean ± SD) in g/m2 83.48 ± 16.72 72.48 ± 16.92 0.19
Diastolic dysfunction (%) 3 (50.0) 11 (45.8) 1.00
Atrial dilation (%) 2 (33.3) 5 (20.8) 0.60
FMD (mean ± SD)*
Baseline diameter in cm 0.439 ± 0.114 0.407 ± 0.057 0.57
% change in diameter 4.3 ± 3.3 4.6 ± 3.0 0.88
Time to peak in seconds 54.4 ± 33.5 73.7 ± 47.9 0.32
cIMT (mean ± SD)**
Carotid plaques (%) 1 (20.0) 8 (33.3) 1.00
Left cIMT in µm 733.8 ± 188.8 747.0 ± 150.5 0.89
Right cIMT in µm 732.7 ± 177.5 727.6 ± 135.2 0.96
Central aortic blood pressure (mean ± SD)**
Central SBP in mmHg 130 ± 18 145 ± 15 0.15
Central DBP in mmHg 87 ± 14 92 ± 8 0.49
Central AIx in % 28.4 ± 7.8 30.7 ± 8.0 0.55
PWV in m/s ( (mean ± SD)*** 8.7 ± 1.3 9.6 ± 1.7 0.21
uACR in mg/mmol (mean ± SD) 3.4 ± 3.6 3.9 ± 13.0 0.89
* in PA (n=5) and EHT (n=23)
** in PA (n=5)
*** in PA (n=5) and EHT (n=22)
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B
PA EHT p-value
ABI (mean ± SD)
Left ABI 1.1 ± 0.0 1.1 ± 0.0 0.70
Right ABI 1.1 ± 0.0 1.1 ± 0.0 0.56
Echocardiography (mean ± SD)
LVMI in g/m2 90.50 ± 7.73 70.70 ± 3.61 0.04
FMD (mean ± SD)*
% change in diameter 4.47 ± 1.48 4.63 ± 0.66 0.92
Time to peak in seconds 67.0 ± 21.9 71.6 ± 9.7 0.85
cIMT (mean ± SD)**
Left cIMT in µm 748.8 ± 62.0 743.4 ± 26.8 0.94
Right cIMT in µm 741.4 ± 62.9 725.3 ± 27.3 0.82
Central aortic blood pressure (mean ± SD)**
Central SBP in mmHg 131 ± 7 145 ± 3 0.07
Central DBP in mmHg 87 ± 4 92 ± 2 0.25
Central AIx in % 29.0 ± 3.5 30.7 ± 1.6 0.67
PWV in m/s (mean ± SD)*** 9.0 ± 0.7 9.5 ± 0.3 0.55
uACR in mg/mmol (mean ± SD) 5.1 ± 5.6 3.4 ± 2.6 0.80
* in PA (n=5) and EHT (n=23)
** in PA (n=5)
*** in PA (n=5) and EHT (n=22)
Abbrevations: ABI, ankle-brachial index; AIx, augmentation index; ARR, aldosterone-to-renin ratio; cIMT, carotid 
intima media thickness; EHT, essential hypertension; FMD, flow-mediated dilation; LVH, left ventricular hypertrophy; 
LVMI, left ventricular mass index; PA, primary aldosteronism; PWV, pulse wave velocity; SLT, salt loading test; uACR, 
urinary albumin-to-creatinine ratio
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DISCUSSION
In a Dutch primary care population we screened patients with newly diagnosed 
hypertension for PA. (8) We demonstrated that the proportion of  patients with LVH was 
higher in patients with PA as compared to patients with EHT. There were no differences 
in ABI, FMD, cIMT, central aortic blood pressure, PWV, and uACR between patients 
with PA and EHT. 
The prevalence of  LVH in patients with PA is in the range of  20-60% in referral 
centres. (7, 21-23) This high proportion of  LVH in these studies may be due to persistent 
exposure to high circulating aldosterone levels, since the diagnosis and treatment of  PA 
are delayed. (6) In our study, echocardiography was performed in patients with newly 
diagnosed hypertension, with hardly any delay in the diagnosis of  PA. Our findings 
therefore suggest that in patients with PA, LVH is already present at the time of  
diagnosing hypertension. 
In addition to the increased prevalence of  LVH, LVMI was higher in patients with PA 
compared to patients with EHT after correction for gender, age and baseline blood 
pressure (Table 4). LVMI is a strong and independent predictor of  future cardiovascular 
events. (24) It has been shown that every g/m2 increase in LVMI results in a hazard ratio 
of  1.013-1.015 for the risk of  cardiovascular events in the general population. (24) 
To prevent progressive cardiovascular damage, it might be important to screen for 
PA as early as possible. However, it remains challenging when and who to screen. In 
our study there were no differences in baseline characteristics between patients with 
PA and patients with EHT. Moreover, none of  the patients with PA presented with 
hypokalemia, which is one of  criteria to screen for PA according to the Endocrine 
Society guideline. This guideline recommends screening also in case of  sustained 
blood pressure >150/100 mmHg. (3) In our cohort, 83% of  the patients with PA had 
a blood pressure above 150/100 mmHg on separate visits at the time of  diagnosing 
hypertension, which highlights the relevance of  this clinical clue in the primary care 
setting.
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Our findings of  an increased risk of  LVH in patients with PA, but lack of  differences 
in other surrogate endpoints of  target organ damage between patients with PA and 
EHT, suggests that the toxic effects of  aldosterone affect mainly the heart but not 
other organ systems. However, others have shown that patients with PA have more 
morphological and functional vascular damage and an impaired endothelial function, 
when compared to matched patients with EHT. (25-29) Importantly, the patients in these 
studies were not included at the time hypertension was diagnosed for the first time. 
Therefore, we speculate that aldosterone-mediated effects on the vascular system may 
become manifest later on, and thus might be prevented by early diagnosis and adequate 
treatment. 
The strength of  our study is that the diagnosis of  PA was made without a substantial 
delay. Furthermore, the diagnoses of  PA and EHT were based on stringent criteria, 
according to the international guideline of  the Endocrine Society. (3) Another strength 
of  our study is that we assessed cardiovascular damage using the combination of  seven 
different cardiovascular risk markers. The results of  our study might be helpful in the 
design and sample size calculation of  future prospective trials. 
A major limitation of  the study is the limited power to detect differences in outcomes 
between the study groups, except for LVH. During the two year inclusion period, 
an ARR was measured in less than 10% of  the patients with newly diagnosed 
hypertension. (8) Only nine patients were diagnosed with PA, which resulted in a lower 
power than anticipated for the current study. Our study was designed as a prospective 
cohort study, but given the lagging recruitment it has a explorative character.
Other limitations are the timing of  the vascular investigations due to logistic difficulties, 
and the ensuing difference in medication use across the groups. We assessed ABI, 
uACR and echocardiography in the patients with PA and ARRposSLTneg patients with 
EHT shortly after their diagnosis. In patients with EHT, these outcomes were assessed 
approximately 18 months after the diagnosis (Table 1). Fifty % of  these patients used 
antihypertensive drugs during a mean period of  16 ± 8 months at the time of  the 
vascular investigations. One might argue that therapy-related improvements in the EHT 
group may have accounted for the differences in LVH and LVMI between patients with 
PA and patients with EHT. However, half  of  the patients with EHT were not treated 
despite being hypertensive with, in some cases, a stage 2 hypertension (systolic blood 
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pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg). Moreover, in 
the treated patients, blood pressure control appeared to be poor. Therefore, the longer 
duration of  hypertension and the inadequate treatment in 50 % of  the patients with 
EHT, may have stimulated LVH in the control group. The fact that we still found an 
increased prevalence of  LVH in patients with PA argues for aldosterone being the 
culprit of  LVH. 
During FMD, carotid ultrasonography, PWV and central aortic blood pressure, blood 
pressure levels did not differ between patients with PA and patients with EHT, as shown 
in Table 3B. However, both patient groups used antihypertensive medications that may 
have altered the outcomes of  these vascular risk markers (Table 3B). (30)
In conclusion, we found a higher prevalence of  LVH in newly diagnosed hypertensive 
patients with PA compared to newly diagnosed patients with EHT in whom PA was 
excluded. This finding suggests that screening for PA with subsequent treatment at the 
time of  diagnosing hypertension might be useful to prevent further progression of  
cardiovascular damage. 
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ABSTRACT
Background Patients with primary aldosteronism (PA) experience more 
cardiovascular events compared to patients with essential hypertension (EHT), 
independent from blood pressure levels. In animals, mineralocorticoid receptor 
antagonists limit ischemia-reperfusion (IR) injury by increasing extracellular adenosine 
formation and adenosine receptor stimulation. Adenosine is an endogenous compound 
with profound cardiovascular protective effects.
Objective We hypothesized that patients with PA have lower circulating adenosine 
levels which might contribute to the observed increased cardiovascular risk. Secondly, 
we hypothesized that by this mechanism, patients with PA are more susceptible to IR 
compared to patients with EHT.
Methods  In our prospective study in 20 patients with PA and 20 patients with 
EHT, circulating adenosine was measured using a pharmacological blocker solution 
that halts adenosine metabolism after blood drawing. Brachial artery flow-mediated 
dilation (FMD) before and after forearm IR was used as a well-established method to 
study IR injury. 
Results Patients with PA had a 33% lower adenosine level compared to 
patients with EHT (15.3 (13.3-20.4) versus 22.7 (19.4-36.8) nmol/l respectively, p<0.01). 
The reduction in FMD after IR however, did not differ between patients with PA and 
patients with EHT (-1.0 ± 2.9 % versus -1.6 ± 1.6 % respectively, p=0.52). 
Conclusions As adenosine receptor stimulation induces various powerful 
protective cardiovascular effects, its lower concentration in patients with PA might 
be an important novel mechanism that contributes to their increased cardiovascular 
risk. We suggest that modulation of  the adenosine metabolism is an exciting novel 
pharmacological opportunity to limit cardiovascular risk in patients with PA that needs 
further exploration.
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INTRODUCTION
Primary aldosteronism (PA) is the most common cause of  secondary hypertension, 
with an estimated prevalence of  10% in the hypertensive population. (1) Importantly, 
patients with PA experience more cardiovascular events, including stroke and myocardial 
infarction, compared to patients with essential hypertension (EHT), independent from 
the blood pressure level. (2) Also, in patients without PA, a high plasma aldosterone level 
is associated with an increased risk of  cardiovascular events. (3) In patients with heart 
failure, plasma aldosterone is increased and treatment with mineralocorticoid receptor 
(MR) antagonists improve outcome. (4, 5) These observations suggest that aldosterone 
has direct adverse cardiovascular effect, over and above the detrimental effect of  blood 
pressure elevation. 
Indeed, preclinical studies have shown that aldosterone has direct adverse cardiovascular 
effects: aldosterone increases atherosclerosis and promotes plaque formation via the 
MR (6, 7), aldosterone reduces coronary blood flow (8), and aldosterone increases infarct 
size in animal models of  myocardial infarction (9), although this latter result has not 
been reported in other studies. (10, 11) In addition, the administration of  MR antagonists 
consistently reduces myocardial infarct size in these animal models. (12)
Schmidt et al recently proposed that the endogenous nucleoside adenosine might be 
involved in these detrimental effects, by showing that the cardioprotective effects of  
MR antagonists are fully dependent on adenosine receptor signaling. (10) Adenosine is 
formed by intra-, and extracellular degradation of  adenosine monophosphate by the 
enzyme ecto-5’-nucleotidase (CD73). Stimulation of  membrane-bound adenosine 
receptors induces various protective effects, including vasodilation, inhibition of  
inflammation and fibrosis, prevention of  atherosclerosis, and protection against IR-
injury. (13) Endogenous adenosine is considered a ‘retaliatory metabolite’ which protects 
the cardiovascular system in situations of  impending danger, and acts as a key mediator 
of  the infarct size-limiting effect of  several pharmacological and non-pharmacological 
strategies. (13)
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We now hypothesized that patients with PA have lower adenosine levels and that this 
contributes to their increased cardiovascular risk compared to patients with EHT. 
Secondly, we hypothesized that a lower adenosine concentration is associated with 
increased susceptibility to IR. We measured circulating adenosine concentrations and 
the activity of  the main adenosine-producing enzyme CD73 on isolated mononuclear 
cells. To study IR in humans in vivo, a safe and well-validated method is examining 
brachial artery flow-mediated dilation (FMD) before and after forearm IR. (14) This 
protocol of  IR results in an immediate decrease in brachial artery FMD, which reflects 
IR-induced endothelial dysfunction. (15, 16)
PATIENTS AND METHODS
The Radboud university medical center serves as a tertiary referral centre for PA in 
The Netherlands. The diagnosis of  PA is made according to the current international 
guideline, by aldosterone and renin measurement, followed by a confirmation test. (17) 
For the inclusion of  control patients with EHT, we asked patients from the outpatient 
clinic of  the Radboud university medical center and the Rijnstate Hospital, Arnhem, 
The Netherlands. 
All volunteers were 18-75 years of  age and provided written informed consent. 
Exclusion criteria were: a history of  atherosclerotic disease, cardiac failure, diabetes 
mellitus or severe renal dysfunction (MDRD <30 mL/min), current smoking, a 2nd or 
3rd degree atrioventricular block on electrocardiography and the usage of  drugs that 
influence adenosine formation: non-steroidal anti-inflammatory drugs, theophylline, or 
dipyridamole. An overview of  the patient selection and inclusion process is depicted 
in Figure 1. 
The study was approved by the Institutional Review Board of  our centre and conducted 
in accordance with Good Clinical Practices and the Declaration of  Helsinki. We 
prospectively registered our study at ClinicalTrials.gov by number NCT 01978132. 
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FIGURE 1. Overview of the selection process of patients 
DIAGNOSIS OF PA AND EHT
Concordant with the guideline of  the Endocrine society, no antihypertensive drugs 
other than calcium channel blockers, doxazosin and/or hydralazin were taken in the 4 
(for spironolactone, eplerenone, amiloride, triamterene or aliskiren) or 2 (for all other 
antihypertensive drugs) weeks prior to aldosterone and renin measurements. (17)
In the Radboud university medical center, plasma active renin concentration was measured 
by an immunoradiometric assay (RENIN III generation, CIS Bio International). Serum 
aldosterone concentration was measured after extraction and paper chromatography 
Analysis FMD (n=19)
• no post-IR, but pre-IR only (n=1)
• Analysis of circulating adenosine 
(n=17)
Analysis of FMD (n=19)
• Analysis of circulating adenosine 
(n=14)
• excluded from analysis (FMD and 
adenosine) due to a caffeine level >1 
mg/l (n=1)
Not eligible (n=176)
• not meeting inclusion criteria (n=77)
• declined to participate (n=36)
• diagnosis uncertain (based on ARR or 
salt loading test) (n=14)
• unable to switch drugs (n=30)
• other reasons (n=19)
Patients with EHT (n=20)Patients with PA (n=20)
FMD (n=19) and adenosine measurement 
(n=17)
• drop out due to intolerance to 
diltiazem (n=1)
• no post-IR FMD due to adverse event 
(n=1)
• unfeasible to draw blood using the 
purpose-built syringe (n=2)
Enrollment
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Inclusion
Assessed for eligibility (n=216)
• patients with PA (n=141)
• patients with EHT (n=75)
FMD (n=20) and adenosine measurement 
(n=15)
• technical failure in adenosine 
measurement (n=2)
• unfeasible to draw blood using the 
purpose-built syringe (n=3)
Experiment
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with recovery correction, as described earlier. (18) In patients from the Rijnstate Hospital, 
plasma aldosterone and plasma renin acticity were measured by radioimmunoassays 
(Labor Stein, Mönchengladbach, Germany and IJsselland Hospital, Capelle a/d IJssel, 
The Netherlands respectively). 
Patients with PA had a baseline aldosterone level of  >0.42 nmol/l and ARR level of  
>0.09 nmol/mU. In all patients with PA the diagnosis was confirmed by a salt loading 
test (aldosterone concentration > 0.28 nmol/l after infusion of  2 L of  saline in 4 hours). 
Patients with confirmed PA underwent sequential adrenal venous sampling of  the right 
and left adrenal vein during cosyntropin infusion to assess uni- or bilateral aldosterone 
overproduction. Criteria for a unilateral aldosterone overproduction were met when 
the left versus right (or vice versa) aldosterone-cortisol-ratio was ≥4.0 and the ratio of  
the contralateral site was ≤1.0, as an indication for contralateral suppression. Of  the 
patients with unilateral aldosterone overproduction who underwent adrenalectomy, we 
screened the pathology reports. 
In all patients with EHT, PA was excluded by a baseline aldosterone concentration of  
<0.42 nmol/l and ARR value of  <0.09 nmol/mU or <0.65 nmol/l per ng/ml/hr.
EXPERIMENTAL DESIGN 
We performed the experiments shortly after the diagnosis of  PA was confirmed. 
Upon screening, most patients with EHT used various antihypertensive drugs. In both 
patients with PA and EHT, we changed the antihypertensive medication into diltiazem, 
with or without doxazosine or hydralazin, to minimize variation in medication and to 
exclude effects on the experiments. (19) At least one week after the change in medication, 
we draw blood to determine the adenosine concentration and performed the FMD 
experiment (see below). Since statins are known to upregulate CD73, these drugs had 
to be temporarily withdrawn during at least one week before the experiments. (20) In 
addition, we aimed to avoid hypokalemia during the FMD experiment by potassium 
suppletion, if  needed. 
On the experimental day, patients took their medication, except for potassium 
suppletion, after brachial FMD measurement, to avoid interference of  these drugs in 
FMD assessment. (21) 
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CIRCULATING ADENOSINE CONCENTRATION
It is notoriously difficult to measure circulating adenosine, because of  the extremely 
short half  life, necessitating immediate pharmacological blockade of  adenosine 
metabolism as soon as blood is withdrawn. We used a state-of-the-art technique, which 
we validated previously. (22) Using a purpose-built syringe, the blood mixes immediately 
at the end of  the needle with a solution containing pharmacological blockers of  the 
proteins involved in adenosine formation, transport, and degradation. 
In more detail, we drew 2.5 mL of  blood before the start of  the experiment that was 
immediately mixed with a 2.5 mL solution containing 40 µmol/L dipyridamole (Sigma), 
10 µmol/L erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (Sigma), 10 µmol/L 
5-iodotubercidin (Biomol), 11.5 µmol/L forskolin (Fluka) and 115 µmol/L IBMX 
(Sigma), buffered in 13.2 mmol/L Na2EDTA, 118 mmol/L NaCl, and 5 mmol/L KCl; 
pH 7.4. 
The hemocrit of  this solution was measured in order to correct for dilution. We directly 
centrifugated the blood mixed with blockers for 10 minutes at 1000 g, at 4 °C. The 
plasma was then stored at -80 °C until analysis. 
After derivatization with chloroacetaldehyde, the formed 1,N6-ethenoadenosine 
concentration was analyzed using reversed-phase high performance liquid 
chromatography and fluorescence detection with excitation and emission wavelength 
set at 280 nm and 420 nm. Separation took place on a Polaris column (Varian, Polaris 
3 µm C18-A 150 x 4.6 mm) with a mobile phase containing 50 mmol/L NH4H2PO4 5 
mmol/l of  hexane sulfonic acid (pH 3.0). Acetonitril was used as the organic modifier.
 
CD73 ACTIVITY ON MONONUCLEAR CELLS
Before start of  the FMD experiment, we drew blood for the isolation of  mononuclear 
cells. We used Cell Preparation Tubes (CPT 8 mL, BD Vacutainer) for the separation 
of  mononuclear cells from whole blood. Within 2 hours after blood collection, we 
centrifuged the tubes for 20 minutes at 1600 g, at 20 °C without brake. We transferred 
the layer of  mononuclear cells and washed the cells twice using phosphate buffered 
saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4; pH 7.4). 
Subsequently, we resuspended the mononuclear cells in 0.5 mL Hank’s balanced salt 
solution (HBSS, Gibco by Life Technologies) at room temperature. We determined the 
activity of  CD73 exposed on the surface of  these intact mononuclear cells measuring 
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the conversion of  1,N6-ethenoadenosine 5’-monophosphate to 1,N6-ethenoadenosine 
with HPLC as previously described. (20) 
ADDITIONAL BLOOD DRAWING 
Before start of  the experiment we drew blood to determine plasma potassium levels 
and caffeine concentrations, as described previously. (23) Subjects with a circulating 
caffeine concentration >1.0 mg/l were excluded from analysis, since caffeine is a potent 
adenosine receptor antagonist. (24)
FLOW-MEDIATED DILATION (FMD)
All FMD experiments were performed in the morning, after an overnight fast and after 
24 hours of  alcohol and caffeine abstinence. 
We measured the brachial blood pressure in the supine position using a manual 
sphygmomanometer, in a quiet room after a period of  five minutes rest. We measured 
the blood pressure 3 times and reported the mean of  the second and third blood 
pressure measurement. 
An experienced sonographer, who was blinded for the diagnosis, examined brachial 
FMD in a darkened, temperature-controlled room of  22.3±0.5 °C, after a minimum 
time of  rest of  15 minutes after venipuncture. We used a 10-MHz multifrequency 
linear-array probe attached to a high-resolution ultrasound machine (Terason T3000, 
Burlington, MA), according to the guideline of  Thijssen et al. (21) 
The patients rested in a supine position with both arms extended and immobilized, 
supported at an angle of  ~80° abduction from the torso. For the assessment of  FMD, 
we positioned a rapid inflation/deflation pneumatic cuff  distal to the olecranon process 
to provide an ischemic stimulus distal from the brachial artery, leading to reactive 
hyperemia and subsequent shear stress. We imaged the brachial artery in the distal third 
of  the upper arm. We recorded baseline diameter and blood flow velocity during 1 
minute. This was followed by inflation of  a pneumatic cuff  around the forearm for 5 
minutes to a pressure of  200 mmHg. We captured changes in brachial artery diameter, 
blood flow velocity and shear rate 30 seconds before cuff  deflation until 3 minutes 
post-deflation continuously. 
For the assessment of  endothelial IR injury, we positioned the rapid inflation/deflation 
cuff  around the upper arm and inflated the cuff  to a pressure of  200 mmHg (or 
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50 mmHg above systolic blood pressure (SBP)) during 20 minutes, followed by 20 
minutes of  reperfusion. After this period of  IR, we repeated the FMD measurements 
as described above. 
Analysis of  the brachial artery diameter was performed offline, in a blinded fashion, 
using custom-designed edge-detection and wall-tracking software, which is independent 
of  investigator bias. (25) Baseline data were calculated across the 1 minute preceding 
cuff  inflation. We used the automatically detected peak diameter after cuff  deflation to 
express the FMD as the % change in diameter ((peak diameter after deflation - baseline 
diameter)/baseline diameter x 100 %). Other outcome measures that were assessed 
include time to peak (sec) and shear rate (area under the curve). 
STATISTICAL ANALYSIS
In a recent study with a similar experimental design, we observed a reduction in FMD 
by forearm IR injury from 6.4 % to 4.4 %. (26) The average reduction in FMD by IR 
was 2.0 % (standard deviation (SD) 2.4 %). To demonstrate a two-fold increase in IR-
damage with an alpha of  0.1 and a power of  80%, a sample size of  18 patients per 
group was required. To account for drop outs, we included 20 patients in both groups. 
We used IBM SPSS Statistics 22 for the analysis of  the data. We expressed normally 
distributed variables as mean ± SD and non-normally distributed variables as median 
(interquartile range). The baseline characteristics were compared using an independent 
t-test for normally distributed values and a Mann-Whitney Test for non-normally 
distributed variables. We assessed differences between proportions with the Pearson 
chi-square test or Fisher’s exact for smaller proportions. We assumed a significance level 
of  ≤0.05. 
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RESULTS
PATIENTS
We included 5 patients with EHT from the Rijnstate Hospital. All other patients (20 
patients with PA and 15 patients with EHT) were recruited from the Radboud university 
medical center. 
As expected, baseline aldosterone, ARR and plasma potassium levels differed significantly 
between patients with PA and patients with EHT. There were no differences regarding 
other baseline characteristics (Table 1). 
Of  the 20 patients with PA, 13 patients had unilateral aldosterone overproduction and 
7 patients had bilateral aldosterone overproduction. 
One patient with EHT dropped out because of  intolerance to diltiazem. In one patient 
with EHT we ended the experiment during the period of  upper arm ischemia, because 
of  sudden appearance of  petechiae of  the ischemic arm. Most likely this was caused 
by a rise in SBP during upper arm occlusion, leading to venous congestion in the arm. 
During follow up, this patient recovered without any symptoms or complaints. We had 
to exclude one patient with PA from the analysis, because of  a circulating caffeine 
concentration >1.0 mg/l. 
On the experimental day, blood pressure and the daily defined dosage of  antihypertensive 
drugs did not differ between patients with PA and patients with EHT (Table 2). Among 
the 19 patients with PA, there was no need for antihypertensive therapy in 6 patients. 
Eleven patients used diltiazem, one patient used diltiazem plus doxazosin and one patient 
used diltiazem, doxazosin and hydralazin. Of  the 19 patients with EHT, 9 patients did 
not use any antihypertensive drug before FMD measurement, 8 used diltiazem only and 
2 patients used diltiazem plus doxazosin.
Despite the usage of  potassium suppletion in 17 of  19 patients with PA, plasma 
potassium values were slightly lower than in patients with EHT (Table 2). 
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Table 1. Baseline characteristics
PA 
(n=20)
EHT 
(n=20) p-value
Demographics
Male (%) 12 (60) 13 (65) 1.00
Mean age (SD) 50.9 (12.2) 48.4 (14.6) 0.21
Screening
Mean SBP (SD) 155 (19) 155 (25) 1.00
Mean DBP (SD) 91 (14) 91 (12) 0.88
Mean heart rate (SD) 71 (17) 70 (13) 0.86
Median duration of known hypertension in years (IQR) 7.5 (2.6-12.5) 6.0 (4.0-11.5) 0.84
Median baseline aldosterone in nmol/l (IQR) 0.81 (0.61-0.93) 0.22 (0.11-0.28) <0.01
Median baseline ARR in nmol/mU (IQR) (n=15) 0.22 (0.17-0.25) 0.01 (0.01-0.02) <0.01
Median baseline ARR in nmol/l per ng/ml/hr (IQR) (n=5) - 0.41 (0.15-0.49) -
Mean plasma sodium in mmol/l (SD) 141.9 (2.7) 141.0 (1.7) 0.14
Median plasma potassium (IQR) 3.8 (3.6-4.0) 4.0 (3.8-4.1) 0.03
Median plasma creatinine in µmol/l (IQR) 75.0 (68.0-84.0) 84.5 (71.5-89.5) 0.13
Median kidney function (MDRD) in ml/min (IQR) 84 (76-91) 79 (75-91) 0.57
Mean total plasma cholesterol in mmol/l (non-fasting) (SD) 5.2 (1.0)n=19*
4.9 (1.0)
n=19* 0.33
Median plasma glucose in mmol/l (non-fasting) (IQR) 5.3 (4.9-5.9)n=20
5.2 (4.8-5.8)
n=18† 0.59
Risk factors
History of smoking (%) 8 (40) 10 (50) 0.75
Median units of alcohol per week (IQR) 3.5 (0-7.0) 2.0 (0-10.0) 0.67
Mean BMI (SD) 27.5 (5.6) 27.4 (4.3) 0.96
Dyslipidemia (%) 4 (20) 6 (30) 0.72
1st grade family history of hypertension or CVD (%) 12 (60) 16 (80) 0.30
* in 1 patient a value of a fasting (versus non-fasting) cholesterol was available
† in 2 patients a value of a fasting (versus non-fasting) glucose value was available
Abbreviations: BMI, body mass index; CVD, cardiovasculair disease; DBP, diastolic blood pressure; IQR, interquartile 
range; MDRD, modification of diet in renal disease; PY, pack years; SBP, systolic blood pressure
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Table 2. Clinical parameters at the moment of FMD measurement
PA 
(n=19)
EHT 
(n=19)
p-value
Mean potassium value in mmol/l (SD)* 3.5 (0.3) 3.9 (0.4) <0.01
Mean SBP in mmHg (SD) 158 (19) 155 (21) 0.66
Mean DBP in mmHg (SD) 96 (9) 93 (10) 0.37
Median heart rate in x/min (IQR) 64 (60-68) 60 (60-68) 0.47
Median number of antihypertensive drugs (IQR) 1 (0-1) 1 (0-1) 0.31
Median DDD antihypertensive drugs (IQR) 0.83 (0.00-1.00) 0.75 (0.00-0.83) 0.20
Mean duration in min between reperfusion and post-FMD 
measurement (SD) †
21.7 (1.9) 22.7 (2.7) 0.20
* n=18 in both patient groups
† no post-IR FMD measurement is available in 1 patient with EHT
Abbrevations: DBP, diastolic blood pressure; DDD, daily defined dosage; IQR, interquartile range; SBP, systolic blood 
pressure
CIRCULATING ADENOSINE LEVELS
Levels of  circulating adenosine were measured in 17 patients with EHT (11 male) and 
14 patients with PA (9 male). Next to the earlier mentioned 2 drop outs, we were not 
able to draw blood using the purpose-built syringe in n=5. In 2 other patients, we did 
not obtain a circulating adenosine concentration due to technical failures. 
The sex distribution, age, and blood pressure did not differ significantly between the 14 
patients with PA and 17 patients with EHT (data not shown). 
As depicted in Figure 2, the concentration of  circulating adenosine was 15.3 (13.3-20.4) 
nmol/l in patients with PA and 22.7 (19.4-36.8) nmol/l in patients with EHT (p=0.008). 
CD73 ACTIVITY 
There was no significant difference in CD73 activity of  intact mononuclear cells of  
patients with PA versus patients with EHT. Patients with PA had a CD73 activity of  
0.43 (0.19-0.55) versus 0.54 (0.33-0.80) nmol/min per mg protein in patients with EHT; 
p=0.21. 
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FIGURE 2. Circulating adenosine concentrations in nmol/l 
Table 3. Brachial artery characteristics before and after IR
Pre-IR Post-IR p-values
PA 
(n=19)
EHT 
(n=19)
PA 
(n=19)
EHT 
(n=18)* Pre-IR Post-IR
Mean brachial artery 
diameters in mm (SD)
0.422 (0.074) 0.418 (0.084) 0.469 (0.084) 0.431 (0.081) 0.86 0.18
Mean FMD  
in mm (SD)
0.441 (0.076) 0.437 (0.083) 0.483 (0.081) 0.445 (0.080) 0.90 0.16
Mean FMD in % (SD) 4.4 (2.1) 4.9 (1.9) 3.3 (2.3) 3.3 (2.0) 0.47 1.00
Median time 
to peak in sec (SD)
54 (38-89) 50 (40-74) 63 (32-75) 50 (31-77) 0.58 0.73
Mean shear rate  
AUC (SD)
21945 (10103) 19968 (8572) 17623 (11737) 19293 (11910) 0.52 0.67
* no post-IR FMD measurement is available in 1 patient with EHT
FMD MEASUREMENT
Brachial artery characteristics before and after IR are shown in Table 3. FMD (peak 
diameter after cuff  deflation), the % FMD, time to peak and shear rate did not differ 
significantly between patients with PA and patients with EHT before and after IR. In 
patients with EHT, % FMD decreased significantly after IR (4.9 ± 1.9 to 3.3 ± 2.0 %, 
p=0.001). The decrease in % FMD was not significant within the group of  patients with 
PA (4.4 ± 2.1 to 3.3 ± 2.7, p=0.14). 
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Post-IR % FMD minus pre-IR % FMD did not differ between patients with PA and 
patients with EHT (-1.0 ± 2.9 % versus -1.6 ± 1.6 % respectively, p=0.52). 
DISCUSSION
In the present study, we show for the first time that patients with PA have lower levels 
of  circulating adenosine compared to patients with EHT. Since adenosine has potent 
cardiovascular protective properties, this mechanism could, at least in part, contribute 
to the increased risk of  cardiovascular complications in patients with PA compared to 
patients with EHT, and might offer novel potential targets for drug treatment. 
Adenosine is an endogenous purine nucleoside with several beneficial effects on the 
cardiovascular system, including vasodilation, anti-atherosclerotic effects, inhibition 
of  inflammation, fibrosis, and limitation of  IR-injury. (27) The importance of  these 
effects is highlighted by previous studies reporting that genetic variants in the 
adenosine metabolism leading to increased endogenous adenosine formation improve 
cardiovascular survival in patients with coronary artery disease. (28) 
Given these beneficial effects of  adenosine receptor stimulation, it is logical to assume 
that a reduction in circulating adenosine impairs cardiovascular function. In line with 
this, we previously reported that patients with severe hyperhomocysteinemia, in whom 
the risk of  cardiovascular events is strongly increased, adenosine-induced vasodilation 
is impaired due to an increased uptake of  adenosine into the intracellular compartment, 
limiting adenosine receptor stimulation. (29) 
In our study, we have now shown that also in patients with PA the endogenous adenosine 
concentration is reduced. We therefore propose that modulation of  the adenosine 
metabolism might prove to be an exciting and novel pharmacological approach to 
reduce the excess risk of  cardiovascular events in patients with PA. We previously 
showed that treatment with MR antagonists does not increase extracellular adenosine 
formation in healthy humans in vivo. (30) It is of  great interest to explore the effects 
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of  drugs known to increase extracellular adenosine levels, including dipyridamole or 
statins, in patients with PA. (31, 32) 
The circulating concentration of  adenosine is the sum of  adenosine production, cellular 
uptake, and intracellular degradation. Activity of  the enzyme CD73, which catalyzes 
the extracellular formation of  adenosine from adenosine monophosphate, did not 
differ between the patients with PA and EHT. Therefore, increased cellular uptake and 
degradation of  adenosine most probably explains the lower adenosine concentration, 
comparable to patients with hyperhomocysteinemia. (29) Future studies should focus on 
unravelling the metabolic changes driving lower adenosine levels, to be able to predict 
how these levels can be increased pharmacologically. 
Since adenosine is known to limit IR injury, we subsequently hypothesized that the 
susceptibility to IR is higher in patients with PA. However, in our study, lower levels of  
circulating adenosine were not associated with increased susceptibility to endothelial IR. 
There are several potential explanations for this finding. First, the beneficial effect of  
adenosine on IR injury is controversial, at least in humans in vivo. Whilst administration 
of  adenosine before reperfusion diminished IS in patients with an anterior wall 
MI (33, 34), several preclinical studies (35-37) and clinical studies (38, 39) failed to show an effect 
of  exogenous adenosine on IR injury. In addition, even if  enhanced adenosine receptor 
stimulation might limit IR injury, this does not necessarily mean that a reduction in 
adenosine receptor stimulation would augment IR injury, particularly considering the 
fact that many endogenous substances regulate IR susceptibility. For example, adenosine 
receptor antagonists did not increase infarct size itself  in preclinical models of  IR 
injury (10), although these antagonists did significantly prevent the beneficial effects of  
ischemic pre-conditioning and post-conditioning. (40, 41)
Future studies in patients with PA should therefore not focus on IR injury, but on 
alternative determinants of  cardiovascular damage. An attractive topic to study is 
atherosclerosis for several reasons. First, patients with PA have an increased risk of  
atherosclerotic complications, including myocardial infarction and stroke, compared to 
patients with EHT. (2) Second, in animal models aldosterone increases atherosclerosis 
and promotes plaque formation via the MR. (6, 7) Third, adenosine has anti-atherosclerotic 
properties (13) and in genetic deletion models, inactivation of  the adenosine metabolism 
leads to progression of  atherosclerosis (42). We therefore propose that the reduced 
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circulating adenosine levels in patients with PA may, at least in part, contribute to 
progression of  atherosclerosis. 
Our study benefits from the use of  stringent criteria for the diagnosis of  PA and EHT, 
detailed clinical characterisation of  the patients, and much care to avoid the use of  
interfering antihypertensive and cholesterol lowering drugs. In addition, having a long 
tradition in human in vivo research on adenosine, we used optimal and well-validated 
methods to detect circulating adenosine. Finally, FMD was measured according to 
expert consensus guidelines that were developed by one of  the authors. (21) 
Nevertheless, some aspects of  our methods and results merit critical discussion. First, 
we studied endothelial IR injury in the forearm vasculature and not directly in myocardial 
tissue. Despite important differences between brachial and coronary arteries however, 
brachial FMD accurately reflects coronary endothelial function (21, 43), and brachial 
FMD is a good predictor of  future cardiovascular events. (44) The reduction in FMD 
immediately after a period of  forearm ischemia has been well-validated in the literature 
to reflect endothelial IR-injury, which can be prevented by strategies that are known to 
also limit histological myocardial infarct size in animal models. (14, 45) 
Secondly, we did not observe a difference in baseline FMD between patients with 
PA and patients with EHT. This is in contrast to previous clinical studies in these 
patients. (46-48) Several explanations can be found for the discrepancies between our study 
and these studies. In contrast to the study of  Nishizaka et al, we used stringent diagnostic 
criteria for PA and EHT, concordant to international guidelines. (46) Importantly, we 
standardized antihypertensive treatment to diltiazem with or without hydralazin and/or 
doxazosin. In previous studies (46-48), different antihypertensive drugs may have modulated 
endothelial function and therefore, their results have to be interpreted with caution. 
(49) Furthermore, the above mentioned studies do not describe any dietary restrictions 
before FMD measurement. (46-48) In our study, patients were 24 hours free of  alcohol and 
caffeine before FMD measurement, as recommended in the expert guideline. (21) Next, 
we excluded patients with an history of  cardiac failure, atherosclerotic disease, severe 
renal dysfunction, diabetes mellitus and/or current smoking. Chou and colleagues do 
not describe any of  these baseline characteristics. (48) It is therefore unclear whether 
the presence of  co-morbidities may have led to the observed difference in baseline 
FMD between patients with PA and EHT. (48) Finally, in the study by Matsumoto et 
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al, a reduction in % FMD was seen only in those patients with PA who suffered from 
aldosterone producing adenomas, and not idiopathic aldosteronism.(47) Likewise, of  the 
35 patients with PA in the study by Chou et al, 91 % had an aldosterone producing 
adenoma.(48) The percentage of  patients with a histologically proven unilateral 
aldosterone producing adenoma in our study was smaller, namely 53 %. Nevertheless, 
we did not observe differences in baseline FMD between the patients with unilateral 
aldosterone producing adenoma and bilateral aldosterone overproduction (4.8 ± 1.9 % 
versus 4.3 ± 2.5 % respectively; p=0.67). Interestingly, we did observe a trend towards 
an increased susceptibility to IR in the subset of  patients with a unilateral aldosterone 
producing adenoma. FMD decreased from 4.8 ± 1.9 % to 2.6 ± 2.2 % in patients with 
a histologically proven unilateral producing adenoma compared to 4.3 ± 2.5 % to 3.8 ± 
1.7 in patients with bilateral aldosterone overproduction; p=0.13. Circulating adenosine 
concentrations did not differ between the patients with a histologically proven unilateral 
producing adenoma and the patients with bilateral aldosterone overproduction (data 
not shown). 
In conclusion, patients with PA have lower levels of  circulating adenosine compared 
to patients with similar blood pressure levels due to EHT. This mechanism provides a 
novel and exciting explanation for the increased risk of  cardiovascular events in patients 
with PA, compared to patients with EHT. Drugs beneficially affecting the adenosine 
metabolism could therefore potentially reduce the risk of  future cardiovascular events 
in patients with PA. 
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ABSTRACT
 
Background The incidence of  cardiovascular events is higher in patients with 
primary aldosteronism (PA) than in patients with essential hypertension (EHT), 
despite similar blood pressure levels. This suggests detrimental cardiovascular effects 
of  aldosterone. Amongst others, it has been suggested that galectin-3 (Gal-3) is a key 
mediator in aldosterone-induced myocardial fibrosis. 
Objective We studied whether patients with PA have higher plasma Gal-3 
concentrations than patients with EHT, and evaluated its reversibility after adrenalectomy.
 
Methods In a retrospective cohort from our tertiary referral centre, we 
measured plasma Gal-3 concentrations in 78 patients with PA, 39 cured PA patients 
after adrenalectomy, and 56 patients with EHT. Paired samples were available in 11 
patients (pre- and post-adrenalectomy). We compared plasma Gal-3 levels by univariate 
analysis of  covariance with correction for cardiovascular risk factors, plasma creatinine 
concentration, plasma potassium levels and alcohol intake. 
Results Adjusted plasma Gal-3 concentrations in patients with PA, patients 
after adrenalectomy, and patients with EHT were 11.39 ± 0.60, 11.64 ± 0.81, and 
11.41 ± 0.73 ng/mL respectively (mean ± SD; p=0.95). In 11 patients of  whom paired 
samples were available, mean Gal-3 concentrations increased from 10.03 ± 1.67 ng/mL 
pre-adrenalectomy to 14.36 ± 2.07 ng/mL post-adrenalectomy (p<0.01). 
Conclusions  In patients with PA, plasma Gal-3 concentrations are not elevated 
when compared to patients with EHT, and levels do not decrease after adrenalectomy. 
These results are in contrast to previous studies and do not support a pathophysiological 
role of  plasma Gal-3 in the increased cardiovascular risk in patients with PA.
Plasma galectin-3 concentrations in patients with primary aldosteronism
87
2.3
INTRODUCTION
Primary aldosteronism (PA) is the most common cause of  secondary hypertension. 
PA is characterized by high circulating aldosterone and low renin levels, indicating the 
autonomous overproduction of  the mineralocorticoid hormone aldosterone, which 
increases blood pressure by stimulating renal sodium reabsorption. Importantly, patients 
with PA have an increased risk for cardiovascular events, including atrial fibrillation, 
stroke, heart failure and myocardial infarction, compared to patients with essential 
hypertension (EHT) with comparable blood pressure levels. (1, 2) Also in patients 
without PA, plasma aldosterone and the aldosterone-renin-ratio (ARR) is positively 
associated with an increased risk of  cardiovascular events. (3) These findings suggest 
that aldosterone has direct adverse effect on the cardiovascular system, independent 
from its blood pressure-increasing effect. 
Indeed, preclinical studies have provided data that aldosterone has direct adverse 
cardiovascular effects, such as promoting apoptosis, vasoconstriction and increasing 
the infarct size in animal models of  myocardial infarction. (4-7) Administration of  
mineralocorticoid receptor (MR) antagonists consistently reduces myocardial infarct 
size in these animal models. (7-11) Furthermore, aldosterone stimulates vascular and 
myocardial fibrosis and hence plays an important pathophysiological role in remodeling 
of  the heart and vessel wall. (12-15) 
Galectin-3 (Gal-3) has recently been proposed as a mediator of  aldosterone-induced 
myocardial fibrosis. This β-galactoside-binding lectin is expressed in epithelial cells, cells 
of  the immune system (predominantly macrophages (16)), fibroblasts, vascular smooth 
muscle cells (VSMC), cardiomyocytes and endothelial cells. (17, 18) Consistent with the 
expression in various cell types, Gal-3 is involved in a variety of  processes, such as cell 
growth, apoptosis, cell-cell adhesion, and cell-matrix interactions. (19) Various factors are 
involved in the regulation of  Gal-3 expression, including activation of  the transcription 
factor NF-κB, activation of  HIF-1α, integrins and various pro-inflammatory 
cytokines. (20) In addition, in vitro studies and experimental murine studies have reported 
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that aldosterone can stimulate Gal-3 secretion and expression in VSMC, fibroblasts, 
macrophages, and cardiac homogenates via MR activation, and that Gal-3 mediates the 
pro-fibrotic effects of  aldosterone. (15, 21-23)
In patients with heart failure, circulating Gal-3 is associated with extracellular matrix 
markers and with adverse long-term cardiovascular outcomes. (24, 25) Aldosterone levels 
are increased and treatment with MR antagonists improves outcome in these patients. 
However, several studies in HF patients could not detect an interaction between the use 
of  MR antagonists and Gal-3 levels, which contradicts a linear relationship between the 
suggested MR mediated effects of  aldosterone and Gal-3. (26-28)
In summary, aldosterone promotes vascular and myocardial fibrosis and preclinical 
studies have demonstrated that this is mediated by Gal-3 production and secretion. 
Patients with overproduction of  aldosterone suffer from more cardiovascular damage, 
including left ventricular hypertrophy (LVH) and heart failure, than patients with EHT. 
It is currently unknown whether this organ damage is mediated by Gal-3. 
Based on the pre-clinical and mechanistic studies, we propose that aldosterone excess 
stimulates Gal-3 secretion in various cells of  the cardiovascular and immune system, 
and that subsequently Gal-3 induces pro-fibrotic and pro-atherogenic effects in the 
vascular wall and myocardium. This mechanism could contribute to the increased 
prevalence of  cardiovascular adverse events in patients with PA compared to patients 
with EHT. To explore this hypothesis, we measured circulating Gal-3 concentrations in 
well-characterized patient groups with PA, EHT, and patients who were cured from PA 
(post-adrenalectomy). 
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METHODS
The Radboud university medical center serves as a tertiary referral centre for PA in 
the Netherlands. Patients with refractory hypertension are screened for PA according 
to current guidelines, by serum aldosterone and plasma renin measurement. Residual 
plasma samples are routinely stored for 2 years at -20 °C. We carefully selected patients 
from the outpatient clinic of  our hospital with PA, EHT or after cure from PA to 
measure Gal-3 in residual plasma. The study protocol was approved by the Institutional 
Review Board of  our centre. 
SAMPLE SELECTION
We selected all serum aldosterone and/or plasma renin measurements that had been 
performed in the period of  July 2014 to July 2015 (n=2432) and then excluded samples 
derived from patients from other hospitals, repeated samples per patient, children 
below 18 years of  age, samples lacking aldosterone measurements and patients with 
adrenal venous sampling (AVS) only (i.e. patients referred for AVS in whom no baseline 
aldosterone and renin were measured in our centre). Furthermore, we excluded patients 
with high aldosterone concentrations (>0.42 nmol/L), but low ARR values (<0.09 
nmol/mU), because these values are suggestive for secondary hyperaldosteronism. Of  
the 195 remaining evaluable patients, we selected patients who underwent a salt loading 
test (SLT) for confirmation of  PA (n=79), and also patients with normal baseline 
aldosterone and ARR values (<0.42 nmol/L and 0.09 nmol/mU respectively) (n=116). 
This latter group of  patients with normal aldosterone and ARR has been used as the 
control group of  patients with EHT. 
Patients using antihypertensive medication that affects the aldosterone concentration, 
or patients who did not suffer from PA or EHT were excluded. In addition to these 
samples, we collected samples from patients with proven PA and EHT from the 
Department of  Vascular Medicine from our hospital that were obtained before or after 
July 2014 (n=88). In 11 PA patients, a paired sample after adrenalectomy was available. 
We included these 11 patients in both the PA group (sample pre-adrenalectomy) and 
post-adrenalectomy group (sample after adrenalectomy). See Figure 1 for an overview 
of  the selection process.
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FIGURE 1. Flow of the selection process of the samples for Gal-3 measurements 
* 11 patients are included in the PA- and post-adrenalectomy group 
Abbrevations: APA, aldosterone producing adenoma; ARR, aldosterone-renin-ratio; AVS, adrenal venous sampling; EHT, 
essential hypertension; PA, primary aldosteronism; SLT, salt loading test
DIAGNOSIS OF PA AND EHT
Concordant with the recently updated guideline of  the Endocrine society and our local 
protocol, no antihypertensive drugs other than calcium channel blockers, doxazosin 
and/or hydralazin were taken in the four (for spironolactone, eplerenone, amiloride, 
triamterene or aliskiren) or two (for all other antihypertensive drugs) weeks prior to 
aldosterone and renin measurements. (29) When baseline aldosterone values exceeded 
0.42 nmol/L and the ARR exceeded 0.09 nmol/mU, a SLT was performed by infusion 
of  2 liters of  saline in 4 hours. PA was confirmed when the serum aldosterone level was 
>0.28 nmol/L after this test. Patients with EHT had a baseline serum aldosterone of  
<0.42 nmol/L and an ARR value of  <0.09 nmol/mU, or a negative SLT (aldosterone 
< 0.14 nmol/L after saline infusion). 
All aldosterone and renin 
measurements from July 
2014-July 2015 (n=2432)
Screening of medical 
records of remaining 
patients (n=195)
Patients with low 
aldosterone and ARR 
values (n=116)
Patients in whom a SLT 
had been performed 
(n=79)
Exclusion (n=65)
• Interfering 
medication or 
diagnosis other than 
PA or EHT (n=65)
Exclusion (n=2237)
• Patients from other hospitals (n=989)
• Repeated measurements per patient 
(n=601)
• Children <18 years (n=128)
• Patients in whom only renin (no 
aldosterone) was measured (n=239)
• Measurements during AVS only (n=81)
• Patients suggestive for having secondary 
hyperaldosteronism (n=199)
Exclusion (n=17)
• Secondary 
hyperaldosteronism (n=2)
• Doubtful result SLT (n=15)
Eligible patients (n=51)
• Residual plasma 
available in n=33
Eligible patients (n=62)
• Residual plasma 
available in n=41
Addition of patients diagnosed 
before and after July 2014 
(n=88)
Patients with PA (n=78*), cured PA patients after 
adrenalectomy (n=39*) and patients with EHT (n=56)
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Patients with PA underwent sequential AVS of  the right and left adrenal vein during 
cosyntropin infusion to assess uni- or bilateral aldosterone overproduction. A technically 
successful AVS was determined by an adrenal vein to peripheral vein cortisol ratio of  
>3. Criteria for a unilateral aldosterone overproduction were met when the left versus 
right (or vice versa) aldosterone-cortisol-ratio was ≥4.0 and the ratio of  the contralateral 
site was ≤1.0, as an indication for contralateral suppression. Of  the patients with a 
suspected unilateral aldosterone producing adenoma (APA), we screened the pathology 
reports to see whether the histology findings were in line with the diagnosis. 
ANALYTICAL METHODS
Plasma renin and serum aldosterone concentrations were measured by the Department 
of  Laboratory Medicine of  our centre. Plasma active renin concentration was measured 
by an immunoradiometric assay (RENIN III generation, CIS Bio International). Serum 
Aldosterone concentration was measured after extraction and paper chromatography 
with recovery correction, as described earlier. (30) 
Plasma Gal-3 levels were quantified in a blinded fashion using an enzyme-linked 
immunosorbent assay (BG medicine, Inc, Waltham, MA, USA). Intra-assay and 
interassay coefficients of  variation of  this assay are 3.2% and 5.6% respectively, with a 
lower detection limit of  1.13 ng/mL and an upper detection limit of  96.6 ng/mL, as 
published. (31) 
CLINICAL PATIENT DATA
We screened the medical records of  all included patients and collected the following 
data: the number of  years of  known hypertension, medication use, cardiovascular risk 
factors (body mass index (BMI), smoking, diabetes mellitus (DM), (family) history 
of  cardiovascular diseases (CVD), and dyslipidemia), alcohol use and if  available, the 
findings on echocardiography. The antihypertensive medication was expressed in a daily 
defined dose (DDD), as defined by the World Health Organisation (www.whocc.no/
atc_ddd_index/). Furthermore, we recorded plasma creatinine levels, urinary albumin, 
systolic blood pressure (SBP), diastolic blood pressure (DBP), serum aldosterone, 
plasma renin, and plasma potassium levels. Apart from urinary albumin, these values 
were obtained just before or at the time at which the plasma samples, used for Gal-3 
measurement, were collected. 
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STATISTICAL ANALYSIS
We used IBM SPSS Statistics 22 for the analysis of  the data. We depicted normally 
distributed variables as mean ± SD and non-normally distributed variables as median 
(interquartile range (IQR)). The baseline characteristics were compared using a one-
way independent ANOVA for normally distributed values and a Kruskal-Wallis test for 
non-normally distributed variables. We assessed differences between proportions with 
the Pearson chi-square test or Fisher’s exact for smaller proportions. We compared the 
paired samples with a paired Student’s t test or Wilcoxon Rank test, according to the 
distribution of  the data. We assumed a significance level of  ≤0.05. 
Mean Gal-3 values between the patients with PA, the patients post-adrenalectomy 
and the patients with EHT were compared by univariate analysis of  covariance with 
the following confounding factors: age, sex, BMI, smoking, DM, units (10 g) of  
alcohol/week, years of  hypertension, SBP and DBP, plasma creatinine and potassium 
concentrations. We based adjustments for most of  these covariates on previous studies 
in which strong correlations were found between these variables and plasma Gal-3 
levels. (32, 33) In our cohort, we found the units of  alcohol per week to be correlated 
to Gal-3 (β=-0.08, R2=0.05, p<0.01). Since hypokalemia can suppress aldosterone 
production, plasma potassium might influence the relationship between aldosterone 
and Gal-3. (29) For these reasons, we added the units of  alcohol per week and the plasma 
potassium concentration as covariates. 
All variables were available, except for 27 missing plasma creatinine values (3 BAH, 3 
APA, 3 post-adrenalectomy and 18 EHT), 2 missing values of  alcohol intake (1 BAH 
and 1 APA) and 4 missing plasma potassium values (1 BAH, 2 post-adrenalectomy and 
1 EHT). 
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RESULTS
PATIENTS
Residual plasma was available from 78 patients with PA, 39 patients cured from PA 
(post-adrenalectomy), and 56 patients with EHT. AVS (performed in n=75) revealed 
a bilateral aldosterone overproduction (bilateral adrenal hyperplasia; BAH) in 32 
patients and an APA in 43 patients. In 3 patients no AVS was performed, but computed 
tomography showed a unilateral adenoma in 2 of  these patients and bilateral adenoma’s 
in 1. The baseline characteristics of  the patients are presented in Table 1. 
Of  the 43 patients with lateralisation of  aldosterone during adrenal venous sampling 
and 28 post-adrenalectomy patients, pathology reports were available in 46 patients. 
In 61% of  the cases, an adenoma was confirmed by the pathologist and 13% had 
nodular hyperplasia with a dominant adenoma. In one patient the pathologist could 
not distinguish between nodular hyperplasia or a cortical adenoma and in another 
patient a pseudocyst was diagnosed. In the remaining 22%, histology revealed nodular 
hyperplasia. 
Patients with PA had significantly higher aldosterone and ARR values, and a lower renin 
concentration, compared to post-adrenalectomy and EHT patients. As depicted in Table 
1, all post-adrenalectomy patients were cured according to biochemical parameters. In 
addition, a SLT was performed in 33 of  39 adrenalectomized patients. The SLT was 
negative in all of  these patients. Post-adrenalectomy, the ARR values were significantly 
lower in comparison to EHT patients (Table 1). 
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TABLE 1. Baseline characteristics of patients with PA (BAH, bilateral adrenal hyperplasia 
and APA, aldosterone producing adenoma), patients post-adrenalectomy and patients with 
EHT
PA
(n=78)
Post-
adrenalectomy
EHT
BAH (n=33) APA (n=45) (n=39) (n=56)
Demographics
Male (%)* 23 (69.7) 28 (62.2) 26 (66.7) 24 (42.9)
Median age (IQR) 53 (47-60) 51 (45-62) 50 (46-56) 55 (45-60)
Characteristics
Median duration of known 
hypertension in years (IQR)
8.0 (1.3-13.5)† 7.0 (2.0-15.0)† 8.0 (4.0-14.0)† 2 (0.0-6.8)
Median DDD antihypertensives (IQR) 1.3 (0.6-2.3)†,‡ 1.5 (0.8-2.9)†,‡ 0 (0-1.0) 0 (0-0.8)
Blood pressure (mmHg)
Median SBP (IQR) 173 (148-180)‡ 167 (149-185)‡ 130 (123-140)† 154 (137-173)
Median DBP (IQR) 97 (90-106)†,‡ 96 (87-103)‡ 84 (80-89)† 90 (84-100)
Median aldosterone level in  
nmol/L (IQR)
0.55 (0.38-
0.94)†,‡
0.86 (0.55-
1.40)†,‡
0.18 (0.14-0.23) 0.25 (0.20-0.30)
Median renin in mU/L (IQR) 5.9 (4.3-9.4)‡ 5.5 (3.9-7.3)†,‡ 14.0 (9.5-19.0) 9.0 (6.5-14.0)
Median ARR in nmol/mU (IQR) 0.10 (0.05-
0.16)†,‡
0.18 (0.11-
0.25)†,‡
0.01 (0.01-0.02)† 0.03 (0.02-0.04)
Mean potassium level in mmol/L 
± SD
3.6 ± 0.4‡ 3.6 ± 0.3†,‡ 4.2 ± 0.4† 3.8 ± 0.3
Median units (10 g) alcohol/week 
(IQR)
2 (0-7) 1 (0-7) 1 (0-3) 2 (0-7)
Median creatinine in µmol/L (IQR) 78.5 (71.0-90.5)
n=30
77.5 (64.0-87.3)
n=42
83.0 (75.3-100.3)†
n=36
73.5 (65.5-81.8)
n=38
Median albumin-to-creatinine ratio in 
mg/mmol (IQR)
2.7 (1.7-9.4)‡
n=19
4.9 (1.1-22.8)†,‡
n=22
0.8 (0.0-1.3)
n=10
1.4 (0.7-3.3)
n=48
(Other) cardiovascular risk factors
Median BMI in kg/m2 (IQR) 28.9 (25.4-32.5) 29.1 (25.6-32.4) 28.4 (26.2-32.3) 28.4 (25.4-31.2)
Smoking (%) 8 (24.2) 6 (13.3) 6 (15.4) 6 (10.7)
Ex-smoker (%) 10 (30.3) 15 (33.3) 14 (35.9) 20 (35.7)
DM type 2 (%)* 5 (15.2) 3 (6.7) 2 (5.1) 0 (0)
Family history of CVD (%) 22 (66.7) 29 (64.4) 22 (56.4) 39 (69.6)
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History of CVD (%) 2 (6.1) 5 (11.1) 3 (7.7) 2 (3.6)
Dyslipidemia (%) 10 (30.3) 6 (13.3) 6 (15.4) 8 (14.3)
Echocardiography
Report available (%)* 17 (51.5) 19 (42.2) 8 (20.5) 39 (69.6)
Left ventricular hypertrophy (%)* 9 (52.9) 10 (52.6) 2 (25.0) 4 (10.3)
Diastolic dysfunction (%)* 10 (58.8) 10 (58.8) 4 (57.1) 15 (38.5)
* p≤0.05, † p≤0.05 compared to EHT, ‡ p≤0.05 compared to post-adrenalectomy
Abbreviations: APA, aldosterone producing adenoma; ARR, aldosterone-renin-ratio; BMI, body mass index; CVD, 
cardiovascular diseases; DDD, daily defined dose; EHT, essential hypertension; PA, primary aldosteronism
In 11 patients of  the APA-group, a paired residual plasma sample was available that had 
been obtained 9.0 + 4.6 months after adrenalectomy, without any interfering medication. 
The 11 patients both clinically and biochemically recovered after adrenalectomy, with 
a significant decrease in median SBP from 164 (140-178) to 133 (122-141) mmHg 
(p=0.01), a decrease in median serum aldosterone from 0.88 (0.61-1.11) to 0.14 (0.13-
0.21) nmol/L (p<0.01), an increase in median plasma renin from 4.3 (3.6-8.1) to 19.0 
(14.0-23.0) mU/L (p=0.01), a decrease in mean ARR from 0.20 ± 0.10 to 0.01 ± 0.01 
nmol/mU (p<0.01) and an increase in mean plasma potassium concentration from 3.5 
± 0.3 to 4.5 ± 0.4 mmol/L (p<0.01). The median DBP tended to decrease from 98 
(85-115) to 82 (74-90) mmHg and the median DDD of  antihypertensives tended to 
decrease from 1 (0-2.25) to 0 (0-1) pre- and post-adrenalectomy respectively, but this 
decrease did not achieve statistical significance (p=0.06 and p=0.06). 
PLASMA GAL-3 VALUES
Without correction for confounders, the mean Gal-3 concentration was not different 
between patients with PA, post-adrenalectomy and EHT (12.12 ± 0.36, 12.88 ± 0.50, 
and 12.42 ± 0.42 ng/mL respectively). 
Mean plasma Gal-3 concentrations did not differ significantly between the groups after 
adjustments for covariates (11.39 ± 0.60, 11.64 ± 0.81 and 11.41 ± 0.73 ng/mL for 
PHA, post-adrenalectomy and EHT respectively). The Gal-3 concentrations in the 
different subgroups of  patients with stepwise correction for covariates are described 
in Table 2. 
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TABLE 2. Plasma Gal-3 concentrations in ng/mL in the patients with PA, post-
adrenalectomy, and the patients with EHT, without and with correction for confounders. 
Values are expressed as mean ± SD
Correction for PA Post-
adrenalectomy
EHT P-value
- 12.12 ± 0.36 12.88 ± 0.50 12.42 ± 0.42 0.46
Age, sex, BMI 12.17 ± 0.37 12.96 ± 0.51 12.39 ± 0.42 0.45
Age, sex, BMI, smoking, DM 11.04 ± 0.58 11.71 ± 0.72 11.05 ± 0.69 0.51
Age, sex, BMI, smoking, DM, 
years of hypertension, SBP and 
DBP
10.86 ± 0.61 11.98 ± 0.77 10.97 ± 0.70 0.29
Age, sex, BMI, smoking, DM, 
years of hypertension, SBP and 
DBP, creatinine
11.16 ± 0.60 12.20 ± 0.78 11.43 ± 0.75 0.42
Age, sex, BMI, smoking, DM, 
years of hypertension, SBP and 
DBP, creatinine, units alcohol/
wk, potassium 
11.39 ± 0.60 11.64 ± 0.81 11.41 ± 0.73 0.95
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; EHT, essential hypertension; 
PA, primary aldosteronism; SBP, systolic blood pressure
We did not find a correlation between serum aldosterone and plasma Gal-3 levels in the 
total cohort of  78 PA patients, 39 cured PA patients after adrenalectomy and 56 EHT 
patients (Spearman’s correlation coefficient -0.11; p=0.17). 
Within the group of  patients with PA, we selected those who had undergone 
echocardiography (n=36) and compared the baseline characteristics between the 
patients with (n=19) and without LVH (n=17). 
The blood pressure was similar in both groups, but patients with LVH used more 
antihypertensive drugs (DDD of  antihypertensive drugs 2.0 (1.7-3.3) in patients with PA 
and LVH versus 0.9 (0-2.1) in patients with PA but without LVH; p=0.02). Otherwise, 
there were no differences in baseline characteristics between the patients with PA and 
LVH and patients with PA but without LVH (data not shown). 
Mean Gal-3 levels did not differ between the patients with and without LVH (12.21 ± 
0.68 and 13.03 ± 0.72 ng/mL respectively, p=0.42). Also after stepwise correction for 
confounders (age, sex, BMI, alcohol intake, diabetes, smoking, years of  hypertension, 
blood pressure, plasma creatinine and potassium levels), Gal-3 levels were not different 
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between the PA patients with and without LVH (11.63 ± 1.00 versus 11.13 ± 1.02 ng/
mL respectively, p=0.64) . 
In the 11 paired samples of  APA-patients, the Gal-3 concentration was 10.03 ± 1.67 
ng/mL before adrenalectomy and increased to 14.36 ± 2.07 ng/mL post-adrenalectomy 
(p<0.01), as depicted in Figure 2. After correction for plasma creatinine levels, plasma 
potassium concentration and blood pressure, the mean Gal-3 concentration was 10.06 
± 0.81 and 14.54 ± 0.81 ng/mL pre- and post-adrenalectomy respectively (p<0.01).
FIGURE 2. Mean plasma Gal-3 levels in the 11 patients of whom paired samples were 
available before and after adrenalectomy 
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DISCUSSION
Based on recent preclinical observations, we hypothesized that plasma Gal-3 levels 
are elevated in patients with PA, compared to patients with EHT, and that this may 
contribute to the increased cardiovascular risk of  patients with PA. In our retrospective 
cohort study however, we did not find differences in the plasma Gal-3 concentrations 
between patients with PA, cured PA patients (post-adrenalectomy), and patients with 
EHT. Furthermore, in a subset of  11 patients with a unilateral producing adenoma 
in which blood samples were available before and after adrenalectomy, Gal-3 levels 
increased after adrenalectomy. 
Our findings are in contrast to previous preclinical studies in which aldosterone, both in 
vitro and in vivo, consistently increased Gal-3 protein levels and expression. (15, 21-23) It should 
be appreciated though that the experimental animal models of  hyperaldosteronism 
substantially differ from the patients with an autonomous overproduction of  
aldosterone. Another important issue that might explain the discrepancy between the 
preclinical findings and our in vivo observations, is the possibility of  publication bias, 
which has shown to play a major role in other animal disease models. (34) In addition, in 
the preclinical studies, Gal-3 secretion and expression was measured in culture media, 
cell extracts and tissue homogenates, but not in the circulation in vivo. One of  the 
potential explanations therefore, is that there is a differential regulation of  Gal-3 in 
plasma and in the various tissue compartments, and that an increased Gal-3 expression 
in myocardial, renal or vascular tissue in patients with PA is not reflected in higher 
circulating Gal-3 levels. 
Several studies demonstrated that the plasma Gal-3 concentrations are elevated in 
patients with heart failure. (35, 36) In these patients plasma Gal-3 concentrations predict 
morbidity and mortality. (37) Furthermore, persistently elevated levels of  Gal-3 predict 
the onset of  heart failure in the general population. (32, 38) The regulation of  the plasma 
Gal-3 concentration in these patients with heart failure might be different however 
than in patients with PA. In this latter group of  patients, only one study group has 
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investigated the circulating Gal-3 levels. (23) Higher plasma Gal-3 concentrations in 
patients with PA compared to EHT were observed by the TAIPAI study group. Mean 
Gal-3 levels returned to normal after adrenalectomy. (23, 39) 
There are several differences between the studies of  the TAIPAI study group and our 
present study that could explain the different results. First, the TAIPAI study group 
measured Gal-3 concentrations in relatively small cohorts of  patients with PA (n=7 
and n=11) and patients with EHT (n=11 and n=17). (23, 39) The selection process of  
these patients was not described and it is unclear whether the 2 studies share a majority 
of  patients or not. We selected a large group of  patients that had been diagnosed with 
PA and EHT according to current guidelines, and carefully corrected for potential 
confounders. In our large cohort of  78 patients with untreated PA, 39 patients post-
adrenalectomy and 56 patients with EHT, no differences in Gal-3 concentrations were 
observed. 
Secondly, we measured Gal-3 concentrations in plasma samples obtained for serum 
aldosterone and plasma renin measurements. At the time of  sampling, patients did 
not take any medication that interfered with the renin-angiotensin-aldosterone 
system. Although Lin et al describe that patients who did not take the MR antagonist 
spironolactone within the previous 6 months were enrolled, it is unclear whether other 
medications interfering with the renin-angiotensin-aldosterone system were taken when 
venous blood was drawn for Gal-3 measurements. (23)
Next, there are differences in the analytical methods. For quantification of  plasma Gal-
3 concentrations we used the BG Gal-3 ELISA-kit. This kit has a reported within run 
and total precision of  2.1%–5.7% and 4.2%–12.0% respectively, and has received FDA 
clearance. (33) A different assay was used by the TAIPAI study group, and importantly, 
plasma Gal-3 concentrations were 10-fold lower in comparison to the observed mean 
Gal-3 values in our study. The Gal-3 concentrations in our study are in the same range 
of  the Gal-3 concentration of  11.4 ± 4.0 ng/mL observed in historical controls from 
the PREVEND study, with comparable age (between 50 and 55 years). (33) Under other 
pathophysiological circumstances, such as heart failure, quantified Gal-3 levels are even 
higher (20-30 ng/mL), with values up to 60-100 ng/mL in patients with end stage renal 
disease. (25, 40)
Finally, differences in ethnic background of  the included patients may explain the 
discrepant findings of  our studies. In the studies of  the TAIPAI study group Asians 
were enrolled, while our cohort consists of  Caucasians. 
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In Table 1 we depicted the findings on echocardiography that were available in almost 
half  of  the PA and more than half  of  the EHT patients. Importantly, the prevalence 
of  LVH and diastolic dysfunction was higher in PA patients than in EHT patients. We 
showed that Gal-3 levels did not differ between the patients with PA and LVH and 
the patients with PA but without LVH. The observation that the difference in cardiac 
damage is not reflected by differences in plasma Gal-3 concentrations, exclude a role of  
plasma Gal-3 in aldosterone-mediated target organ damage in humans in vivo. 
Interestingly, although we did not observe differences in circulating Gal-3 between the 
patients with PA, patients with EHT, and patients treated for PA, we did observe a 
significant and consistent increase in Gal-3 concentrations in the subgroup of  11 patients 
from whom paired blood samples were available before and after adrenalectomy. We do 
not have a clear explanation for this interesting finding. There is no relevant difference 
between the subgroup and the total group with regard to serum aldosterone and ARR 
values, medication use, comorbidities or other baseline characteristics. In addition, there 
was no relevant difference between the timing of  plasma samples that were taken 11.9 
± 4.8 months after adrenalectomy in the 39 post-adrenalectomy patients, compared 
to 9.0 ± 4.6 months in the 11 patients. Antihypertensive medication use might have 
influenced our results. As mentioned before, none of  the patients used medication 
that affects serum aldosterone or plasma renin concentrations. It is unclear however, if  
the tolerated antihypertensive medication or the change in DDD have interfered with 
plasma Gal-3 concentrations. 
The strength of  our study is clearly the use of  stringent diagnostic criteria for PA, 
and cure from PA after surgical treatment. Moreover, when investigating the Gal-
3 concentrations in the 3 patient groups, the extensive phenotyping of  the patients 
allowed us to rigorously correct for all potential confounders. 
Nevertheless, our study has some limitations. First, our study is a retrospective analysis, 
which is prone to bias related to missing variables. As described, the number of  missing 
plasma creatinine concentrations in our cohort was substantial (n=27). When we 
analyzed only those patients in whom there were no missing values for the confounders 
depicted in Table 2, unadjusted mean plasma Gal-3 levels were 12.25 ± 0.37, 13.00 ± 0.51 
and 12.75 ± 0.50 ng/mL in PA patients, patients post-adrenalectomy and EHT patients 
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respectively; p=0.45. These levels do not differ from the unadjusted mean plasma Gal-3 
concentrations in the total cohort (12.12 ± 0.36, 12.88 ± 0.50, and 12.42 ± 0.42 ng/
mL). Also, adjusted Gal-3 variables in the patients without any missing variables did not 
differ from the results in Table 2 (data not shown). Therefore, we do not expect that 
the presence of  missing variables in our retrospective analysis was a confounder itself.
In addition, echocardiography was performed in only half  of  the PA patients and more 
than half  of  the EHT patients, which might have introduced potential bias. Indeed, 
SBP levels were higher in the patients in whom echocardiography was performed (154 
(138-176) versus 147 (133-168) mmHg in patients with and without echocardiography 
respectively; p=0.01). Adjusted plasma Gal-3 concentrations in patients in whom 
echocardiography was performed however did not differ between the subgroups (11.55 
± 0.88, 11.60 ± 1.69 and 11.56 ± 1.11 ng/mL for patients with PA, cured PA patients 
after adrenalectomy and patients with EHT respectively; p=1.00). 
Secondly, our samples had been stored for a period of  maximally 2 years, at -20 °C. 
The product insert of  the BG medicine galectin-3 assay reports that galectin-3 is stable 
for at least 2 years when stored at -70 °C. In the study by Christenson et al on the 
assay characteristics of  galectin-3, there were no major differences in galectin-3 levels 
between samples stored at -20 °C and samples stored at -70 °C, during at least 6 months 
of  storage and 6 freeze/thaw cycles. (41) In our study, there was a maximum of  2 
freeze/thaw cycles. Therefore, it is unlikely that our results are affected by analytical 
problems. Moreover, by adding the storage time as a covariate in the analysis, plasma 
Gal-3 levels remained comparable between the subgroups (11.76 ± 0.58, 11.98 ± 0.78 
and 11.62 ± 0.70 ng/mL for PA, post-adrenalectomy and EHT patients respectively, 
p=0.91) and results did not change in the 11 paired samples (mean Gal-3 concentrations 
9.77 ± 1.03 and 14.82 ± 1.03 ng/mL pre- and post-adrenalectomy respectively, p=0.02).
In conclusion, in our retrospective cohort study we did not observe differences in 
plasma Gal-3 concentrations between patients with PA, patients that had undergone 
adrenalectomy for PA, and patients with EHT. Our results are in contrast to preclinical 
studies and two small clinical studies in which Gal-3 has been proposed as a key mediator 
in aldosterone-mediated fibrosis. 
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PERSPECTIVES
We demonstrated, for the first time, that there is no association between aldosterone 
excess and plasma Gal-3 concentrations in humans in vivo. It is therefore highly 
unlikely that increases in plasma Gal-3 production contribute to the increased risk 
of  cardiovascular events in patients with PA, compared to patients with EHT. This 
does not exclude however, a predictive role of  Gal-3 on cardiovascular morbidity and 
mortality. 
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ABSTRACT
Despite state-of-the-art reperfusion therapy, morbidity and mortality remains significant 
in patients with an acute myocardial infarction. Therefore, novel strategies to limit 
myocardial ischemia-reperfusion injury are urgently needed. Mineralocorticoid receptor 
(MR) antagonists are attractive candidates for this purpose, since several clinical trials 
in patients with heart failure have reported a survival benefit with MR antagonist 
treatment. MRs are expressed by several cells of  the cardiovascular system, including 
cardiomyocytes, cardiac fibroblasts, vascular smooth muscle cells, and endothelial cells. 
Experiments in animal models of  myocardial infarction have demonstrated that acute 
administration of  MR antagonists, either before ischemia or immediately at the moment 
of  coronary reperfusion, limit infarct size. This action appears to be independent 
of  the presence of  aldosterone, which is the endogenous ligand for the MR. The 
cardioprotective effect is mediated by a nongenomic intracellular signaling pathway, 
including adenosine receptor stimulation, and activation of  several components of  the 
Reperfusion Injury Salvage Kinase (RISK) pathway. In addition to limiting infarct size, 
MR antagonists can improve scar healing when administered shortly after reperfusion 
and can reduce cardiac remodeling post myocardial infarction when initiated after initial 
infarct healing. Clinical trials are currently being performed studying whether early 
administration of  MR antagonists can indeed improve prognosis in patients with an 
acute myocardial infarction, independent of  the presence of  heart failure. 
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INTRODUCTION
In 2008, more than 17 million people died of  cardiovascular diseases worldwide, 
according to summary tables of  the World Health Organisation. In low-, middle- and 
high-income countries, ischemic heart disease and cerebrovascular disease are the 
leading cause of  death. Percutaneous coronary intervention and thrombolysis are the 
main strategies to restore perfusion in patients with an acute myocardial infarction. 
Despite state-of-the-art reperfusion strategies, mortality and morbidity in patients with 
an acute myocardial infarction remain significant. This is caused, at least in part, by 
the fact that reperfusion itself  also contributes to tissue injury, a phenomenon which 
has been termed “lethal reperfusion injury”. (1) Therefore, novel therapeutic options to 
limit ischemia-reperfusion (IR) injury are urgently needed to improve outcome in these 
patients. 
It has been suggested that the mineralocorticoid receptor (MR) antagonists 
spironolactone and eplerenone could potentially serve this goal, because these drugs 
reduce mortality in patients with heart failure. (2-4) These reported effects of  MR 
antagonists are consistent with the observations that the endogenous ligand for the 
MR, aldosterone, can have detrimental cardiovascular effects. Patients with autonomous 
adrenal overproduction of  aldosterone (primary aldosteronism; PA) have an increased 
risk of  cardiovascular and cerebrovascular events, and cardiac remodeling, independent 
of  blood pressure levels. (5-7) Also, in patients without PA, a high aldosterone level or 
high aldosterone-to-renin ratio is associated with an increased risk of  cardiovascular 
events. (8) In the setting of  an acute myocardial infarction, aldosterone levels, even 
within the normal range, are associated with cardiovascular death and heart failure. (9)
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Preclinical studies have now provided convincing evidence that MR antagonists 
have beneficial effects on various pathophysiological processes that contribute to 
cardiovascular morbidity and mortality (Figure 1). MR antagonists attenuate the process 
of  atherosclerosis (10-15), modulate endothelial function and blood flow in animal studies 
(16-19) and in various patient groups (20-27), limit myocardial IR-injury, prevent IR-induced 
arrhythmias (28-35), and beneficially modulate cardiac remodeling. Protective effects 
against IR-injury have not only been reported in the heart, but also in the kidney (36, 37), 
the brain (38, 39), and the retina (40).
FIGURE 1. Overview of the various pathophysiological processes that ultimately lead to 
cardiovascular morbidity and mortality which can be affected by MR antagonists 
Atherosclerosis/inflammation
Endothelial function/blood flow
IR-injury
Arrhythmias Remodeling
Outcome
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In this review paper, we will summarize current knowledge on the effects of  MR 
antagonists on myocardial IR-injury and post-infarction remodeling. To appreciate the 
molecular mechanisms underlying these beneficial effects, detailed knowledge about the 
distribution and function of  the MR throughout the body is essential. Therefore, we 
will discuss the expression of  the MR receptor in cardiovascular tissues, the effects of  
MR antagonists on IR-injury and the underlying mechanisms, and the effects of  MR 
antagonists on post-infarction remodeling.
EXPRESSION AND FUNCTION OF THE MR IN THE 
CARDIOVASCULAR SYSTEM
CHARACTERISTICS OF THE MR
From the classical physiological perspective the MR is expressed in the distal tubular 
cells of  the kidney. The endogenous ligand is aldosterone, which is synthesized in 
the zona glomerulosa of  the adrenal cortex. In this paradigm the role of  this major 
mineralocorticoid is to regulate blood pressure and water balance by promoting the 
reabsorption of  sodium and the excretion of  potassium. The MR displays similar 
affinity for aldosterone and glucocorticoid hormones. Despite a 100- to 1000-
fold higher concentration of  these latter hormones than aldosterone, the MR in 
aldosterone target cells is not stimulated by glucocorticoids under normal physiological 
conditions. The enzyme 11-β-hydroxysteroid dehydrogenase type 2 (11βHSD2), co-
expressed with the MR, converts cortisol into the inactive metabolite cortisone (Figure 
2). In rodents, where corticosterone instead of  cortisol is the major glucocorticoid, 
corticosterone is metabolized to 11-deoxycorticosterone by 11βHSD2. Cortisone 
and 11-deoxycorticosterone have a much lower affinity for the MR. (41, 42) In this way 
11βHSD2 protects the MR from stimulation by cortisol and confers specificity to 
aldosterone binding. 
The isozyme 11βHSD type 1 (11βHSD1), in vitro catalyzes interconversion of  cortisol 
and cortisone (43), but in vivo the enzyme converts cortisone into cortisol only. Taken 
together, this suggests that MR stimulation by aldosterone only takes place in cells that 
express 11βHSD2, but not in cells expressing 11βHSD1, both types, or none of  these 
enzymes.
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FIGURE 2. Mineralocorticoid target cell and the function of the enzyme 
11-β-hydroxysteroid dehydrogenase type 2
Abbreviations: 11βHSD2, 11-β-hydroxysteroid dehydrogenase type 2; NAD+/NADH, nicotinamide adenine dinucleotide
Alternative mechanisms of  mineralocorticoid selectivity for aldosterone, including 
intrinsic discriminating properties of  the MR itself, and distinct molecular ligand-MR 
interactions, have been described. Kinetic studies have shown that aldosterone has 
a 5-times lower off-rate from the human MR than cortisol, pointing to an intrinsic 
discriminating property of  the receptor, which leads to an increase in transcriptional 
activity by aldosterone (44). In addition, there are indications that the expression of  
co-activators of  the MR can increase aldosterone-mediated transactivation (45). These 
mechanisms have been reviewed elsewhere (42, 46-49) and we will not further discuss them 
here since they do not seem to bear relevance to cardioprotection by MR antagonists. 
EXPRESSION OF THE MR AND 11βHSD IN CELLS OF THE 
CARDIOVASCULAR SYSTEM
From the above it follows that the role of  MR stimulation by aldosterone or by 
glucocorticoids can only be understood if  it is known whether 11βHSD2 and 
perhaps 11βHSD1 are co-expressed with the MR. This is important, because the MR 
is expressed not only in the distal tubular cells of  the kidney, but also in other cell 
types that are relevant to the cardiovascular system, including cardiomyocytes, cardiac 
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fibroblasts, vascular smooth muscle cells, endothelial cells, and mononuclear cells 
of  the immune system. (42, 47, 48, 50, 51) Also in other tissues, including brain (47, 52, 53) and 
retina (54), expression of  the MR has been reported. Not all of  these cell types co-
express 11βHSD. Table 1 provides an overview of  the studies which examined the 
presence of  11βHSD type 1 and 2 within cells of  the cardiovascular system. Before 
the 1990s researchers were not aware of  the existence of  two 11βHSD enzymes and, 
hence, no distinction was made between 11βHSD1 and 11βHSD2. Most studies at 
that time assessed the presence of  11βHSD in rat organ tissues by measurement of  
the conversion of  3H-corticosterone to 3H-11-deoxycorticosterone, assuming that this 
indicated the presence of  11βHSD type 2. However, in vitro 11βHSD1 converts the 
substrates bidirectionally (43), and therefore, conversion of  corticosterone or cortisol 
into 11-deoxycorticosterone or cortisone, respectively, in in vitro experiments does not 
necessarily indicate the presence of  11βHSD2. From the 1990s onwards, Northern 
blot analysis permitted the differentiation between the two types of  11βHSD. (55, 56) 
Moreover, when it was discovered that both enzymes needed different co-factors, the 
addition of  NADP+ (11βHSD1) and NAD+ (11βHSD2) provided a pharmacological 
method of  discrimination. Table 1 is not exhaustive for studies examining the presence 
of  11βHSD within cells in the cardiovascular system, but is limited to papers using 
appropriate assays to distinguish between the two types. In animal models, no 11βHSD2 
was demonstrated in whole heart (57-64) and cardiac fibroblasts (64, 65), suggesting that in 
these cell types effects of  MR stimulation are more likely to be mediated by cortisol 
binding. Studies in rat vascular endothelial cells, human cardiomyocytes and human 
vascular smooth muscle cells show expression of  11βHSD2. (66-71) In contrast to 
the studies which detected 11βHSD2 in human cardiac myocytes (66, 67), two other 
studies (58, 72) and all animal studies in Table 1 showed that cardiomyocytes lack 11βHSD2. 
Under pathological conditions, however, modulation of  the expression of  11βHSD1 
and -2 in these cell types has been reported. In salt-sensitive rats and spontaneously 
hypertensive rats, activity and mRNA expression of  11βHSD1 and 11βHSD2 in 
the heart and mesenteric arteries was reduced, when compared to salt-resistant and 
normotensive rats respectively, but no association between these changes in 11βHSD 
expression and cardiac hypertrophy were found. Importantly, plasma aldosterone levels 
were not measured in the rats. (73) Takeda et al reported increased aldosterone levels and 
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an up-regulation of  11βHSD2 in young stroke-prone spontaneously hypertensive rats, 
which was further increased by high sodium intake. (74) Chronic intermittent hypobaric 
hypoxia leads to an up-regulation of  11βHSD2 in the free ventricular walls and septum 
tissues of  rats in vivo. (75) In patients with rheumatic valve disease, the presence of  atrial 
fibrillation was associated with increased mRNA expression of  11βHSD2 in atrial 
tissue. (76) Finally, mRNA expression of  11βHSD1 is enhanced in epicardial adipose and 
ascending aorta tissues of  patients with the metabolic syndrome and coronary artery 
disease, compared to patients with the metabolic syndrome only. (77)
TABLE 1. Schematic overview of the co-expression of 11βHSD1 and -2 in different cell 
types
Reference Species 11βHSD type 1 
– and or 2
Detection Finding
HEART
Walker  
1991 (155)
Rat 
Heart tissue
NADPH+ dependent 
11βHSD present
Pharmacologically Conversion of B into A
Immunohistochemistry Localized enzyme in 
cardiomyocytes and 
mRNA expression by in 
situ hybridization
Expression found in cardiac 
muscle
Walker  
1992 (156)
Rat 
Heart tissue
NADPH+ dependent 
11βHSD present
Pharmacological Conversion of A to B
Albiston  
1994 (72)
Human 
Heart tissue
11βHSD2 absent mRNA detection by 
Northern blotting
No mRNA detection in heart 
tissue
Slight  
1994 (157)
Ox, pig, horse, rat, 
rabbit, dog and 
human 
Heart tissue
NADPH+ dependent 
11βHSD present
Pharmacologically Conversion of B into A
(highest in pig, rat and rabbit)
No conversion of F to E in any 
of the species
Rat 
Heart tissue
NADPH+ dependent 
11βHSD present
Pharmacologically Bidirectional conversion of A 
and B
Lombes 
1995 (66)
Human 
Cardiomyocytes
NAD+ dependent 
11βHSD present
Pharmacologically Conversion of B to A
Agarwal 
1995 (158)
Sheep 
Heart tissue
11βHSD2 present at 
low levels
mRNA detection RT-PCR products, but no cDNA, 
detectable
Human 
Heart tissue
11βHSD2 absent RNA blot No transcripts detectable
Brown  
1996 (57)
Mouse from 
embryonic day 
9-after birth
Heart muscle
11βHSD2 absent mRNA expression by 
11βHSD2 sense in situ 
hybridizations
No detection of 11βHSD2 
mRNA in embryo and fetus 
Slight  
1996 (67)
Human 
Tissue from failing 
explanted hearts 
and donor hearts
11βHSD1 absent 
and 11βHSD2 
present
Pharmacologically Conversion of B to A with NAD+ 
twice that formed with NADP+.
No reduction of A into B in 
presence of NADP+
mRNA detection 11βHSD2 expression
Smith  
1996 (68)
Human 
Myocytes from 
diseased heart
11βHSD2 absent Immunohistochemistry No 11βHSD2 detected
Li  
1996 (159)
Rat 
Heart tissue
11βHSD2 absent Total RNA by Northern 
blotting
No 11βHSD2 detected 
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Smith and 
Krozowski  
1996 (58)
Rat 
Heart tissue
11βHSD1 present 
and 11βHSD2 
absent
Pharmacologically Increased conversion of F, or B 
into A ,and E resp. after addition 
of NADP+. 
Inability of NAD+ to augment 
metabolism suggests absence of 
11βHSD2
mRNA detection 11βHSD1 gene expression
Roland 
1996 (59)
Rat 
Heart tissue
11βHSD2 absent RNA expression by in 
situ hybridization
Levels of 11βHSD2 RNA in heart 
below limits of detection
Condon 
1997 (60)
Mouse 
Heart tissue
11βHSD2 absent mRNA expression by 
northern blot analysis
No 11βHSD2 detectable
Náray-Fejes-
Tóth 1998 
(61)
Rabbit 
Heart tissue
11βHSD2 absent Western blot with a 
11βHSD2 antibody
No 11βHSD2 in heart present
Immunohistochemistry No11βHSD2 detected
Romero 
2000 (62)
Ox 
Heart tissue
11βHSD2 absent mRNA detection No detectable levels of 
11βHSD2 after RT-PCR
Moore  
2000 (63)
Mouse 
Heart tissue
11βHSD1 present 
and 11βHSD2 
absent
mRNA expression 
by labeled antisense 
probes
Detection of 11βHSD1 in heart
Brereton  
2001 (65)
Rat 
Cardiomyocytes
11βHSD1 absent Immunohistochemistry No 11βHSD1 immunoreactivity
Western blot Low signal detected (presence 
11βHSD1 in fibroblasts 
detected)
Sheppard 
2002 (64)
Rat 
Cardiomyocytes
11βHSD1 present 
and 11βHSD2 
absent
Pharmacologically 11βHSD1 acts as a reductase 
only, converting A to B
mRNA expression 11βHSD1 detected
Thompson 
2004 (160)
Mouse from 
embryonic 
day 12.5 until 
postnatal day 0.5
Heart tissue
11βHSD 1 present at 
low levels
11βHSD2 present at 
day 12.5
mRNA detection by in 
situ hybridization
After embryonic day 12.5 no 
11βHSD2 expression
Klusonová  
2008 (161)
Chicken 
Heart tissue
11βHSD 1 present at 
low levels
Pharmacologically Little conversion of A into B
mRNA expression RT-PCR of 11βHSD1 products 
detectable
VASCULAR SMOOTH MUSCLE CELL
Funder  
1989 (162)
Rat in vivo
Adrenalectomized 
at 9 d of age
11βHSD present Pharmacologically Conversion of B into A by 
pooled mesenteric vascular 
arcade and aortic minces
Binding study 15 min after s.c. administration 
of aldosterone and 
corticosterone, mesenteric 
vascular arcade highly 
aldosterone-specific
Walker  
1991 (155)
Rat 
Aorta, coronary 
artery, mesenteric 
artery and caudal 
artery 
NADPH+ dependent 
11βHSD present
Pharmacologically Conversion of B into A
Immunohistochemistry Localized enzyme in smooth 
muscle cells throughout the 
vessel walls
mRNA expression by in 
situ hybridization
Expression found in VSMCs of 
aorta and mesenteric artery
Slight 
1994 (157)
Ox, pig, horse, rat, 
rabbit, dog and 
human 
Aortic tissue
NADPH+ dependent 
11βHSD present
Pharmacologically Conversion of B into A with high 
levels in pig
No conversion of F to E in any 
of the species >>
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Kornel 
1994 (163)
Rabbit 
VSMCs from aorta
NADP+ preferable 
11βHSD present
Pharmacologically Conversion of F to E 
Binding study High affinity binding of 
3H-aldosterone, not interfered by 
GR blocker
Brem 
1995 (164)
Rat 
Aorta
11βHSD present Pharmacologically Conversion of B into A and vice 
versa. 4 times greater oxo-
reductase reaction. 
Greater activity in both 
directions in quiescent VSMCs
mRNA expression by 
northern blot analysis
Decrease in 11βHSD-specific 
mRNA in growing fase
Brem 
1998 (70)
Rat 
Aortic VSMC
11βHSD1 present 
and 11βHSD 2 
nearly absent
mRNA detection Little or no detectable RT-PCR 
products
Smith  
1996 (68)
Human 
VSMCs of 
arterioles in 
skin, heart and 
saphenous vein
11βHSD2 present Immunohistochemistry Lower amounts in venous 
smooth muscle cells
Hatakeyama 
1999 (69)
Human 
CASMC
Both types present Pharmacologicallv Bidirectional conversion of E 
and F, favoring oxoreduction 
of E to F
mRNA detection RT-PCR products of both 
enzymes detectable
VASCULAR ENDOTHELIAL CELL
Brem  
1998 (70)
Rat 
Aortic ECs and 
endothelium intact 
aorta
Both types present Pharmacologically Conversion of A to B greater 
than B to A. Oxoreductase 
activity was reduced half when 
a 11βHSD1 antisense oligomer 
was added
Equal conversion with NAD+ or 
NADP+.
mRNA detection Readily detectable RT-PCR 
products
Souness 
2002 (71)
Rat 
Aortic ECs 
Both types present Pharmacologically Conversion of A to B, and 
contractile respons to PE 
decreased after 11βHSD2 
antisense incubation. 
Vice versa after 11βHSD1 
antisense incubation. 
CARDIAC FIBROBLAST
Slight 
1993 (165)
Rat 
Cardiac fibroblasts
NADP+ independent 
11βHSD present
Pharmacologically Conversion of B to A.
No conversion of F to E
Brereton 
2001 (65)
Rat 
Interstitial 
fibroblasts of 
endocardium 
and adventitial 
fibroblasts of 
blood vessels
11βHSD1 present 
and 11βHSD2 
absent
Immunohistochemistry 11βHSD1 detected
Western blot 11βHSD1detected in fibroblasts 
of endocardium and blood 
vessels
Sheppard 
2002 (64)
Rat 
Cardiac fibroblasts
11βHSD1 present 
and 11βHSD2 
absent
mRNA expression mRNA expression of 11βHSD1 
only
Pharmacologically 11βHSD1 acts as a reductase 
only, converting A to B
Abbreviations: A=3H-11-dehydrocorticosterone, B = 3H-corticosterone, E = cortisone, F = cortisol
CASMC, coronary artery smooth muscle cells; EC, endothelial cell; GR, glucocorticoid receptor; NAD+, Nicotinamide 
Adenine Dinucleotide; NADP+, Nicotinamide Adenine Dinucleotide Phospate; resp., respectively; s.c., subcutaneously; 
VSMC, vascular smooth muscle cell
The cardioprotective effects of mineralocorticoid receptor antagonists
121
3.1
If  detrimental cardiovascular effects of  aldosterone are mediated by MR stimulation, it 
may be expected that in the absence of  11βHSD2, cortisol may also elicit unfavorable 
effects. Indeed experimental evidence exists that confirms this hypothesis. (42) In isolated 
rat hearts, Mihailidou et al have shown that both aldosterone and cortisol increased 
infarct size, an effect which was blocked by spironolactone. (78) In contrast, evidence 
suggests that glucocorticoids can act as a MR antagonist in cells lacking 11βHSD2. 
The underlying mechanism is unknown, but it has been assumed that glucocorticoids 
prevent aldosterone-mediated transactivation, by occupying the MR but without 
inducing transcription. (79, 80)
GENOMIC AND NONGENOMIC EFFECTS OF MR STIMULATION
Despite the fact that glucocorticoids may also stimulate the MR, the great majority of  
studies have focused on aldosterone as the ligand of  interest to cause cardiovascular 
damage. The higher risk of  cardiovascular events and cardiac remodeling in patients 
with primary hyperaldosteronism (5-7), and the favorable effects of  MR antagonists on 
cardiovascular mortality and morbidity (2-4), suggest a direct role of  aldosterone on the 
different cell types within the cardiovascular system. These actions can be mediated 
via the MR, and in that case can be specific for aldosterone if  11βHSD2 is present, as 
outlined above, but it has also been suggested that there are MR-independent effects of  
aldosterone. Binding of  the ligand to the cytosolic MR induces receptor dimerization 
and migration to the nucleus, followed by gene transcription, which is not a fast 
process and is called the ‘genomic’ pathway. (81) The rise in blood pressure in response 
to activation of  the renin-angiotensin-aldosterone-system system is an example of  a 
genomic effect of  aldosterone. 
Next to this relatively slow process, which may take hours, aldosterone has rapid, ‘non-
genomic’ effects, which do not depend on transcription. Figure 3 provides a schematic 
overview of  the genomic and non-genomic effects of  aldosterone. The extra-nuclear 
‘non-genomic’ signaling effects occur within minutes and can be provoked by binding 
of  aldosterone to the MR localized in the cell membrane, or to other membrane 
receptor(s). Arguments that support non-genomic effects of  aldosterone via a membrane 
receptor or membrane MR are, next to rapid response, that effects are insensitive to 
transcription inhibitors and that albumin-complexed aldosterone, that cannot enter 
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cells, induces similar responses. (49) A membrane-associated aldosterone receptor distinct 
from the MR has not yet been identified, although promising candidates have been 
proposed. (82) It is estimated that about 50% of  the rapid effects of  aldosterone occur 
without involvement of  the MR (82), because various non-genomic effects of  aldosterone 
have been described that cannot be blocked by MR antagonists. (42, 83) This does not, 
however, hold true for all studies, as shown in Table 2. Therefore, non-genomic effects 
of  aldosterone can also be exerted via the classical MR. Glucocorticoids have been 
shown to mimic some of  the non-genomic effects of  aldosterone, although less 
potent. (83) 
FIGURE 3. Schematic overview of the genomic (right) and non-genomic (left) effects of 
aldosterone
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Very recently, Toda et al reviewed the effects of  short-term as opposed to chronic 
exposure to aldosterone on endothelial function and vascular tone in humans, animals 
and isolated cells. (84) In healthy volunteers, there is a great inconsistency in the acute, 
non-genomic, effects of  aldosterone infusion on endothelial function. Schmidt et al 
proposed that the effect (vasoconstriction, vasodilation or no effect) depends on the 
dosage of  aldosterone infusion, with a vasodilator effect at high levels of  aldosterone 
and a vasoconstrictive effect at low dosages. (85) In animal studies, short-term exposure 
to aldosterone most often led to vasodilation, mediated by endothelium-derived nitric 
oxide. After persistent administration of  aldosterone to healthy subjects, a decrease in 
nitric oxide and an impairment of  endothelial function was seen. When aldosterone was 
given into the coronary artery of  hypoperfused dogs in vivo over 60 minutes, coronary 
blood flow was reduced and protein kinase C (PKC) was activated. The effect on CBF 
was blunted by a PKC inhibitor, and not by spironolactone. (86)
Other non-genomic effects of  aldosterone were demonstrated in ventricular myocytes 
of  rabbits and rats, in which aldosterone increased intracellular sodium concentrations 
via the Na+/K+/2Cl- co-transporter and the Na+/H+ exchanger (87) and caused cell 
swelling. (88) Also in endothelial cells, aldosterone led to an increase in absolute cell volume 
via the Na+/H+ exchanger. (89) In an in vitro study in cardiomyocytes of  rats, aldosterone 
increased the percentage of  apoptosis through calcineurin-dependent pathways.(90) In 
porcine coronary vascular smooth muscle cells (VSMCs), incubation with aldosterone 
led to increased levels of  intracellular cyclic adenosine monophosphate. Since this 
effect was not blocked by the MR antagonist spironolactone, nor by inhibitors of  
transcription factors and protein synthesis, this effect of  aldosterone on cyclic adenosine 
monophosphate appears to be non-genomic and independent of  the MR. Aldosterone, 
together with isoproterenol, had synergistic effects on this phosphorylation.(91) In 
subsequent research, the influence of  the adrenergic state on the effects of  aldosterone 
was tested in healthy subjects. After pretreatment with the beta-blocking agent esmolol, 
aldosterone increased mean arterial pressure within minutes. After pretreatment 
with the beta-agonist, dobutamine, the mean arterial pressure was decreased by 
aldosterone. (92) Blunting of  the human baroreceptor sensitivity by aldosterone supports 
the idea of  an interaction between the adrenergic system and aldosterone. This effect 
of  aldosterone occurred within a short time frame and pretreatment with canrenoate 
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could not prevent the effects of  aldosterone on the baroreceptor sensitivity. Therefore, 
non-genomic effects, independent of  the MR, were presumed to be responsible for this 
mechanism. (93) In VSMCs of  rats, aldosterone has been shown to have a profibrotic 
role via c-Src (tyrosine kinase) pathways (94), to cause hypertrophy by upregulation of  
NADPH oxidase 1 via activation of  Src and activating transcription factor 1 (95), to 
stimulate proliferation via big mitogen-activated protein kinase 1 (96), and aldosterone 
has been shown to increase intracellular sodium concentrations MR-independently (97). 
Furthermore, aldosterone increased intracellular calcium concentrations in VSMCs, with 
involvement of  phospholipase C and PKC. (83, 98) An increase in calcium concentration 
was also seen in porcine endothelial cells. (98, 99) 
In conclusion, the ‘classic’ intracellular MR is present in many cardiovascular tissues, 
and for this reason it may play a role in cardiovascular (patho)physiological situations. 
Stimulation of  the MR in these tissues may not always be due to aldosterone, as it 
may also be due to cortisol, depending on whether or not 11βHSD2 is co-expressed 
with the MR. To complicate matters further, membrane receptor(s) for aldosterone 
and membrane-associated MR may also exist in these tissues, which may explain the 
various rapid intracellular responses to aldosterone. These ‘non-genomic’ rapid actions 
are often, but not always blocked by MR antagonists.
We now turn to the effects of  MR antagonists on IR injury and post-infarction cardiac 
remodeling. It appears that most of  these actions are non-genomic, demonstrating that 
extrarenal MR physiology substantially differs from renal tubular MR physiology.
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EFFECTS OF MR ANTAGONISTS ON IR INJURY
The effects of  MR antagonists on myocardial IR injury have been studied in several 
animal models (rats, mice, and rabbits) of  myocardial infarction, both ex vivo and in 
vivo. In animal in vivo studies of  permanent coronary occlusion, the administration of  
eplerenone and spironolactone, either started before occlusion or immediately after 
occlusion, respectively, did not affect myocardial infarct size, suggesting that reperfusion 
is essential for infarct size-limitation by MR antagonists. (100-112) In Langendorff  isolated 
perfused rat hearts, the administration of  MR antagonists, commencing before coronary 
occlusion, consistently reduced myocardial infarct size (Table 2). Recently, it appeared 
that eplerenone not only confers cardioprotection when administrated before the 
induction of  ischemia, but also when administration at the moment of  reperfusion. (113)
The dosages of  the MR antagonist used in the isolated perfused heart studies varied 
among the studies (Table 2). Loan Le et al studied the dose-effect relationship of  
MR antagonists on infarct size and found spirinolactone 10 nM and eplerenone 100 
nM to be the lowest concentrations to significantly reduce infarct size. (114) In other 
studies, a 10-fold higher dose of  spironolactone (115) and 10-fold and 100-fold higher 
dose of  eplerenone (80) also reduced infarct size (113). It has to be realized, however, that 
in this ex vivo infarction model, the endogenous ligands of  the MR aldosterone and 
glucocorticoids are not present. Therefore, the results of  these experiments do not 
necessarily predict the effects of  MR antagonists in vivo. 
Schmidt et al have studied the effects of  the MR antagonist potassium canrenoate, 
which can be administered intravenously, on myocardial infarct size in rats, mice and 
rabbits in vivo. In mice, potassium canrenoate was given in incremental dosages as a 
bolus five minutes before coronary reperfusion to study dose-dependent effects on 
infarct size. Canrenoate in a dosage of  0.03 mg/kg significantly reduced infarct size, 
with a maximum effect at 1 mg/kg. Also, in a rabbit model of  myocardial infarction 
in vivo, an intravenous bolus of  1 mg/kg canrenoate reduced infarct size, an effect that 
persisted after 72 hours of  reperfusion. (113)
The role of aldosterone and mineralocorticoid receptor antagonists in cardiovascular damage 
126
3.1
TABLE 2. Schematic overview of the effects of aldosterone and MR antagonists on IR injury, 
derived from animal studies
Reference Animal 
Species and 
experimental 
design
Intervention Effect on IR injury Mechanistic insight
MYOCARDIAL ISCHEMIA
Rochetaing
2003 (166)
Rat Langendorff, 
25’ of global 
low flow I, 30’ R
Sp (50 mg/kg 
orally) for 1 month 
before surgery
Sp improved contractile 
recovery and reduced 
ventricular tachycardia 
during reperfusion
Sp increased reactive hyperemia
Fujita  
2005 (86)
Dog
Low flow (CPP 
33% of control 
CBF)
Aldo (0.1 nM) Aldo: ↓ CBF in ischemic 
heart (37.4±3.8 to 
19.3±5.2 mL/100 g/
min), further reduced 
FS and increased lactate 
extraction
Aldo might worsen IR-injury by ↓ CBF
↓ CBF and FS abolished by PKC 
inhibitor GF109203x, but not by 
spironolactone
Chai  
2005 (115)
Rat Langendorff 
LAD occlusion 
45’ I, 3h R
Perfusion with Sp 
(100 nM), or Aldo 
(100 nM) starting 
15’ before I
Sp: IS ↓ 68 ± 2 to 45±3% 
and ↓ fibrillation
Aldo: IS = 68 ± 2 to 
71±5%
In hearts without IR Aldo increased 
LVP and decreased CBF; Sp alone 
did not affect these parameters, but 
blocked LVP increase by Aldo
Chai  
2006 (80)
Rat Langendorff
LAD occlusion 
45’I, 3h R
Perfusion with 
Aldo (100 nM), 
Epl (1 µM) or 
combined Aldo+Epl 
starting 15’before I
Epl: IS ↓ 68±2 to 53±4%
Aldo: IS = 
Epl + Aldo: IS ↓ 
(comparable to Epl alone)
In heart without IR, Aldo and Epl 
increased LVP, Aldo reduced CF. Epl 
did not block Aldo actions.
Epl enhanced LVP recovery after IR, 
Aldo did not affect LVP and CF after 
IR.
Takeda (112) Rat Permanent 
LAD occlusion
Sp (100 mg/kg/d 
orally) starting 
immediately after 
I, for 14 d
IS = (Massons’s trichrome 
staining)
Sp  ↓  LVEDP, ↑LV dP/dT, 
↓ apoptosis (3.5% vs 5.8% 
in controls)
Sp suppressed expression of MR 
and 11βHSD2 mRNA, which were 
upregulated in untreated MI group
Barbato 
2002 (167)
Rat Langendorff Perfusion with 
Aldo (10 nM), Sp 
(10 nM), or Aldo 
plus Sp (10 and 
1000 nM resp)
Aldo: ↑ contractility (by 
45%) in 2-4 min
Sp: ↑ contractility (by 
41%) in 2-4 min
Addition of Sp to Aldo: ↑ contractility 
(106%) instead of blocking Aldo effect
Mulder
2008 (168)
Rat Coronary 
artery occlusion 
during 3 weeks
Sp (80 mg/kd/d) 
or FAD286 (4 mg/
kg/d) starting 8 d I 
for 7 or 90 d
Sp and FAD286 improved 
CO and reduced total 
peripheral resistance after 
7 d 
Sp and FAD286 reduced myocardial 
ROS concentration after 7 days 
FAD286 prevented decrease in 
myocardial AT1 and AT2 receptor, and 
ACE-2 expression
Mihailidou  
2009 (78)
Rat Langendorff
LAD occlusion
30’ I, 2.5h R
Sp (10 nM, 1 
µM), Aldo (1, 10 , 
100 nM) starting 
before I
Aldo dose-dependently ↑ 
IS, prevented by Sp 
Sp  ↓ IS
Cortisol also ↑ IS, blocked by Sp
↑ IS by Aldo and cortisol abolished by 
radical scavenger Tempol
Aldo and cortisol ↑ apoptosis
Sp ↓ apoptosis
Sp also ↓ IS in adrenalectomized rats
Schmidt 
2011 (113)
In situ mouse 
hearts LAD 
occlusion 
30’I, 2h R
Can (0.003, 0.03, 
0.3, 1, 10 mg/kg) 
iv bolus 5’before R
↓ IS, dose-dependent 
(37.8±7.5% to max 
7.3±4.7 (1 mg/kg)) and ↓ 
troponin I release
Protection abolished in CD73 -/- mice 
and Ado2B receptor -/- mice
In situ rabbit 
hearts LAD 
occlusion 30’I 
4h/72h R
Can (1 mg/kg) iv 
bolus 5’before R
↓ IS up to 72h
Rat Langendorff
Coronary artery 
occlusion 30’ I, 
2h R
Epl (10 µM) in 
perfusate starting 
5’before R, and 
Epl+inhibitors
Epl: ↓ IS (40.8±5.3 to 
10.9±7.2%)
Can: ↓ IS (40.8±5.3 to 
10.2±3.8%)
Protection abolished by co-
administration of 8-SPT, wortmannin, 
chelerythrine, and U0126
Protection abolished by co-
administration of Aldo (500 nM)
↑ phosphorylation of Akt and ERK1/2 
by MR blockade at reperfusion
Loan Le  
2012 (114)
Rat Langendorff
LAD occlusion
30’ I, 2.5h R
Sp (1, 3, 10, 1000 
nM), Epl (100, 
1000 nM) starting 
15’ before I
Sp (10, 100 nM) en Epl 
(100, 1000 nM) ↓ IS
↓ IS by Sp not blocked by androgen 
receptor antagonist flutamide
Sp and Epl attenuated apoptotic index
Sp and Epl prevented degradation of 
antiapoptotic protein ARC
In vitro: MR activation ↓ ARC 
expression, prevented by Sp
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RENAL ISCHEMIA
Mejia-Vilet 
2007 (36)
Rat, bilateral 
renal I 
20’, 24h R
Sp (20 mg/kg 
orally) for 1, 2, or 
3 days
Sp prevented fall in renal 
function, RBF and tubular 
injury (histologically, and 
urinary markers).
Sp 2 and 3 d before I/R 
prevented apoptosis
Sp: ↑ eNOS phosphorylation, ↓ ROS 
formation, ↓ kidney lipoperoxidation,
Ramirez 
2009 (124)
Rat, bilateral 
renal I 
20’, 24h R 
Adx 3 days before 
I/R
Adx prevented renal 
dysfunction, tubular 
damage (histologically and 
by urinary markers), and 
decrease in renal plasma 
flow
Adx prevented IR-induced increasein 
oxidative stress and ↑ eNOS 
phosphorylation.
Adx prevented increased expression of 
Rho-kinase and ETA 
Sanchez-
Pozos 2012 
(37)
Rat, bilateral 
renal I 
20’, 24h R
Sp (20 mg/kg 
orally) 0, 3, 6 and 
9 h after I
Sp at 0 and 3h: prevented 
renal dysfunction, tubular 
damage, and decrease 
in RPF
At 6h and 9h: partial and 
no effect resp. 
Sp prevented increase in oxidative 
stress, and prevented upregulation of 
Rho kinase, endothelin, ETA receptor, 
and AT1 receptor upregulation
CEREBRAL ISCHEMIA
Dorrance  
2001 (39)
Stroke-prone 
spontaneously 
hypertensive rats
Permanent 
occlusion MCA 
for 6 h
Sp (3.3 mg/d 
orally) for 6 weeks
↓ IS (51.69±3.60 to 
22.00±6.69%) after 6 h of 
occlusion
Sp: ↓ EGFR mRNA in aorta (no effect 
on EGF mRNA levels) 
Iwanami  
2009 (38)
Permanent 
occlusion left 
MCA
Epl (± 150 mg/
kg/d orally) 
for 2 weeks 
(pretreatment)
↓ infarct volume (72.7 to 
46.9 mm3) after 24 h of 
occlusion
Epl: ↓ ROS and improvement in 
cerebral blood flow in penumbra
Frieler  
2011 (125)
Myeloid specific 
MR  -/- mice
MCA occlusion
90’ I, 24h R
- ↓ IS (32 to 11%)
No difference in MCA 
blood flow during 
ischemia.
↓ activated microglia/macrophages ↓ 
TNF-α, IL-1β, MCP-1, IL-6, MIP-1α
HIND LIMB
Kobayashi  
2010 (126)
Rat 
Permanent 
unilateral 
hindlimb 
ischemia
Epl (30 mg/kg/d) 
for 3 weeks after I
↑ blood perfusion ratio 
(ischemic/normal)
↑ neovascularization (capillary 
density)
↑ number, colony formation, and 
migration of EPGs
↑ eNOS, VEGF, Ang 1, Ang 2, and 
eNOS protein expression
↓ NAD9P)H oxidases and MR 
expression
RETINA
Liu  
2012 (40)
Rat  
Raising intra-
ocular pressure 
(unilateral)
45’ I, 7d R
Sp (1, 10, 100 
mg/kg/d) for 7 
d, starting 1 d 
before I
Sp 10 and 100: prevented 
IR-induced retinal ganglion 
cell death, and prevented 
the reduction in IPL and 
INL thickness (10 and 100 
mg/kg dose)
-
Abbreviations: ACINUS, Apoptotic chromatin condensation inducer in the nucleus; Adx, adrenalectomy; Ado, adenosine; 
Aldo, aldosterone; Ang, angiotensin; AT1, angiotensin 1; Can, canrenoate; CBF, coronary blood flow; CHEL, chelerythrine 
(PKC inhibitor); Cort, cortisol; CPP, coronary perfusion pressure; Dexa, dexamethasone; EGF, epithelial growth factor; 
EGFR, epithelial growth factor recetor; eNOS, endothelial nitric oxide synthase; EPG, endothelial progenitor cell; Epl, 
eplerenone; ERKi, ERK inhibitor; ETA, endothelin A; Flut, flutamide; I, ischemia; ICAD, inhibitor of caspase-activated DNAse; 
IL, interleukin; INL, inner nuclear layer; IPL, inner plexiform layer; iv, intravenously; LVP, left ventricular pressure; MCA, 
middle cerebral artery; MCP-1, monocyte chemoattractant protein-1; Mife, mifepristone; MIP-1α, macrophage inflammatory 
protein-1α; R, reperfusion; RBF, renal blood flow; ROS, reactive oxygen species; sc, subcutaneously; Sp, spironolactone; SPT, 
8-p-sulphophenyltheophylline (adenosine receptor blocker); TNF-α, tumor necrosis factor-α; WORT, wortmannin (PI3-kinase 
inhibitor)
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MECHANISMS OF PROTECTION
There are several important questions which relate to the underlying mechanism of  
MR antagonist-induced cardioprotection. First, are the protective effects due to 
antagonism of  endogenous ligands of  the MR, including aldosterone and cortisol, or 
due to inverse agonism of  the MR. Secondly, does the cardioprotective effect involve a 
classical ‘genomic’, or a ‘nongenomic’ effect? Thirdly, what is the intracellular pathway 
that is activated upon binding of  the MR antagonist to the MR? These questions will be 
discussed in this paragraph.
The first question to be answered is whether endogenous aldosterone can aggravate 
myocardial IR-injury. Several Langendorff  studies investigated the effect of  
administration of  exogenous aldosterone on infarct size, but these studies reported 
inconsistent results. Chai et al showed that perfusion with 100 nM of  aldosterone, 
commenced before coronary occlusion, did not affect infarct size. (80, 115) In the study 
by Schmidt et al, perfusion with 500 nM of  aldosterone, starting immediately before 
reperfusion, did not affect infarct size either. (113) In contrast, Mihailidou et al reported 
a dose-dependent increase in infarct size with 1, 10, and 100 nM of  aldosterone, 
administered before coronary occlusion. (78) These results, however, are not relevant 
to the potential effects of  endogenous aldosterone. It has to be realized that ex vivo 
Langendorff  perfused hearts are not exposed to circulating endogenous aldosterone. 
Therefore, the observation that MR antagonists confer cardioprotection in this 
model, suggests that the effect of  MR antagonists is independent from the binding 
of  endogenous aldosterone. It has been suggested previously that aldosterone is 
produced locally in the heart during ischemia (116), but more recent studies have provided 
convincing evidence against such a local cardiac aldosterone synthesis. (117, 118) Indeed, 
Chai et al showed in a pharmacokinetic study in Langendorff  perfused rat hearts that 
cardiac aldosterone was derived from uptake of  circulating aldosterone. During wash-
out, aldosterone disappeared within minutes and during buffer perfusion there was 
no aldosterone detectable anymore in cardiac tissue. (80) A more definitive answer to 
the question whether endogenous aldosterone is required for the cardioprotective 
effects of  MR antagonists was provided by the elegant study by Mihailidou et al, who 
studied the effect of  spironolactone in rats after adrenalectomy. (78) Also in isolated 
perfused hearts from these rats, administration of  spironolactone significantly 
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reduced myocardial infarct size. Surprisingly, adrenalectomy did not protect against IR 
injury, which might be expected since administration of  exogenous aldosterone and 
glucocorticoids increased infarct size in this study. A possible explanation is that the 
administered dosages of  aldosterone and cortisol exceed physiological levels, although 
the concentration of  aldosterone reflects normal levels. (87) These observations suggest 
that spironolactone acts as an inverse agonist at the MR. Indeed, previous in vitro 
studies support this concept of  inverse agonism by spironolactone. (119) 
Finally, the role of  glucocorticoids has been explored in the study by Mihailidou 
et al. (78) This is highly relevant, since, as discussed in paragraph 2, MRs have equal affinity 
for aldosterone, cortisol, and corticosterone, circulating levels of  glucocorticoids are 
>100-fold higher than circulation aldosterone, and cardiomyocytes lack expression of  
11βHSD2 (Table 1). It has been suggested, however, that in cardiomyocytes, endogenous 
glucocorticoids do not act as MR agonists, but rather MR antagonists. In the study by 
Mihailidou et al perfusion with cortisol also increased infarct size, which was prevented 
by spironolactone (78). It was suggested that cortisol acted as MR agonist in the situation 
of  ischemia and reperfusion because increased oxidative stress drives MR activation by 
glucocorticoids. The fact, however, that adrenalectomy did not abolish the infarct size-
limiting effect of  spironolactone excludes that endogenous glucocorticoids are involved 
in MR antagonist-induced cardioprotection.
Does the cardioprotective effect of  MR antagonists involve a genomic or non-
genomic mechanism? The observation that the administration of  eplerenone or 
canrenoate immediately before reperfusion limits infarct size, measured two hours after 
reperfusion, suggests a rapid non-genomic effect. (113) Additional evidence in favor of  
a nongenomic effect is that the cardioprotective effect of  canrenoate was abolished 
when its administration was delayed and given more than one minute after the onset of  
reperfusion. (113) 
Several studies have tried to elucidate the underlying mechanism of  MR antagonist-
induced cardioprotection (Table 2). Limitation of  IR-induced apoptosis plays a pivotal 
role in the cardioprotective effect of  these drugs. In rat Langendorff  experiments, the 
administration of  spironolactone or eplerenone significantly reduced the number of  
apoptotic cells after IR. (78, 114) Also after permanent coronary ligation, spironolactone 
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reduced the occurrence of  apoptosis. (112) These effects might represent antagonism 
of  a pro-apoptotic effect of  endogenous aldosterone. Indeed, the administration of  
aldosterone or cortisol increased the occurrence of  apoptosis in isolated rat hearts (78), 
and in rat neonatal cardiac myocytes, aldosterone dose-dependently induced apoptosis 
and enhanced mitochondrial permeability transition pore opening (90). The direct 
pro-apoptotic effects of  aldosterone in isolated cardiomyocytes were attenuated by 
concomitant administration of  MR antagonists. (120, 121) It has recently been reported 
that MR antagonists limit IR-induced apoptosis by preventing degradation of  the 
anti-apoptotic protein apoptosis repressor with caspase recruitment domain (ARC) 
during IR. (114) Additional in vitro studies, have shown that MR activation by aldosterone 
promotes ARC degradation, which is blocked by spironolactone, demonstrating that 
this mechanism is mediated via the MR. (114)
In an elegant series of  experiments in rat Langendorff-perfused hearts, Schmidt et 
al have studied whether MR antagonist-induced cardioprotection is mediated by 
similar pathways that are activated by ischemia pre- and postconditioning, which have 
been described in detail in previous reviews (122, 123). (113) Indeed, adenosine receptor 
stimulation, and activation of  the reperfusion injury salvage (RISK)-pathway appeared 
to be critical for MR-antagonist-induced cardioprotection. In a mouse model of  
myocardial infarction, the protective effect of  the canrenoate was completely abolished 
in CD73 (the enzyme catalyzing extracellular conversion of  AMP into adenosine) as 
well as adenosine A2b receptor knock-out mice. In addition, the nonspecific adenosine 
receptor antagonist 8-p-sulphophenyltheophylline completely abolished the protective 
effect of  eplerenone in isolated perfused rat hearts. In the same series of  experiments, 
the cardioprotective effect of  eplerenone was abolished by co-administration of  the 
PKC inhibitor chelerythrine, the extracellular signal-regulated kinase inhibitor U0126, 
and the phosphoinositide 3-kinase inhibitor wortmannin. In addition, canrenoate and 
eplerenone increased phosphorylation of  the extracellular signal-regulated kinase 1/2, 
and Akt, which was prevented by wortmannin. (113)
The effect of  MR antagonists on IR-injury has not only been investigated in the heart, 
but also in the kidney, the brain, and the retina. These studies have revealed alternative 
pathways that can also contribute to the protective effects of  these drugs. In a series of  
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experiments, Bobadilla’s group has explored the effects of  spironolactone on renal IR-
injury (Table 2). Transient bilateral renal ischemia induced a rapid increase in circulating 
aldosterone, a reduction in renal plasma flow, severe tubular damage, and a decreased 
creatinine clearance. Pretreatment with spironolactone for one day completely 
prevented these changes. (36) In addition, adrenalectomy, performed three days before 
renal ischemia, similarly prevented IR-injury (124), suggesting that the beneficial 
effects of  spironolactone are due to prevention of  MR stimulation. Interestingly, the 
administration of  spironolactone immediately or three hours after renal reperfusion 
also prevented tubular damage. (37) This is in contrast to previous myocardial models of  
IR-injury, where the protective effect of  canrenoate was lost when its administration 
was delayed for more than one minute after reperfusion (113), illustrating that the infarct-
size limiting effect of  the heart probably differs from the renoprotective effect. The 
underlying mechanism of  renoprotection appears to be prevention of  the reduction of  
renal plasma flow by increased eNOS expression (36, 124), and prevention of  up-regulation 
of  the vasoconstrictor substances Rho-kinase and the endothelin ETA receptor 
(37, 124), 
and further prevention of  tubular injury by limiting oxidative stress (37).
Also in mouse models of  stroke, pretreatment with MR antagonists have proven to be 
beneficial. (38, 39, 125) In two mouse models of  permanent occlusion of  the middle cerebral 
artery, pretreatment with spironolactone (6 weeks) or eplerenone (2 weeks) reduced 
cerebral infarct size. (38, 39) It was suggested that this is mediated by a beneficial effect of  
these drugs on the cerebral vessels, which would increase collateral blood flow to the 
penumbra. Indeed, administration of  eplerenone increased blood flow in the peripheral 
region of  the middle cerebral artery territory. (38) Therefore, the smaller infarct size in 
these studies could be mediated by a reduced ischemic burden, rather than increased 
cerebral intrinsic tolerance against ischemia and reperfusion. This increased blood 
flow was not observed in the study by Frieler et al, which measured cerebral infarct 
size after transient (90 min) middle cerebral artery occlusion in myeloid-specific MR 
knock-out mice. Infarct size appeared to be significantly reduced compared to wild type 
mice, suggesting that the MR receptor on monocytes and macrophages importantly 
modulates IR injury. In myeloid specific MR knock-out mice, there was a reduction in 
activated microglia and macrophages in the ischemic core, and a reduction in mRNA 
expression of  pro-inflammatory cytokines including, TNF-α, IL-1β, MCP1, and 
The role of aldosterone and mineralocorticoid receptor antagonists in cardiovascular damage 
132
3.1
IL-6. (125) In retinal IR injury, spironolactone prevented a decrease in inner layer 
thickness and in the number of  retinal ganglion cells. Aldosterone decreased the number 
of  retinal ganglion cells in rat eyes exposed to retinal IR, but did not affect retinal 
thickness. (40) Finally, after unilateral hind limb ischemia in rats, eplerenone improved 
proliferation and function of  endothelial progenitor cells. (126)
In conclusion, in animal studies in which the heart is subjected to IR, MR antagonists 
limit infarct size, when administered either before ischemia, or immediately after the 
onset of  reperfusion. The infarct-size limiting effect of  MR antagonists in ex vivo 
heart models in which endogenous aldosterone is absent, and in adrenalectomized 
animals suggests that this cardioprotective effect is independent from the endogenous 
ligand aldosterone. The cardioprotective effect of  the MR antagonist canrenoate was 
completely abolished in CD73 and adenosine receptor knock-out mice, and after 
concomitant administration of  pharmacological blockers of  the signaling pathways 
that are also active in ischemic pre- and postconditioning, including the RISK pathway. 
These results suggest that the underlying mechanism of  protection of  MR antagonists 
depends on activation of  adenosine and the RISK pathway. The observation that in 
mice, genetic deletion of  the myeloid-specific MR reduces cerebral infarct size, suggests 
an important role for the MR on monocytes. 
EFFECTS OF MR ANTAGONISTS ON POST-INFARCTION 
REMODELING
Cardiac remodeling can be defined as the process of  cellular and interstitial changes 
in the myocardium with subsequent changes in morphology (hypertrophy), structure 
(chamber dilatation) and function (impairment) of  the heart resulting from altered 
loading conditions and/or cardiac injury. Cardiac remodeling plays a critical role in 
the development of  heart failure. Therefore, interventions that prevent excessive 
remodeling will prevent heart failure and improve survival. In this section, we focus on 
the effect of  MR antagonists on cardiac remodeling after myocardial infarction. Infarct 
size is an important predictor of  cardiac remodeling. (127, 128) MR antagonists can reduce 
infarct size in experimental settings as described in the previous paragraph. 
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In the current section, we aim to describe the effect of  MR antagonists on the 
remodeling process itself  and subsequent development of  heart failure. In this context, 
the effect of  MR antagonists on infarct size can be regarded as a confounder that 
should be taken into account when interpreting the studies that describe the effect of  
these drugs on cardiac remodeling. MR antagonists may not only affect remodeling, 
which typically occurs in the non-infarcted part of  the heart, but may also affect repair 
and scar formation in the infarcted area. This potential action of  MR antagonists could 
indirectly interfere with remodeling by affecting the loading conditions of  the non-
infarcted areas of  the heart. Therefore, we will start with a brief  description of  the 
effect of  MR antagonists on repair and scar formation in the infarcted area. 
EFFECT OF MR ANTAGONISTS ON REPAIR AND SCAR FORMATION 
IN THE INFARCTED AREA IN ANIMAL STUDIES
Myocardial infarction results in a substantial and acute loss of  myocardial cells as well as 
disruption of  the microcirculation. Cell necrosis triggers an inflammatory response and 
invasion of  inflammatory cells. Early invasion of  inflammatory cells may contribute 
to reperfusion injury. However, approximately 7 days after coronary occlusion, 
infiltration of  bone marrow derived dendritic cells in the infarct zone occurs and 
mediate differentiation of  macrophages to the M2 phenotype which play an essential 
role in the orchestration of  the repair phase and scar formation. (129) Aldosterone may 
modulate dendritic cell function. (130) Cardiac myofibroblasts (cells with characteristics 
of  fibroblasts and smooth muscle cells) play an important role in scar formation and 
contraction. (131) Aldosterone may stimulate proliferation of  these cells. (132)
In cardiomyocyte-specific MR knock-out mice, infarct healing was improved with 
increased infiltration of  macrophages, enhanced infarct neovessel formation and 
collagen structural organization associated with reduced infarct expansion. (133) The 
authors claimed that MR signaling in cardiomyocytes hinders normal scar formation 
by reducing early macrophage-infiltration and subsequent scar formation. (133) Oral 
treatment of  Wistar rats with high doses of  eplerenone (100 mg/kg/day), starting 
immediately after coronary occlusion increased macrophage infiltration in the infarct 
zone and reduced subsequent thinning and dilation of  the infarct zone, mimicking 
the observations in cardiomyocyte MR knock-out mice. This benefit of  eplerenone 
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on infarct healing was not observed when treatment was initiated 3 days after start of  
the coronary occlusion. (101) However, in a study with Sprague Dawley rats, oral high 
dose eplerenone (150 mg/kg/day) was started 24 hours after coronary artery occlusion 
and did not affect infarct healing. (100) These limited preclinical data suggest that MR 
antagonists improves scar healing only when introduced immediately after reperfusion. 
However, the role of  the MR in this effect of  eplerenone has not yet been established 
nor is known whether clinically relevant doses have a similar effect. It is currently 
not known how MR antagonists affect angiogenesis, cardiac myofibroblasts, collagen 
formation or infiltration by bone marrow-derived progenitor cells in the infarct zone.
EFFECT OF MR ANTAGONISTS ON CARDIAC REMODELING IN THE 
NON-INFARCTED AREA IN ANIMAL STUDIES
Loss of  contractile myocardial tissue immediately alters the loading conditions of  the 
remaining functional myocardium, with increased wall stress and myocardial cell stretch. 
These alterations result in release of  cytokines (including TNF-α, IL-1 and IL-6) and 
neurohormones (including the renin-angiotensin-aldosterone system), catecholamines 
and other transmitters of  the sympathetic nervous system, endothelin-1, vasopressin). 
Acting in concert, these hemodynamic and neurohumoral factors trigger a remodeling 
process in the non-infarcted myocardium. This remodeling process involves an 
altered gene program, hypertrophy, apoptosis of  myocardial cells, increased reactive 
oxygen species signaling and oxidative stress, mitochondrial dysfunction, altered 
intracellular calcium handling and changes in the extracellular matrix. Starting as an 
adaptive hypertrophic response, ongoing myocardial cell loss, fibrosis and metabolic 
derangements result in progressive myocardial dysfunction, ventricular dilatation and 
reduced ejection fraction, well known as the clinical syndrome of  heart failure (reviewed 
elsewhere: (134, 135)).
Several lines of  evidence point to a role for aldosterone and its receptor in cardiac 
remodeling in response to altered cardiac loading conditions:
First, plasma aldosterone levels are increased in patients who present with a myocardial 
infarction and the plasma aldosterone concentration at presentation of  acute myocardial 
infarction is associated with prognosis including the occurrence of  heart failure. (136) 
Likewise, in animal models of  acute myocardial infarction, plasma aldosterone levels 
are increased. (101, 103) 
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Secondly, patients with primary hyperaldosteronism may develop cardiac hypertrophy 
in excess to what is expected from their increase in blood pressure (7, 137) and this 
hypertrophy is reversed by adrenalectomy. (138) However, the independence from blood 
pressure has been challenged by others. (139, 140) Furthermore, in studies in transgenic 
mice with genetically determined hyperaldosteronism, cardiac remodeling is only 
observed when hyperaldosteronism is combined with salt-induced hypertension (141), 
although the role of  hypertension in the effect of  salt intake in this model has recently 
been challenged by the same authors (142). 
Another important point is that against a background of  hypertension induced 
by increased salt intake, nephrectomy and nitric oxide-deficiency, which induced 
hypertension with normal aldosterone levels, wild type but not macrophage MR 
knock-out mice developed cardiac fibrosis, suggesting an important role for the 
MR in cardiac remodeling. (143) In contrast and to complicate matters, in mice with 
selective cardiomyocyte knock-down of  the MR (using anti-sense mRNA) cardiac 
fibrosis and heart failure was induced in the absence of  hypertension or chronic 
hyperaldosteronism.(144) As for aldosterone, these results suggest an essential modulating 
role of  altered cardiac loading conditions (such as systemic blood pressure) in MR-
related development of  cardiac remodeling, although differences in target cells may 
play a role as well.
And lastly, after myocardial infarction, cardiomyocyte-specific MR knock-out mice show 
less hypertrophy, fibrosis, apoptosis and mitochondrial dysfunction in non-infarcted 
myocardium after coronary occlusion (133) as compared with non-engineered controls. 
However, in these experiments, the MR knock-out mice also showed improved infarct 
healing. Therefore, it is not clear whether the observations in the non-infarcted area 
occurred independent from reduced changes in loading conditions and neurohumoral 
activation after myocardial infarction due to improved infarct healing.
Based on these observational data in humans and experimental evidence in animals 
on the role of  aldosterone and MR in cardiac remodeling, one might hypothesize that 
aldosterone receptor antagonists should reduce maladaptive cardiac remodeling of  the 
non-infarcted myocardium independent from its potential action on infarct healing. 
Indeed, an increasing body of  evidence in both animals and humans indicate that MR 
antagonists reduce cardiac remodeling post MI when initiated after initial infarct healing. 
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TABLE 3. Schematic overview of the effects of MR antagonists on post-infarction cardiac 
remodeling in animal studies
Reference Animal 
species and 
experimental 
design
Intervention Effect on cardiac 
remodeling
Mechanistic insight
Delyani  
2001 (100)
Rat
LCA ligation
Epl (150 mg/kg bid 
orally) for 3, 7, or 
28 d, starting 24 h 
after MI
No effect on infarct 
healing
↓ fibrosis in viable 
myocardium
-
Suzuki  
2002 (146)
Dog 
Intracoronary 
microembolizations
Epl (10 mg/kg 
bid orally) for 3 
months, starting 
2 weeks after last 
embolization
↓ LVEDV, LVESV, LVEF
↓ MCSA
↓ reactive fibrosis
↓ replacement fibrosis
-
Mill  
2003 (169)
Rat
LCA ligation
Sp (20 mg/kg orally) 
for 1 month, starting 
immediately after MI
Infarct size unaffected 
(by study design) 
↓ collagen content
No effect on ventricular 
hypertrophy.
Effect unrelated to 
hemodynamic adjustments
Fraccarollo 
2003
(145)
Rat
LCA ligation
Epl (100 mg/kg/d 
orally) for 9 weeks, 
starting from the 
10th day post-MI
↓ LVEDP, and LVEDV
collagen content in non-
infarcted myocardium 
almost prevented
↓ β-MHC and ANP expression
↓ collagen I gene expression
↓ Ca-ATPase down regulation 
in non-infarcted area.
 Additive to ACEi.
Wang  
2004 (147)
Mouse
LCA ligation
Epl (200 mg/kg/d 
orally) for 12 weeks, 
starting 2 weeks 
after MI
↓ LV weight
↑LVEF, CO, and ↓ LVA
↓ interstitial collagen
↓ MCSA
Further improvement of EF, 
LVA, LV weight, and RV weight 
when combined with ACEi.
Matsumoto 
2004 (105)
Rat
LCA ligation
Sp (100 mg/kg/d 
orally), Can (10 
mg/kg/d orally), 
or combined for 
4 weeks, starting 
after MI
↓ LVEDP, LVEDV, LVDd, 
and E/A ratio
Can: ↓ LV weight, ↑ 
LVEF
↓ transcriptional activity of 
AP-1 and NF-κB 
↓ mRNA expression of ANP, 
BNP, collagen I and III in non-
infarcted myocard
Effects additive to ACEi.
Perrier  
2004 (31)
Rat ventricular 
myocytes
isolated 1 and 3 
weeks after LCA 
ligation
RU28318 (50 µg/h 
s.c., starting after MI 
Prevents electric 
remodeling: ↓ Cm 
and APD; ↑ slope 
conductance
RU28318 blunted Cav1.2 and 
Kv4.2 mRNA alterations
Masson 
2004 (106)
Forty rat
LAD ligation
Epl (average 120 
mg/kg/d orally) for 
3 months, starting 
18 d post-surgery
Restoration of diastolic 
function (peak E 
velocity, E wave 
deceleration time, and 
IVRT)
↓ myocardial interstitial 
collagen and ↓ aortic fibrosis
Lal  
2004 (107)
Rat
LCA ligation
Sp (80 mg/kg/d 
orally) or Sp (100 
ng/hr icv), for 6 
weeks starting 1 and 
3 (icv) d after MI
↑ LV dP/dtmax and ↓ 
LVEDP
↓ RV weight, and 
prevention increase 
in LV and RV internal 
circumference
↓ interstitial fibrosis
Sp icv: ↑ LVPSP
↓ cardiomyocyte hypertrophy 
and Attenuation of laminin 
and fibronectin accumulation 
in septal and peri-infarct zones 
of LV
Authors suggest contribution 
of CNS pathways (however, 
no plasma drug levels were 
reported)
Huang  
2005 (108)
Rat
LCA ligation
Sp (400 ng/kg/hr 
icv) for 4 weeks, 
starting 3 d after MI
↑ LVPSP, LV dP/dtmax 
and ↓ LVEDP
Prevention of sympathetic 
hyperactivity and impairment of 
baroreflex function
Enomoto 
2005 (109)
Rat
LCA ligation
Epl (100 mg/kg/d 
orally) for 4 weeks, 
starting after MI
↓ LVEDP, LVEDd, 
LVEDV and LV weight
↑ LVEF and ↓ E:A ratio
Attenuation 
cardiomyocyte 
hypertrophy and 
interstitial fibrosis
↓ transcription activity of 
AP-1 and NF-κB;  ↓ mRNA 
expression of ANP, BNP, 
collagen I and III, PAI-1, 
and MCP-1 in non-infarcted 
myocard
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Fraccarollo 
2005 (102)
Rat
LCA ligation
Epl (100 mg/kg/d 
orally) for 9 weeks, 
starting from the 
10th day post-MI
↓ LVEDP, LVESV, and 
LVEDV
↓ AT1-receptor and ACE up-
regulation, ↓ endothelin-1 
expression in non-infarcted 
myocardium
Attenuation of collagen I and 
–III expression
Nehme  
2005 (170)
Rat
LCA ligation
Sp (10 mg/kg/d 
orally) for 30 d, 
starting 3 months 
after MI
No significant effect 
on LVEDP and heart 
weight
↑ Einc of carotid artery
↓ LVEDP after treatment with 
Sp and lisinopril (1 mg/kd/d) 
↓ collagen density in carotid 
media
Milliez  
2005 (110)
Rat
LCA ligation
Sp (10 mg/kg/d) 
for 30 d, starting 3 
months after MI
↓ atrial and LV fibrosis
↓ P-wave duration 
No significant effect 
on LVEDP after sp or 
lisinopril alone
↓ LVEDP after treatment with 
Sp and lisinopril (1 mg/kd/d) 
Kang 
2006 (103)
Rat
LAD ligation
Epl (30 mg/kg/d 
orally) for 6 weeks, 
starting 1 d after MI
↓ LVEDP, RV weight
↑ survival
No effect on LVEF, 
LVEDV, and LVEDV/M
↓ plasma norepinephrine, 
TNA-α, IL-1β, IL-6
↓ COX-2 staining in small 
blood vessels in PVN
↓ Fra-like activity, TNF-α, and 
IL-1β in PVN neurons
Takeda  
2007 (112)
Rat
LCA ligation
Sp (100 mg/kg/d 
orally) for 2 weeks, 
starting after MI
↓ LVEDP, ↑ dP/dtmax 
and dP/dtmin 
↓ collagen volume 
fraction
↓ MR and 11βHSD2 RNA
Fraccarollo 
2008 (101)
Rat
LCA ligation vs 
sham-operated
Epl (100 mg/kg od 
orally) for 2, 3, or 7 
d, starting after MI
↓ thinning and 
dilatation of infarcted 
wall
↓ LV dysfunction
↑ neovascularization
↑ macrophage infiltration
↑ MCP-1, TNF-α, IL-1β, IL-6, IL-
10, IL-4, and factor XIIIa protein 
expression 
Kanashiro-
Takeuchi 
2009
Rat
male vs female
LCA ligation
Epl (100 mg/kg/d 
orally) for 4 weeks, 
starting from the 3rd 
d post-MI
↓LVDd and LVSd, and 
↑ EF in females
↓ cardiac fibrosis in 
females
(not in males)
Altered gene expression rather 
in females than in males
Igf1 signalling pathway putative 
candidate to explain sex-specific 
effects of Epl
Noda  
2012 (111)
Rat
LCA ligation
Sp (100 mg/kg/d 
orally) for 4 weeks, 
starting 3 weeks 
after MI
↓ LVEDP, ↑ dP/dtmax 
and dP/dtmin, ↓LVDd, 
↑ FS 
↓ reactive fibrosis
↓ mRNA expression of ANP, 
BNP, collagen I and III, and
↓ lipid peroxidation, ↓NADPH 
oxidase-dependent and ↓ 
mitochondrial superoxide 
production in non-infarcted 
myocardium
Addition of olmesartan (10 
mg/kg/d) synergistically 
improved oxidative stress and 
cardiac function 
Abbreviations: β-MHC, β-myosin heavy chain; ACE, angiotensin converting enzyme; ACEi, angiotensin converting 
enzyme inhibitor; ANP, atrial natriuretic peptide; AP-1, activator protein-1; APD, action potential duration; AT1-
receptor, angiotensin-1-receptor; BNP, brain natriuretic peptide; dP/dtmax and dP/dtmin, maximal rates of pressure rise 
and decline; Cm, membrane capacitance; Cv1.2, Ca
2+ channel alpha1C subunit; Can, canrenoate; CO, cardiac output; 
Einc, incremental elastic modulus; Epl, eplerenone; FS, fractional shortening; icv, intracerebroventricular; Igf, insulin-like 
growth factor; IL, interleukin; Kv4.2, K
+ channel 4.2 subunit; IVRT, isovolumic relaxation time; LCA, left coronary artery; 
LVA, left ventricular systolic area; LVDd, left ventricular end-diastolic dimension; LVEDP, left ventricular end diastolic 
pressure; LVEDV, left ventricular end diastolic volume; LVEDV/M, left ventricular end diastolic volume-to-mass ratio; 
LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; LVPSP, left ventricular peak systolic 
pressure; LVSd, left ventricular end-systolic dimension; MCP-1, monocyte chemoattractant protein-1; MCSA, myocyte 
cross-sectional area; MI, myocardial infarction; NF-κB, nuclear factor κB; PAI-1, plasminogen activator protein-1; PVN, 
paraventricular nucleus; RV, right ventricle; Sp, spironolactone; TNF-α, tumor necrosis factor-α
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In animals, this hypothesis has best been tested in models of  permanent coronary 
artery occlusion to prevent any confounding by reduced infarct size (100-111) (see previous 
chapter). Most studies used dosages of  spironolactone or eplerenone in the range of  
100 – 150 mg/kg/day (see Table 3 for an overview). When treatment with eplerenone 
was started from the 10th day post-infarction (to prevent effects on infarct healing), 
beneficial effects on LV dilation, cardiac function, fibrosis, or collagen content are 
observed in most studies (102, 106, 111, 145-147). However, at dosages in the range of  10-20 mg/
kg/day, benefits on cardiac function are less consistent (103, 110) suggesting that the benefit 
of  MR-antagonists may involve non-specific actions of  these drugs, thus challenging 
the specificity of  the high doses of  MR antagonists for blocking the MR. To the best 
of  our knowledge, the effects of  MR-antagonists on post MI remodeling have not 
been studied in MR-knock out animals to further address the role of  the MR in these 
observations.
CURRENT CLINICAL EVIDENCE FOR THE 
CARDIOPROTECTIVE EFFECTS OF MR ANTAGONISTS 
Only a few studies have explored the effect of  early post-MI treatment with MR 
antagonists in humans. In a randomized open-label clinical trial, 65 patients presenting 
with acute myocardial infarction were treated with blockade of  MRs at reperfusion. 
This intervention improved LVEF and LVEDV at 1 month as compared with 69 
patients who did not receive an MR antagonist. (148) In the EPHESUS trial, published in 
2003, the vast majority of  patients were on concomitant ACE inhibitor (86%) and beta-
blocker (75%) treatment, reflecting current clinical practice. EPHESUS investigated 
3313 patients after acute myocardial infarction complicated by heart failure (LVEF 
≤40% on echo plus pulmonary congestion on X-ray or pulmonary rales or presence 
of  a third heart sound or diabetes). Eplerenone was initiated 3-14 days after the event 
at 25 mg/d and up-titrated to 50 mg/d, as tolerated. Patients on eplerenone had a 15% 
relative risk (RR) reduction for overall mortality (95% CI 0.75-0.96, p=0.008), a 17% RR 
reduction to die from a cardiovascular cause (95% CI 0.72-0.94, p=0.005) and an 11% 
RR reduction (95% CI 0.64-0.97, p=0.03) to die from sudden cardiac death. The mean 
duration of  follow-up was 16 months. (3) 
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Although these trials support the use of  MR antagonists early after presentation with 
myocardial infarction, the role of  improved scar formation versus reduced maladaptive 
remodeling in the non-infarct area in this clinical benefit is not known. Hopefully, recent 
advances in imaging may provide more insight on the mechanism of  this observed 
benefit in humans. (149) More trials are needed to prove additional clinical benefit of  early 
(immediately upon reperfusion) versus delayed (after initial infarct healing) initiation of  
therapy with MR antagonists. Moreover, the need for prolonged treatment with MR 
antagonists after an acute MI with preserved cardiac function has not been explored yet.
The effects of  MR-antagonists on cardiac remodeling have been studied in relatively 
small trials (<350 patients per study arm) in patients who already have some degree of  
systolic myocardial dysfunction as expressed by a reduced LVEF (on average ranging 
from 20 to 51%), mainly as a result of  a previous myocardial infarction (see (150) for 
a recent meta-analysis and references). In these patients, MR antagonists improved 
LVEF, LVEDV and LVESV indexes, and reduced a plasma marker of  collagen turnover 
(amino-terminal peptide of  procollagen type-III). These studies used relatively low 
doses of  12.5-100 mg spironolactone, 25-50 mg canrenoate or 25-50 mg eplerenone 
per day. MR antagonists do not only have an impact on cardiac function, but also reduce 
lethal arrhythmia’s in patients with heart failure. In a recent meta-analysis including 
eight randomized trials which specifically investigated the impact of  MR antagonism on 
sudden cardiac death in patients with an LVEF ≤45%, MR antagonists reduced odds 
for sudden cardiac death by 23% (95% CI 0.66-0.89, p=0.001). (151)
These beneficial effects of  MR antagonists on cardiac remodeling have been 
substantiated by large clinical trials with clinically relevant endpoints (hospitalization 
and mortality) in patients with mild to severe systolic heart failure. (2, 4) 
First, the RALES trial, published in 1999, enrolled 1663 patients with a history of  
at least one episode of  New York Heart Association (NYHA) class IV heart failure 
within 6 months prior to randomization, a NYHA class ≥III at baseline and an ejection 
fraction ≤35%. Ischemic heart disease was the predominant underlying condition (54% 
of  patients). Indeed, the relative risk for both, overall mortality (HR 0.70, 95% CI 
0.60-0.82, p<0.001) and cardiovascular death (HR 0.69, 95% CI 0.58-0.82, p<0.001) 
was reduced by approximately one third in the spironolactone group, when compared 
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to placebo. (2) The main limitation of  this study was the low number of  patients treated 
with beta-blockers (≈10%) in these early days of  therapy with MR antagonists. 
The EMPHASIS trial, published in 2011, investigated the effect of  eplerenone in 2737 
patients with chronic systolic heart failure (LVEF ≤35%) and mild symptoms (NYHA 
class II). Ischemic heart disease was the underlying condition in 69% of  patients. The 
RR for overall mortality was reduced by 22% (95% CI 0.64-0.95, p=0.01), while the RR 
for cardiovascular death was diminished by 23% (95% CI 0.62-0.96, p=0.02). (4) Reverse 
cardiac remodeling and an improved left ventricular function are directly attributed to 
treatment with MR antagonists and may explain, how this therapy improves long-term 
survival in a heart failure population. (150) This benefit occurs with low doses of  the MR 
antagonist and even with optimal background pharmacotherapy with ACE inhibition 
or angiotensin receptor antagonism and beta blockade. (152)
In patients with diastolic dysfunction and preserved systolic left ventricular function 
(LVEF >50%) and NYHA class II-III, a recent small randomized double-blind placebo 
controlled trial observed a significant improvement of  diastolic function in response to 
1 year treatment with spironolactone (25 mg/day) but without any effect on exercise 
capacity. Larger clinical trials are needed to explore the clinical relevance of  this 
observation for the treatment of  diastolic heart failure. (153) 
Based on the findings of  the above mentioned randomized clinical trials, the European 
Society of  Cardiology has updated their guidelines for the treatment of  acute and 
chronic heart failure in 2012. (154) In particular, spironolactone or eplerenone are now 
recommended on top of  ACE inhibitor and beta-blocker treatment for all heart failure 
patients with persisting symptoms (NYHA class II-IV) and a LVEF ≤35% (class I, 
level of  evidence A). Eplerenone is recommended in patients with an acute coronary 
syndrome and acute heart failure in the presence of  an LVEF ≤40% (class I, level of  
evidence B).
Preliminary results from the REMINDER trial (NCT 01176968) indicate that MR 
antagonist treatment might also be beneficial in patients after an acute coronary 
syndrome (ACS), even in the absence of  heart failure. Early analyses were presented at 
the Conference of  the American College of  Cardiology in March 2013. In this study, 
1012 patients with STEMI and a LVEF >40% were initiated on eplerenone or placebo 
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within 24 hours after the event. The hazard to hit the primary combined endpoint 
(comprising of  time to first event of  cardiovascular mortality, re-hospitalization or 
extended initial hospital stay due to diagnosis of  heart failure, sustained ventricular 
tachycardia or fibrillation, LVEF ≤40% or BNP above age adjusted cut-off) fell by 43% 
(95% CI 0.44-0.74, p<0.0001) in the eplerenone group. Another study, the ALBATROSS 
trial (NCT 01059136), is currently recruiting patients (target: n=1600) presenting with 
ACS, with and without heart failure. MR antagonism will be initiated as early as possible 
after the event (<72 hours) and the first dose will be applied intravenously (potassium 
canrenoate), followed by spironolactone treatment. The primary combined endpoints 
consist of  the 6 months rate of  death, resuscitated cardiac arrest, potentially lethal 
ventricular arrhythmia, indication for implantable cardioversion devices and occurrence 
of  heart failure. First results may be expected within the upcoming 12 months.
In summary, there is striking evidence in favor of  MR antagonism in patients with heart 
failure for ischaemic and non-ischaemic causes. Further, some early promising data 
indicate that therapy with MR antagonists might also be extended to all patients after 
ACS in future.
CONCLUSION AND FUTURE PERSPECTIVES
In conclusion, the expression of  the MR on various cell types in the heart allows for 
direct effects of  MR antagonists on ischemia-reperfusion injury and postinfarction 
remodeling. Administration of  MR antagonists before ischemia or immediately upon 
reperfusion potently limit infarct size in animal models. This rapid nongenomic effect 
appears to be independent from the presence of  the endogenous ligand aldosterone, 
since it also occurs in isolated heart preparations and in adrenalectomized rats. In 
addition to limiting infarct size, MR antagonist also appear to facilitate scar healing and 
reduce postinfarction remodeling. In patients with heart failure, there is strong evidence 
that MR antagonist improve prognosis. With interest we await further studies on the 
immediate administration of  MR antagonists in patients with an acute myocardial 
infarction aiming to reduce infarct size.
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ABSTRACT
Background It has been suggested that mineralocorticoid receptor antagonists have 
direct cardioprotective properties, because these drugs reduce mortality in patients with 
heart failure. In murine models of  myocardial infarction, mineralocorticoid receptor 
antagonists reduce infarct size. Using gene deletion and pharmacological approaches, it 
has been shown that extracellular formation of  the endogenous nucleoside adenosine 
is crucial for this protective effect. We now aim to translate this finding to humans, 
by investigating the effects of  the selective mineralocorticoid receptor antagonist 
eplerenone on the vasodilator effect of  the adenosine uptake inhibitor dipyridamole, 
which is a well-validated surrogate marker for extracellular adenosine formation. 
Methods In a randomised, double-blinded, placebo-controlled, cross-over 
study we measured the forearm blood flow response to the intrabrachial administration 
of  dipyridamole in 14 healthy male subjects before and after treatment with placebo or 
eplerenone (50 mg bid for 8 days). 
Results  The forearm blood flow during administration of  dipyridamole (10, 
30 and 100 µg·min-1·dl-1) was 1.63 (0.60), 2.13 (1.51) and 2.71 (1.32) ml·dl-1·min-1 during 
placebo use, versus 2.00 (1.45), 2.68 (1.87) and 3.22 (1.94) ml·dl-1·min-1 during eplerenone 
treatment (median (interquartile range); p=0.51). Concomitant administration of  the 
adenosine receptor antagonist caffeine attenuated dipyridamole-induced vasodilation to 
a similar extent in both groups. The forearm blood flow response to forearm ischemia, 
as a stimulus for increased formation of  adenosine, was similar during both conditions. 
Conclusion In a dosage of  50 mg bid, eplerenone does not augment extracellular 
adenosine formation in healthy human subjects. Therefore, it is unlikely that an 
increased extracellular adenosine formation contributes to the cardioprotective effect 
of  mineralocorticoid receptor antagonists.
The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study
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INTRODUCTION
Despite state-of-the-art reperfusion strategies, mortality and morbidity in patients with 
an acute myocardial infarction remain significant. This is caused, at least in part, by ’lethal 
reperfusion injury’. (1) Therefore, novel therapeutic options to further limit ischemia-
reperfusion (IR) injury are urgently needed to improve outcome in these patients. 
It has been suggested that the mineralocorticoid receptor (MR) antagonists 
spironolactone and eplerenone could potentially serve this goal, because these drugs 
reduce mortality in patients with heart failure. (2-4) Indeed, recent studies in murine 
models of  myocardial infarction have shown that MR antagonists can directly limit 
infarct size (5-8), and have beneficial effects on left ventricular remodeling (9, 10).
The underlying mechanisms of  the infarct size-limiting effect are not yet fully 
understood, but it has been suggested that the endogenous purine nucleoside 
adenosine is crucially involved. Adenosine is an endogenous purine nucleoside, which 
is formed by intra-, and extracellular degradation of  adenosine monophosphate by 
the enzyme ecto-5’-nucleotidase (CD73). Degradation of  adenosine only occurs in 
the intracellular compartment. As a consequence, facilitated diffusion of  adenosine 
over the cellular membrane by the equilibrative nucleoside transporter (ENT) is 
normally directed inwards. Stimulation of  membrane-bound adenosine receptors 
(A1, A2A, A2B, and A3) induces various effects, including vasodilation, inhibition of  
inflammation, and protection against IR-injury. Indeed, endogenous adenosine acts as 
a key mediator of  the infarct size-limiting effect of  several drugs, including statins and 
metformin. (11, 12) A recent series of  experiments, using genetic and pharmacological 
approaches in mouse and rat models of  myocardial infarction, convincingly 
demonstrated that the cardioprotective effects of  the MR antagonists eplerenone and 
canrenoate were crucially dependent on extracellular adenosine formation by CD73 and 
adenosine receptor stimulation. (6)
Based on these previous animal studies, we now hypothesize that MR antagonists 
increase the extracellular adenosine concentration by activating CD73, which has 
previously also been reported for statins (13), and we aim to test this hypothesis in 
humans in vivo. Measurement of  circulating endogenous adenosine is extremely difficult 
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(14), because the half  life of  adenosine in blood is very short, due to rapid uptake and 
degradation by circulating erythrocytes. (15) Therefore, we used the vasodilator effect 
of  the ENT inhibitor dipyridamole as a read-out for endogenous adenosine formation 
by CD73, as previously described by our group.(16, 17) The results of  this study will give 
novel insight into the pharmacology of  MR antagonists, which can be used to optimize 
pharmacological cardioprotective strategies, for example avoid the use of  adenosine 
receptor antagonists, such as caffeine, in patients treated with MR antagonists. 
METHODS
STUDY POPULATION
After approval by the Institutional Review Board of  our centre, we included 14 healthy 
male volunteers. They had no history of  cardiovascular disease or asthma, did not smoke 
and did not use any medication. In all participants we performed a physical examination, 
electrocardiography, and laboratory investigation to exclude cardiovascular and 
pulmonary disease, hypertension (SBP >140 mmHg or DBP >90 mmHg), hypotension 
(SBP <100 mmHg or DBP <60 mmHg), diabetes mellitus (fasting venous glucose >6.9 
mmol/l or random glucose of  >11.0 mmol/l), renal dysfunction (MDRD <60 mL/
min), liver enzyme abnormalities (alanine aminotransferase (ALAT) twice upper limit), 
and hyperkalemia (plasma potassium ≥4.8 mmol/l). 
All volunteers provided written informed consent before enrollment. The study was 
conducted in accordance with Good Clinical Practices and the Declaration of  Helsinki 
and was prospectively registered at ClinicalTrials.gov by number NCT01837108.
STUDY DESIGN
We performed a single center, double-blinded, randomised, placebo-controlled 
cross-over study. Tablets of  50 mg of  eplerenone were over-encapsulated and fully 
mimicking placebos were created by the Department of  Clinical Pharmacy of  the 
Radboud University Medical Centre. Study medication was taken bid during 8 days. 
We advised the participants to have a diet low in potassium. On the 7th and 8th day of  
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treatment, we measured forearm blood flow (FBF) with the use of  venous occlusion 
plethysmography. After a wash-out period of  at least 4 weeks, the participants crossed-
over to the alternative treatment arm. Blood pressure was measured at baseline, on day 
3-5, on day 7 and 8. 
VENOUS OCCLUSION PLETHYSMOGRAPHY
All experiments were performed in a temperature-controlled room (24 ± 0.5 °C), in the 
morning after an overnight fast and at least 24 hours of  caffeine and alcohol abstinence. 
On the days of  the experiments, 75 minutes after supervised intake of  the study drug, a 
27-gauge needle (B. Braun Medical B.V.) was inserted into the brachial artery of  the non-
dominant arm for intra-arterial drug administration. Fifteen minutes later, baseline FBF 
was measured during the infusion of  normal saline. During the experiment, the total 
volume infused into the brachial artery was kept constant at 100 µl·min-1·dl-1 of  forearm 
volume. We measured FBF in both arms with venous occlusion plethysmography, 
using mercury-in-silastic-strain gauges. The hand circulation was occluded during the 
measurements, as described previously. (18) Drugs were administered for 5 minutes per 
dose. On day 7, we performed 3 experiments, which were all separated by a wash-out 
period of  30 minutes to prevent any cross-over effects:
1. We measured FBF during the administration of  incremental dosages of  dipyridamole 
(10, 30 and 100 µg·min-1·dl-1 of  forearm volume) into the brachial artery. (10) 
2. Subsequently, we measured the vasodilator response to 2 minutes and 5 minutes of  
arterial occlusion (‘post-occlusive reactive hyperemia’ (PORH)). Forearm ischemia 
was induced by inflation of  an upper arm cuff  to 200 mmHg, as described 
previously. (13) PORH was used as a stimulus for increased endogenous extracellular 
adenosine formation.
3. Finally, on day 7, we measured FBF during simultaneous administration of  
dipyridamole (10, 30 and 100 µg·min-1·dl-1) and the adenosine receptor antagonist 
caffeine (90 µg·min-1·dl-1) into the brachial artery. 
On day 8, we recorded the forearm vasodilator response to the administration of  
sodium nitroprusside (SNP) (0.6 and 0.06 µg·min-1·dl-1) and adenosine (1.5 and 5.0 
µg·min-1·dl-1) to exclude non-specific effects of  eplerenone on vasomotor function and 
adenosine sensitivity. Figure 1 illustrates the design of  the study. 
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FIGURE 1. Schematic overview of the experimental protocol
BLOOD AND URINE SAMPLING
Three to 5 days after the start of  the study medication, the plasma potassium 
concentration was measured in venous blood. Volunteers were excluded and study 
medication was discontinued if  the plasma potassium was ≥5.1 mmol/l. 
At day 6, the participants collected a 24-hours urine sample. Urinary sodium and 
creatinine were determined to ensure that salt intake was approximately the same during 
both treatment periods.
Before the experiment on day 7, blood was drawn for the determination of  potassium, 
sodium, creatinine, plasma caffeine concentration (to check compliance with caffeine 
abstinence), aldosterone, renin, and plasma eplerenone concentration. On day 8 we 
measured the plasma caffeine concentration only. Subjects with a circulating caffeine 
concentration >1.0 mg/l were excluded from analyses. 
ANALYTIC PROCEDURES
Plasma caffeine concentrations were determined using reversed-phase HPLC 
with ultraviolet detection set at 273 nm, according to Schreiber-Deturmeny and 
Bruguerolle. (19) After data monitoring and data lock, eplerenone concentrations were 
determined by LC-MSMS. Liquid chromatographic separation was performed at a 
temperature of  30 °C with a mobile phase consisting of  solvent A (0.1% (v/v) formic 
acid (HCOOH) in water) and solvent B (0.1 % (v/v) HCOOH in acetonitrile). For 
the mass spectrometric analysis, heated electrospray ionization was operated at a spray 
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voltage of  + 4.5 kV, a capillary temperature of  225 °C and a vaporizer temperature of  
382 °C. Positive ion mode was used with selected reaction monitoring for the quantitative 
analysis of  eplerenone, using the most abundant product ion for quantification.
OUTCOMES
The primary outcome was the FBF response to the intrabrachial administration of  
incremental dosages of  dipyridamole, after treatment with eplerenone, compared to 
placebo. 
Secondary outcomes were the FBF response to the intrabrachial administration of  
incremental dosages of  dipyridamole with concomitant administration of  caffeine, and 
the FBF response to incremental periods of  arterial occlusion. 
STATISTICAL ANALYSIS
For sample size calculation, we assumed a 25% increase in the primary endpoint, a 
standard deviation of  the logarithm of  the FBF of  0.35, and a correlation between 
both experiments of  0.7. This assumption was based on the previous findings that MR 
antagonists reduced infarct size in preclinical studies with approximately 30% (6), and 
that rosuvastatin, which increases CD73 activity with approximately 50% approximately 
doubles dipyridamole-induced forearm vasodilation (13,17). The power of  the study was 
set at 80% with a two-sided alpha of  0.05. As results, 12 evaluable subjects were needed. 
In order to have 12 evaluable subjects, we included 14 eligible participants. 
FBF analyses were done offline before unblinding of  the study. We averaged all 
individual FBF responses during the last 4 minutes of  the baseline FBF (normal saline), 
the last 2 minutes of  the FBF response to dipyridamole, sodium nitroprusside, and 
adenosine. For the PORH, we selected the highest FBF after reperfusion and also 
averaged FBF values for each consecutive minute. Results are expressed as the median 
absolute FBF (interquartile range) in ml·dl-1·min-1. In an additional analysis, to correct 
for any possible systemic effects on FBF during the experiments, we divided the FBF 
in the experimental arm by the FBF in the non-experimental arm. This analysis was 
performed with untransformed data. 
A linear mixed model was used to compare differences between the treatments, with 
the log FBF during placebo and eplerenone treatment as the dependent variable with 
the following fixed factors: treatment (eplerenone versus placebo), dose, period, and 
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the interaction between treatment and dose. To correct for repeated measurements, we 
used a heterogeneous compound symmetry structure for the residuals. 
For the comparison of  the plasma potassium values, blood pressure, and heart rate on 
a single moment as well as the measurements in the 24 hours urine samples and plasma 
sodium, serum aldosterone, and plasma renin values, we used a paired sample t-test, 
after testing for normality.
RESULTS
SUBJECTS
We screened 20 subjects for eligibility. Two participants withdrew from participation 
and 4 participants were excluded, because of  a DBP <60 mmHg (n=3), and a SBP 
>140 Hg (n=1). The baseline characteristics are depicted in Table 1. 
TABLE 1. Baseline characteristics of the male participants
Clinical characteristics Value (mean ± SD)
Age - years 21.9 ± 3.0
BMI - kg/m2 23.6 ± 1.9
SBP: Syslic blood pressure (SBP) in mmHg 127 ± 8
DBP: Diastolic blood pressure (DBP) in mmHg 70 ± 8
HR – beats/min 59 ± 9
Blood plasma
Potassium - mmol/L 3.9 ± 0.3
Creatinine - µmol/L 82.2 ± 9.7
Non-fasting glucose - mmol/L 5.3 ± 0.6
ALAT - U/L 30.0 ± 5.3
Non-fasting cholesterol - mmol/L 3.8 ± 0.6
Abbreviations: ALAT, alanine aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; HR, heart rate; 
SBP, systolic blood pressure; SD, standard deviation
The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study
167
3.2
FBF responses to the different stimuli were obtained in all 14 subjects, with the 
exception of  the FBF response to SNP and adenosine in 1 subject, because insertion 
of  the arterial needle failed. All baseline plasma caffeine concentrations were below 0.6 
mg/l, and therefore none of  the subjects had to be excluded from analysis. Please see 
Figure 2 for the flow diagram of  the various different phases of  this cross-over trial. 
Assessed for eligibility (n=20)
Excluded (n=6)
• Not meeting inclusion criteria (n=4)
• Declined to participate (n=2)
Randomized (n=14)
Allocated to placebo (n=14)
• Received allocated intervention (n=14)
Allocated to eplerenone 50 mg bid (n=14) 
during 8 days
• Received allocated intervention (n=14)
Venous plethysmography on day 7 and 8
• One procedure unsuccessful on day 8
Analysed (n=14)
• Excluded from analysis (n=0)
Enrollment
Analysis
Follow-Up
Allocation
FIGURE 2. Consort 2010 flow diagram 
Eplerenone treatment did not significantly affect blood pressure and plasma potassium, 
but there was a significant decrease in the plasma sodium concentration (Table 
2). Urinary sodium concentration did not significantly differ between placebo and 
eplerenone treatment. Furthermore, eplerenone treatment almost doubled the serum 
aldosterone and plasma renin concentrations (p<0.05), with an unchanged aldosterone-
to-renin-ratio (Table 2; p=0.30). 
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TABLE 2. Hemodynamic and laboratory values during the study (means ± SD)
Placebo Eplerenone p-value
Blood plasma
Potassium day 3-5 - mmol/L 3.9 ± 0.26 3.9 ± 0.28 0.78
Potassium day 7 - mmol/L 3.6 ± 0.23 3.7 ± 0.27 0.12
Sodium day 7 - mmol/L 140.0 ± 1.4 139.1 ± 1.4 <0.05
Creatinine day 7 - µmol/L 82.1 ± 6.8 84.6 ± 6.4 <0.05
Aldosterone day 7 - nmol/L 0.65 ± 0.41 1.20 ± 0.50 <0.05
Renin day 7- mE/L 27.7 ± 18.1 44.8 ± 26.7 <0.05
ARR 34.2 ± 21.0 38.0 ± 16.9 0.30
24hr urine (day 6)
Total amount - mL 1475.6 ± 520.0 1635.4 ± 677.4 0.34
Sodium - mmol/L 85.7 ± 50.3 104.7 ± 44.4 0.15
Creatinin - mmol/L 13.3 ± 6.2 12.0 ± 5.2 0.52
Blood pressure - mmHg
SBP day 3-5 126 ± 9 129 ± 7 0.57
DBP day 3-5 65 ± 7 67 ± 11 0.54
SBP day 7 123 ± 10 120 ± 8 0.19
DBP day 7 62 ± 10 62.6 ± 8 0.58
SBP day 8 124 ± 11 126 ± 10 0.52
DBP day 8 65 ± 8 63 ± 6 0.34
Heart rate - beats per minute
HR day 3-5 63 ± 10 62 ± 9 0.42
HR day 7 59 ± 11 58 ± 10 0.51
HR day 8 61 ± 11 60 ± 7 0.74
Abbreviations: ARR, aldosterone-to-renin-ratio; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood
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FIGURE 3. FBF response to A dipyridamole and B dipyridamole (D) in incremental dosages 
during concomitant administration of caffeine (C) in a constant dosage of 90 µg·dL-1·min-1, 
during placebo (grey) and eplerenone (black) treatment in the experimental (filled squares) 
and non-experimental (open squares) arm 
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OUTCOMES
Baseline FBF before intra-arterial infusion of  dipyridamole was 1.34 (0.82) ml·dl-
1·min-1 during placebo and 1.47 (1.05) ml·dl-1·min-1 during eplerenone treatment. The 
incremental dosages of  dipyridamole increased FBF in the experimental arm to 1.63 
(0.60), 2.13 (1.51) and 2.71 (1.32) ml·dl-1·min-1, and 2.00 (1.45), 2.68 (1.87) and 3.22 
(1.94) ml·dl-1·min-1 during placebo and eplerenone treatment, respectively. There was 
no significant increase in FBF response to dipyridamole during eplerenone treatment 
compared to the placebo experiment (Figure 3A; p=0.51). Similarly, the FBF ratio 
did not differ between placebo and eplerenone treatment (p=0.79). In none of  the 
experiments changes in FBF in the non-experimental arm were observed.
Caffeine significantly blunted the dipyridamole-induced vasodilator response during 
placebo and eplerenone treatment (p<0.001), but there was no difference between both 
treatment periods (Figure 3B; p=0.98).
FIGURE 4. PORH after 2 minutes of arterial occlusion PORH in the first 3 minutes after 2 
minutes of arterial occlusion during placebo (grey) and eplerenone (black) treatment in the 
experimental (filled squares) and non-experimental (open squares) arm
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FIGURE 5. FBF response to A sodium nitroprusside (SNP) and B adenosine, during placebo 
(grey) and eplerenone (black) treatment in the experimental arm (filled squares) and non-
experimental arm (open squares)
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The peak (absolute) FBF's after 2 and 5 minutes of  arterial occlusion were 20.00 (9.73) 
and 27.60 (7.45) ml·dl-1·min-1 respectively during placebo, and 23.05 (12.35) and 27.75 
(16.05) ml·dl-1·min-1 respectively during eplerenone use (p=0.91). Figure 4 shows that 
the PORH after 2 minutes of  arterial occlusion was not potentiated by eplerenone 
(p=0.73). The averaged FBF after 5 minutes of  arterial occlusion was 11.24 (4.94) in 
the 1st minute, 3.18 (1.52) in the 2nd minute, and 2.42 (0.99) ml·dl-1·min-1 in the 3rd 
minute after arterial occlusion during placebo use. During eplerenone treatment, FBF 
was 11.97 (6.60), 2.65 (2.14), and 2.72 (1.78) ml·dl-1·min-1 in the first 3 minutes after 5 
minutes of  arterial occlusion. Eplerenone did not potentiate the PORH after 5 minutes 
of  arterial occlusion (p=0.58).
The vasodilator response to SNP and adenosine did not differ between placebo and 
eplerenone treatment (Figure 5).
The plasma eplerenone concentration on t=0 was 0.17 ± 0.13 µg/ml (mean ± SD). 
During placebo, the eplerenone concentration was 0.0 µg/ml in all cases.
SAFETY
There were no serious adverse events. In none of  the subjects, plasma potassium 
exceeded 4.6 mmol/l. Thirteen adverse events occurred in 9 different participants. 
During eplerenone treatment 1 subject experienced a short period of  abdominal pain 
on day 4 of  the treatment and another subject had a mild headache on day 7. During 
placebo use 2 subjects had a short period of  headache, 1 subject experienced light 
headedness during sports activities, 1 subject had symptoms of  hay fever and another 
subject developed a skin rash. Due to dislocation of  the arterial needle, a very small 
amount of  the infused volume was administered extra-arterially in 3 subjects. Another 
subject developed 3 small, pulsating, yellowish hives just medial from the arterial needle 
during dipyridamole infusion, which resolved spontaneously. One subject experienced 
pain in his left shoulder during the experiment, which resolved after we repositioned the 
participant. Finally, 1 subject developed a forearm hematoma after several unsuccessful 
attempts to cannulate the brachial artery on day 8.
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DISCUSSION
This study indicates that the selective MR antagonist eplerenone does not have an effect 
on the extracellular adenosine formation in humans in vivo, excluding this mechanism as 
an explanation for the beneficial cardiovascular effects of  MR antagonism observed in 
patients with heart failure. 
The Randomized Aldactone Evaluation Study (RALES), Eplerenone Post–acute 
myocardial infarction Heart failure Efficacy and Survival Study (EPHESUS), and 
Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure 
(EMPHASIS-HF) showed that treatment with MR antagonists reduces the mortality 
and the number of  hospitalizations in patients with mild to severe systolic heart 
failure (2-4). In animal models of  myocardial infarction, MR antagonists limit infarct size 
when administered either prior to ischemia or just before the onset of  reperfusion, and 
protect against cardiac remodeling, as reviewed by van den Berg et al. (20) 
The underlying mechanism of  the beneficial effects of  MR antagonists in patients is 
not yet understood. However, results from animal studies suggest that extracellular 
adenosine formation is crucial for the protective effect of  MR antagonists against 
myocardial IR injury. In an elegant series of  experiments in mice and rabbits, Schmidt 
et al showed that the MR antagonists canrenoate and eplerenone reduce infarct size in a 
dose-dependent manner. Moreover, by using pharmacological approaches and models 
of  targeted gene deletion, the investigators convincingly demonstrated an important role 
for endogenous adenosine in the cardioprotective effect. The infarct size-limiting effect 
of  canrenoate was completely abolished in CD73 knock-out mice and in adenosine 
A2b receptor knock-out mice. Similar results were obtained in isolated rat hearts. In 
rats, administration of  eplerenone at 10 µM at the moment of  reperfusion resulted in 
a reduction of  the infarct size from 40 to 10%, which was completely blocked by co-
administration of  the adenosine receptor blocker 8p-sulfophenyladenosine. (6)
Based on this series of  experiments, we hypothesized that the selective MR antagonist 
eplerenone increases extracellular formation of  adenosine, by activation of  the enzyme 
CD73. Interestingly, increased endogenous adenosine receptor stimulation has also been 
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implicated in the cardioprotective effect of  other drugs, including statins, methotrexate 
and metformin. (12, 21, 22)
It is difficult to investigate the potential effects of  drugs on endogenous adenosine 
because the half  life of  adenosine in blood is extremely short due to rapid uptake 
and degradation of  adenosine by erythrocytes and endothelial cells. (16) In a normal 
physiological situation, the transmembranous adenosine concentration gradient drives 
extracellular adenosine into the cytosol. (23) The ENT-inhibitor dipyridamole inhibits 
this facilitated diffusion and thereby increases the extracellular adenosine concentration, 
which can subsequently activate membrane-bound adenosine receptors at the site of  
adenosine formation. (16, 24) These observations justify the use of  dipyridamole-induced 
vasodilation as a read-out of  extracellular adenosine formation. We have previously 
shown, using a similar experimental design as the present study, that rosuvastatin 
augments dipyridamole-induced forearm vasodilation and post-occlusive reactive 
hyperemia and limits forearm ischemia-reperfusion injury via adenosine receptor 
stimulation. (13, 17) Moreover, rosuvastatin increased the activity of  CD73 on circulating 
human mononuclear cells. (13) 
In the present study, we could not confirm a relation between treatment with eplerenone 
and the extracellular adenosine system in healthy humans in vivo. We showed that a one-
week treatment with eplerenone 50 mg bid does not potentiate dipyridamole-induced 
vasodilation and does not affect PORH after 2 and 5 minutes of  arterial occlusion. 
These findings are in sharp contrast to the previous observations in animal models of  
myocardial infarction. (6)
How can this discrepancy be explained? First, it has been recognized that many 
promising findings in animal studies cannot be confirmed in human studies. (25) In 
general, this translational failure can be explained by methodological shortcomings in 
animal studies, e.g. the lack of  a formal sample size calculation, selection bias due to 
the lack of  randomization, unblinded researchers, and inadequate statistical analyses. (25) 
The scientific basis for our hypothesis is based on only one preclinical study by Schmidt 
et al. (6) This study, however, described a series of  experiments in which a pivotal role 
for endogenous adenosine in the infarct size-limiting effect of  the MR antagonists 
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canrenoate and eplerenone was consistently observed in different animal species and by 
using various methodological approaches, including pharmacological inhibitor studies 
and gene deletion models.
Translational failure could also result from fundamental differences between the animal 
models and the human situation. With regard to adenosine metabolism, it is known for 
fundamental differences exists between rats and humans (e.g. the rat ENT1 transporter 
is less sensitive to inhibition with dipyridamole than the human ENT1). (26) However, 
other drugs that modulate adenosine levels seem equally effective in humans and in 
animal models. (17, 21, 22, 27) 
Thirdly, a major difference in drug concentration between the animal studies and the 
human situation is often present. In our study, the circulating eplerenone concentration 
immediately before the intake of  the last medication dose (trough concentration) 
averaged 0.17 µg/ml (0.41 µM). Given a bioavailability of  70%, and an apparent volume 
of  distribution of  43-90 liters, the eplerenone concentration at the moment of  the 
experiment is approximately 1.7 µM. In a rat Langendorff  model, in which the heart is 
perfused with a buffer solution (6), a cardioprotective effect of  eplerenone was observed 
with 10 µM, but not with 1 µM. Given a plasma protein binding of  50%, the effective 
concentration in the rat study is approximately 10-times higher than the concentration 
in our study. We used 50 mg of  eplerenone bid, which is higher than the dosages 
administered in the clinical trials in patients with heart failure in which eplerenone 
showed beneficial effects. (3, 4) Therefore, we cannot exclude that eplerenone does affect 
adenosine formation at higher concentrations, which are not relevant however for the 
clinical situation. In addition, in our study, eplerenone was administered during one 
week, in contrast to the single dose administration in the animal studies. As expected, 
the serum aldosterone and plasma renine levels had almost doubled after 6 days of  
treatment with eplerenone. Although this increase in aldosterone does probably not 
affect our results, because eplerenone blocks the MR, MR-independent effects of  
aldosterone have been described previously (20). In theory, any non-MR-mediated effects 
of  aldosterone on adenosine metabolism might have influenced our result. Finally, it 
is important to realize that our experiments were performed in healthy subjects, and 
not in patients with cardiovascular disease or heart failure. This was done because we 
aimed to demonstrate a general pharmacological mechanism of  eplerenone and also 
because the preclinical studies that were fundamental to our hypothesis were performed 
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in healthy animals. We cannot exclude, however, that the effects of  MR antagonists are 
different in patients with cardiovascular disease, such as heart failure.
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ABSTRACT
Background Despite rapid reperfusion, mortality and morbidity in patients with 
an acute myocardial infarction remain significant. Therefore, novel pharmacological 
strategies to further limit ischemia-reperfusion (IR) injury are warranted. In animal 
models of  myocardial infarction, mineralocorticoid receptor antagonists potently limit 
infarct size. In the current study we aimed to translate these findings to the human 
situation and investigated for the first time in human myocardial tissue whether 
eplerenone limits IR-injury.
Methods  In 24 patients undergoing elective cardiac surgery, the right atrial 
appendage was harvested, and two trabeculae were dissected from each appendage and 
suspended in an organ bath. We induced contraction by electrical field stimulation. 
Recovery of  contractile force after a period of  simulated ischemia and reperfusion was 
used as well-validated endpoint of  IR-injury. From each patients, the trabeculae were 
randomized to either ischemic preconditioning (IP) or no IP (n=12; positive control 
experiment) or to superfusion with eplerenone (10 µM) or vehicle (n=12) in a paired 
approach. 
Results IP improved recovery from 19.9 (SEM 3.3) % to 26.3 (SEM 4.3)% 
(p<0.05). During vehicle and eplerenone superfusion, mean recovery of  contractile 
function after simulated ischemia and reperfusion was 45.2 (SEM 5.6)% and 36.5 (SEM 
4.1)% (p=0.14).
Conclusion Eplerenone does not limit IR-injury in human atrial tissue ex vivo. 
Our results are in sharp contrast to preclinical studies demonstrating cardioprotective 
effects of  mineralocorticoid receptor antagonist. With great interest we await the results 
of  the MINIMISE-STEMI study, in which the effect of  MR antagonism on myocardial 
infarct size in humans is currently under investigation. 
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INTRODUCTION
Rapid myocardial reperfusion is essential to limit infarct size in patients with a myocardial 
infarction. Paradoxically, reperfusion itself  can also aggravate injury (“reperfusion 
injury”). (1) Therefore, mortality and morbidity of  these patients remain high, and novel 
strategies to reduce ischemia-reperfusion (IR) injury are needed. It has been suggested 
that mineralocorticoid receptor (MR) antagonists might serve this goal, since these 
drugs reduce morbidity and mortality in patients with heart failure. (2-4) 
Indeed, direct cardioprotective effects of  these drugs are consistently demonstrated 
in several murine models of  myocardial infarction. (5-10) The acute administration of  
MR antagonists, either before the onset of  ischemia or at the moment of  reperfusion, 
profoundly reduced infarct size. (Reviewed in (11)) In an elegant series of  experiments it 
has been shown that the cardioprotective effects of  the MR antagonists eplerenone and 
canrenoate depend on extracellular adenosine formation. (9) Adenosine is an endogenous 
purine nucleoside, and stimulation of  membrane-bound adenosine receptors induces 
various effects, including attenuation of  inflammation, vasodilation and protection 
against IR. (12)
 
Whether these cardioprotective effects of  MR antagonists also hold true in humans 
is yet unknown. In the current study, we aimed to translate the preclinical findings to 
the human situation for the first time and test the hypothesis that the MR antagonist 
eplerenone limits IR-injury in human myocardial tissue. We used the recovery of  
contractile function after a period of  simulated IR in human atrial trabeculae as a well-
established model of  myocardial IR-injury. (13-15) 
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METHODS
PATIENTS 
Adult patients undergoing elective coronary artery bypass surgery (CABG), valve surgery 
or aortic surgery, with extracorporeal circulation were asked to participate. Exclusion 
criteria were atrial arrhythmias, right ventricular failure, known atrial enlargement, the 
use of  mineralocorticoid receptor antagonists, and the use of  oral antiarrhythmics 
(except beta-blockers), sulfonylurea derivates, dipyridamole, or theophylline. Patients 
were asked to abstain from caffeine consumption 24 hours before surgery, since 
caffeine is an effective adenosine receptor antagonist which prevents the protective 
effects of  ischemic preconditioning and might interfere with any protective effects of  
eplerenone. (14) All volunteers provided written informed consent before enrollment. 
The study protocol was approved by the Institutional Review Board of  our centre. The 
study was conducted in accordance with Good Clinical Practices and the Declaration of  
Helsinki and was prospectively registered at ClinicalTrials.gov (NCT02118753). 
EXPERIMENTAL DESIGN
We used the experimental set up as described previously. (13, 14) Briefly, the right atrial 
appendage was harvested by the cardiothoracic surgeon before the introduction of  
the extracorporal circulation and immediately placed in cold (4°C) modified Tyrode's 
solution (NaCl 118.5 mmol/l, KCl 4.8 mmol/l, NaHCO3 24.8 mmol/l, KH2PO4 1.2 
mmol/l, MgSO4 1.4 mmol/l, CaCl2 1.8 mmol/l, glucose 10.0 mmol/l, and pyruvate 10.0 
mmol/l), which was gassed with 95% oxygen and 5% CO2. Two atrial trabeculae were 
dissected, vertically suspended in an organ bath, and linked to a force transducer. Each 
trabecula was superfused with pre-oxygenated Tyrode’s buffer. Electrical field stimulation 
was performed in unstretched condition at 1 Hz using platinum ring electrodes placed 
on both sides of  the trabeculae (pulse duration 60 ms; pulse current 40 mA). After 30 
minutes of  stimulation at unstretched conditions to allow recovery from transportation 
and preparation, trabeculae were gradually stretched over 15 minutes until maximal 
contractile force was achieved. After 20 minutes of  equilibration, a baseline recording 
was performed during 10 min. Those trabeculae that failed to produce at least 0.2 g of  
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developed force at the end of  baseline were excluded. After 30 minutes of  equilibration, 
the trabeculae were subjected to 90 minutes of  simulated ischemia, followed by 105 
minutes of  reperfusion. Simulated ischemia was accomplished by superfusing the 
trabeculae with substrate-free modified Tyrode’s solution (7.0 mM choline chloride 
substituted for glucose and pyruvate) and rapid pacing at 3 Hz. The superfusate was 
pumped into an artificial lung filled with 95% N2/5% CO2, which resulted in a low 
pO2 of  10 to 20 mm Hg. For each patient, the trabeculae were randomized to either 
an intervention or control to allow paired analysis of  the effects of  the interventions. 
First, as a positive control experiment, we studied the effect of  ischemic preconditioning 
(IP) in 12 pairs of  trabeculae, according to the experimental design we published 
previously. (14) Briefly, immediately after baseline recordings, the trabeculae of  each 
patient (n = 12) were randomly assigned to either a stimulus for IP or continued 
superfusion with Tyrode’s solution. IP was induced by 5 min of  simulated ischemia and 
5 min of  simulated reperfusion. 
Subsequently, the trabeculae of  12 patients were randomly assigned to superfusion with 
eplerenone (10 µM, kindly provided by Pfizer) or vehicle (dimethyl sulfoxide, DMSO 
<0.1 %). Administration of  eplerenone started 10 minutes before simulated ischemia 
and continued throughout the experiment. 
DATA RECORDING AND STATISTICAL ANALYSIS
The differences between the maximal tension during contraction and the minimal 
tension during relaxation were averaged for every 5 minutes (‘contractile force’). 
Recovery of  contractile force in the last 10 minutes of  reperfusion as a percentage of  
the last 10 minutes of  equilibration was used as the primary endpoint.
For sample size calculation, we assumed a mean averaged percentage recovery of  18.7 
± 3.20 %, and a test-to-test correlation coefficient of  0.5. A total of  12 subjects was 
required to detect a 37.5 % change in averaged percentage recovery, which is a relevant 
reduction of  ischemia-reperfusion injury, with a power of  80% at a significance level 
of  0.05. 
Data are presented as mean (SEM) and were analysed with SPSS 22 for Windows. We 
assumed a one-sided (IP) and two-sided (eplerenone versus vehicle) significance level 
of  0.05. Data were checked for normality and analyzed accordingly (Wilcoxon Rank test 
or Student’s t-test).
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RESULTS
Of  the 83 patients who initially signed their informed consent, successful paired 
experiments in two two trabeculae were performed in 24 patients. The reasons for 
exclusion of  the patients, and the reasons for drop-out are depicted in Figure 1. The 
baseline characteristics of  the patients are presented in Table 1. 
Signed informed consent 
(n=83)
Excluded (n=42)
• No caffeine abstinence (n=3)
• Surgery cancelled (n=2)
• Switch to off-pump procedure (n=2)
• No analyst available (n=33)
• Surgery of participants at the same 
time (n=2)
• End of study (n=1)
Included 
(n=41)
Allocated to "eplerenone vs vehicle" (n=20)
• Received allocated intervention (n=12)
• Did not receive allocated intervention (n=8)
• No appendage harvested, because the size 
was too small (n=1)
• No atrial appendage harvested (n=2)
• Technical problems during ex vivo experiment 
(n=1)
• Right atrial appendage harvested, but 
trabeculae not useful (n=3)
Analysed (n=12)
• Excluded from analysis (n=0)
Enrollment
Allocated to "ischemic preconditioning" (n=21)
• Received allocated intervention (n=12)
• Did not receive allocated intervention (n=9)
• No appendage harvested, because the size 
was too small (n=3)
• Right atrial appendage harvested, but 
trabeculae not useful (n=6)
Analysed (n=12)
• Excluded from analysis (n=0)
Analysis
Allocation
FIGURE 1. Progress of participants during the experiment 
Eplerenone does not limit ischemia-reperfusion injury in human myocardial tissue
187
3.3
TABLE 1. Baseline characteristics
Variable (n) Setting 1 preconditioning 
(n=12)
Setting 2 eplerenone 
vs control (n=12)
Men 11 12
Age (mean ± SD) 55.4 ± 11.9 66.4 ± 8.1
Type of surgery
CABG 6 8
AVR 4 2
CABG + AVR 0 1
Aortic surgery 2 1
Cardiovascular risk factors
Hypertension 4 10
Diabetes mellitus 1 1
Current of former smoker 4 5
Positive family history 3 4
Dyslipidemia 7 4
BMI > 30 kg/m2 2 1
Medication
Aspirin 8 10
Beta blocker 10 9
ACE-inhibitor 4 5
ATII receptor antagonist 2 4
Ca-channel antagonist 1 5
Diuretic 1 5
Nitrate 1 1
Lipid lowering drug 9 4
Glucose lowering therapy 1 1
Abbreviations: ACE, angiotensin converting enzyme; ATII, angiotensin II; AVR, aorthic valve surgery; BMI, body mass 
index; Ca, calcium; CABG, coronary artery bypass grafting
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In the positive control experiment, IP improved recovery from 19.9 (SEM 3.3)% to 
26.3 (SEM 4.3)% (p=0.048), corroborating our previous finding. (14) In the second set 
of  experiments mean recovery of  contractile function after reperfusion was 45.2 (SEM 
5.6)% and 36.5 (SEM 4.1)%, during vehicle and eplerenone superfusion, respectively 
(p=0.14; Wilcoxon Rank test). After exclusion of  one outlier with a recovery of  98.6% 
in the control trabecula, the results remained unchanged (40.4 (SEM 3.1)% and 36.0 
(SEM 4.4)% for vehicle and eplerenone respectively; Figure 2; p=0.17 (Student’s t-test)). 
FIGURE 2. The contractile force (difference between maximal tension during contraction 
and minimal tension during relaxation) in paired trabeculae (n=11) during eplerenone 
exposure (10 µM) (filled circles) or control (open squares); exclusion of 1 outlier
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DISCUSSION
Our study is the first to investigate the direct effects of  mineralocorticoid receptor 
antagonism on ischemia-reperfusion injury in human cardiac tissue. In contrast 
to various recent preclinical studies, in which administration of  MR antagonists 
consistently reduced myocardial infarct size in animal models of  myocardial 
infarction (11), we did not observe any protective effect of  eplerenone against IR-injury 
in human myocardial tissue. 
Post-ischemic recovery of  contractile force of  human atrial trabeculae has been 
validated previously as a reliable and reproducible surrogate model of  human myocardial 
IR-injury. Ischemic preconditioning consistently reduced IR-injury in this model in 
previous studies (13, 14), which was reproduced by the first series of  experiments in our 
current study. Moreover, the protective effect of  IP in this model is critically dependent 
on adenosine receptor stimulation (14), opening of  adenosine triphosphate-dependent 
potassium (KATP) channels, and activation of  protein kinase C 
(13). These mechanisms are 
of  similar importance in IP-mediated cardioprotection in animal models of  myocardial 
infarction using histological infarct size as endpoint of  IR-injury (16). These findings 
highlight that the mechanism of  cardioprotection by IP is largely similar in animal 
models of  myocardial infarction and the model we used in the current study.
 
In models of  acute myocardial infarction in mice, rats, and rabbits, acute administration 
of  spironolactone, eplerenone, or canrenoate profoundly limits infarct size. (6-10) 
Pathways analysis revealed that increased extracellular adenosine formation and 
subsequent stimulation of  adenosine A2B receptors is critical for eplerenone-induced 
cardioprotection. (9) Why do these consistent findings not translate to a cardioprotective 
effect of  eplerenone in our current study? 
First, it is known that in general the external validity of  animal studies is limited due 
to biological differences between animals en humans. This is illustrated by the fact that 
about 500 neuroprotective treatment strategies improve outcome in animal models of  
ischemic stroke, while only two have proven effective in patients. (17) In addition, we 
used the recovery of  contractile function as a marker for IR-injury. This differs from 
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the studies in animals, in which histological infarct size is used as the primary endpoint. 
However, the protective effect of  IP and pivotal involvement of  adenosine, PKC, 
and KATP-channels that has been demonstrated in many animal models of  myocardial 
infarction, could previously be confirmed in the atrial trabeculae model. (13, 14)
A second potential explanation relates to the presumed mechanism of  eplerenone-
induced cardioprotection. In animals, increased adenosine formation and receptor 
stimulation is critical for this effect. We have recently demonstrated, however, that 
eplerenone does not increase extracellular adenosine formation at relevant dosages in 
humans in vivo. (18) This finding is consistent with the lack of  a cardioprotective effect 
in humans. 
Thirdly, one could argue that the presence of  the endogenous ligand aldosterone is 
required for the protective effect of  MR antagonists. However, cardioprotective 
effects were also observed in hearts from adrenalectomized rats (8) and in Langendorff  
perfusion models (11), showing that the cardioprotective effect of  MR antagonists in 
animals is independent from the presence of  aldosterone. 
Finally, it is important to consider the dose and timing of  administration of  eplerenone. 
The concentration of  eplerenone that we used (10 µM), has been shown to limit IR-
injury in a previous study (9) and is approximately 6 times higher than the calculated 
(peak) plasma levels in healthy adults after a one week treatment of  eplerenone 50 mg 
bid. (18) Administration of  eplerenone was started only 10 minutes before simulated 
ischemia. However, the limited duration of  exposure to eplerenone does not explain its 
lack of  benefit in the current study, since also in the animal studies, acute administration 
of  MR antagonists effectively reduced infarct size. (11)
In summary, eplerenone does not limit IR-injury in human myocardial tissue. These 
results are in sharp contrast to previous observations in animal models of  IR. Based 
on these promising preclinical data, a large clinical trial was recently initiated to 
investigate whether MR antagonist limit infarct size in patients with an acute myocardial 
infarction. (19) Therefore, patients with a STEMI will be randomized to an intravenous 
bolus of  canrenoate before coronary reperfusion, followed by three months of  oral 
spironolactone. With great interest we await the results of  this randomized controlled 
trial. (19) 
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SUMMARY
The adrenocortical hormone aldosterone plays a key role in blood pressure regulation. 
Autonomous overproduction of  aldosterone, which occurs in patients with primary 
aldosteronism (PA), results in hypertension and/or hypokalemia. Next to the well 
known risks of  hypertension on cardiovascular events (1, 2), it has been suggested that 
aldosterone itself  has direct toxic effects on the cardiovascular system: preclinical data 
demonstrate that aldosterone promotes oxidative stress, fibrosis and apoptosis, and 
increases infarct size (IS) in animal models of  coronary occlusion (3-8), and treatment 
with mineralocorticoid receptor (MR) antagonists consistently reduces IS in these 
models. (8) Similarly, in the human in vivo situation, patients with PA display a higher risk 
of  atrial fibrillation, heart failure, myocardial infarction (MI), stroke and left ventricular 
hypertrophy (LVH) than patients with essential hypertension (EHT) and similar blood 
pressure levels (9), and treatment with MR antagonists reduces morbidity and mortality 
in patients with heart failure. (10-12)
To be able to improve treatment of  patients with PA to prevent cardiovascular disease, 
it is important to better understand how aldosterone impacts on the cardiovascular 
system and how MR antagonists can prevent these effects. This thesis is dedicated to 
unravelling the adverse cardiovascular effects of  aldosterone and beneficial effects of  
MR antagonists with the ultimate aim to improve diagnosis and treatment of  patients 
with PA. 
In chapter 2.1, we investigated whether patients with PA already have cardiovascular 
damage early in the disease, using an active screening strategy in patients with 
hypertension. Patients with a newly diagnosed hypertension from more than 50 primary 
care centres were systematically screened for PA. Of  361 hypertensive patients in 
whom an aldosterone-to-renine ratio (ARR) was calculated, the diagnosis of  PA (with a 
positive salt loading test (SLT)) was made in 9 individuals. (13) We assessed cardiovascular 
risk markers in 6 of  these patients with PA and 24 matched control patients with EHT. 
Interestingly, 2 of  the patients with PA (33.3 %) compared to none of  the patients 
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with EHT had LVH (p=0.04). We did not observe differences in ankle-brachial index, 
carotid intima media thickness, flow-mediated dilation (FMD), pulse wave velocity, 
central aortic blood pressure and urinary albumin-creatinine-ratio between patients 
with PA and patients with EHT. The absence of  differences in these latter outcome 
measures can be explained by the lack of  power. Nevertheless, given the difference in 
LVH, we conclude that in patients with PA target organ damage is present already in the 
early phase of  their disease, suggesting that early active diagnosis and treatment might 
be of  benefit. 
The exact underlying mechanisms of  the deleterious effects of  aldosterone as well 
as the beneficial effects of  MR antagonists on the cardiovascular system are not yet 
fully elucidated. Most of  the suggested mechanisms are retrieved from preclinical 
studies. (8) In an elegant series of  animal experiments, it has been suggested that the 
protective effects of  MR antagonists on ischemia-reperfusion (IR) injury depend on 
adenosine receptor signalling. (14) Indeed, the endogenous nucleoside adenosine has 
powerful cardioprotective properties. (15) 
In chapter 2.2, we aimed to translate these findings to the human in vivo situation. 
We hypothesized that patients with PA have reduced circulating adenosine levels and 
increased susceptibility to IR compared to patients with EHT. This could, at least in 
part, explain the higher risk of  future cardiovascular events in these patients. 
Although measurement of  circulating adenosine levels is challenging due to its rapid 
half-life of  less than a second, we previously validated a method to overcome the 
continuation of  adenosine formation and breakdown in the vacutainer after blood 
drawing. Using a purpose-built syringe, the blood mixes immediately at the end of  the 
needle with a solution containing pharmacological blockers of  the proteins involved 
in adenosine metabolism. We measured forearm FMD before and after 20 minutes of  
ischemia and 20 minutes of  reperfusion of  the upper arm as a safe and well-validated 
model to study IR injury in the in human in vivo situation. 
For the inclusion of  our patients we used stringent diagnostic criteria to diagnose and 
exclude PA. Although we did not match for baseline characteristics, we ended up with 
2 comparable groups of  20 patients with PA and 20 patients with EHT. There were 
no differences in sex distribution, age, duration of  hypertension and blood pressure 
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between the study groups. We found that patients with PA have significantly lower 
levels of  circulating adenosine, but unaffected susceptibility to IR. 
The reduced circulating adenosine level in patients with PA provides a novel and exciting 
explanation for the increased risk of  cardiovascular events in these patients compared 
to patients with EHT. Drugs beneficially affecting the adenosine metabolism could 
therefore potentially reduce the risk of  future cardiovascular events in patients with PA.
We explored yet another underlying mechanism of  the increased risk for cardiovascular 
complications in patients with PA in chapter 2.3. In preclinical studies, aldosterone 
promotes vascular and myocardial fibrosis and experimental studies demonstrate that 
this is mediated by galectin-3 (Gal-3) production and secretion. (16-19) We proposed 
that aldosterone excess stimulates Gal-3 secretion in various cell types of  the 
cardiovascular and immune system, and that subsequently Gal-3 induces pro-fibrotic 
and pro-atherogenic effects in the vascular wall and myocardium in humans in vivo. We 
measured circulating Gal-3 concentrations in a retrospective cohort compromising 78 
patients with PA, 56 patients with EHT, and 39 patients who had been cured from PA 
(post-adrenalectomy). In these well-characterized patient groups, we did not observe 
a difference in plasma Gal-3 values. Also after correction for potential confounders, 
circulating Gal-3 values were not higher in patients with PA compared to patients with 
EHT or cured patients with PA. Therefore, we concluded that it is highly unlikely that 
increases in plasma Gal-3 production contribute to the increased risk of  cardiovascular 
events in patients with PA, compared to patients with EHT.
Finally, in chapter 3, we focused on the cardioprotective effects of  MR antagonists. In 
chapter 3.1, we reviewed the literature on the beneficial effects of  MR antagonists on 
IR injury and post MI remodeling. In preclinical studies, MR antagonists limit IR injury 
when administered either before the onset of  ischemia, or just before reperfusion. (8) 
These cardioprotective effects of  MR antagonists therefore appear to be mediated by 
nongenomic (rapid) intracellular signaling pathways. As described above, one of  the 
suggested underlying mechanisms of  cardioprotection by MR antagonism is adenosine 
receptor stimulation. (14) 
In chapter 3.2, we aimed to confirm this proposed action of  MR antagonists in the human 
in vivo situation. We investigated whether treatment with the MR antagonist eplerenone 
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increases extracellular adenosine concentrations in humans in vivo. To circumvent the 
methodological difficulties of  directly measuring circulating adenosine concentrations, 
we measured the forearm blood flow response to the intrabrachial administration of  
dipyridamole as a read out parameter for extracellular adenosine formation. 
To understand this model of  extracellular adenosine assessment, it is important to 
bear in mind the human adenosine metabolism: adenosine is an endogenous purine 
nucleoside, which is formed by intra-, and extracellular degradation of  adenosine 
monophosphate by the enzyme ecto-5’-nucleotidase, which is also named CD73. 
Degradation of  adenosine occurs in the intracellular compartment. As a consequence, 
facilitated diffusion of  adenosine over the cellular membrane by the equilibrative 
nucleoside transporter (ENT) is normally directed inwards. Stimulation of  membrane-
bound adenosine receptors induces various effects, including vasodilation, inhibition 
of  inflammation, and protection against IR-injury. (15, 20) Dipyridamole increases the 
extracellular endogenous adenosine concentration by inhibition of  the ENT transporter 
and induces local vasodilation. (20) Therefore, the vasodilator effect of  dipyridamole 
accurately reflects extracellular adenosine formation by the CD73 enzyme. (21) 
From our placebo-controlled cross-over study described in chapter 3.2 we concluded 
that a one-week treatment with eplerenone in a dosage of  50 mg bid does not affect 
extracellular adenosine formation in healthy volunteers. It is therefore unlikely that an 
increased extracellular adenosine formation contributes to the cardioprotective effect 
of  mineralocorticoid receptor antagonists in the human in vivo situation. 
However, healthy volunteers substantially differ from older patients with comorbidities. 
Therefore, we readdressed our hypothesis in a human ex vivo experiment including 
patients scheduled for cardiac surgery. Of  these patients, we used the right atrial 
appendage that was harvested by the cardiothoracic surgeon before the introduction 
of  the extracorporal circulation. We dissected two trabeculae from each appendage 
and suspended these in an organ bath. We induced contraction by electrical field 
stimulation and used the recovery of  contractile force after a period of  simulated IR 
as a well-validated endpoint of  IR-injury. (22-24) From each patient, the trabeculae were 
randomized to either superfusion with eplerenone (10 µM) or vehicle. As described in 
chapter 3.3, eplerenone did not limit IR-injury in human atrial tissue ex vivo. Our results 
are conflicting with the findings in preclinical studies summarized in chapter 3.1, in 
which MR antagonists limit IR injury when administered just before the onset of  IR. 
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GENERAL DISCUSSION, CLINICAL 
IMPLICATIONS AND FUTURE PERSPECTIVES
Despite the serious risk of  cardiovascular events in patients with PA, which necessitates 
early diagnosis and treatment, it is recognized that there is a mean delay in diagnosis of  
PA of  approximately 8 years. (25) Most likely this is caused by the absence of  the typical 
clinical characteristic of  hypokalemia in 37-56 % of  the patients with PA (25), as well as 
unawareness of  PA amongst physicians or the presumption that PA is a rare disease 
not to be looked for routinely. In contrast, PA appears to be the most common cause 
of  secondary hypertension. (26) In the primary care hypertensive population prevalence 
rates of  PA of  3-12 % have been reported, versus 1-30 % in referral centres. (27, 28) 
By systematic screening for PA in the primary care setting, in combination with extensive 
measurements of  cardiovascular adverse effects, and by exploring novel mechanisms 
that could mediate the increased cardiovascular risk of  patients with PA, this thesis 
might be helpful for improving the diagnostic and therapeutic strategy in these patients 
in the future. 
In chapter 2.1, we reported that patients with PA display LVH already in the early phase 
of  their disease, when early diagnosis is actively pursued by systematic screening of  all 
patients with a novel diagnosis of  hypertension in the primary care setting. Our finding, 
although with cautions given the small sample size, should encourage physicians to 
screen for PA, at least in high risk patient groups, to prevent (further) cardiovascular 
damage. (13) When adhering to the current international guideline however (13), none of  
the patients that participated in our study described in chapter 2.1 would be eligible for 
ARR measurement, because these patients did not have clinical clues for PA, i.e. therapy 
resistant hypertension or hypokalemia. 
Therefore, one might suggest to screen all patients with a newly diagnosed 
hypertension for PA. It has been reported that ARR testing in the hypertensive 
population leads to a 10-fold increase in detection rate of  PA and 10-fold increase in 
adrenalectomies. (29) Screening for PA in primary care however has proven to be 
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challenging: in a previous study from our centre examining the prevalence of  PA in 
patients with a newly diagnosed, never treated hypertension, less than 10 % of  the 
3748 patients with a newly diagnosed hypertension were actually screened. (30) More 
importantly, the low prevalence rate of  PA of  2.6 % (CI 1.4-4.9 %) in this primary care 
population questions health benefits and cost-effectiveness of  screening all patients 
with a newly diagnosed hypertension for PA. 
We included the 9 patients with PA who were diagnosed in this previous study from 
our centre. (30) Due to the lower than expected prevalence rate of  PA, our study in 
chapter 2.1 did not have sufficient power to detect differences in ankle-brachial index, 
carotid intima media thickness, FMD, pulse wave velocity, central aortic blood pressure 
and urinary albumin-creatinine-ratio between patients with PA and patients with EHT. 
Another important limitation of  our study is the use of  antihypertensive drugs during 
the vascular experiments that may have altered the outcome measures. 
A possible explanation for the low screening rate as well as low prevalence rate is that 
PA might be a continuous pathologic disorder, with mild symptoms and biochemical 
disturbances in the early phase of  the disease and the development of  typical, more 
severe clinical characteristics when PA progresses. Mildly elevated blood pressure levels, 
as well as the absence of  hypokalemia might have withheld the general practitioners to 
measure aldosterone and renin concentrations in the patients with a newly diagnosed 
hypertension. (30) Furthermore, the sensitivity of  the screening test for PA might be 
lower in patients with a recently diagnosed hypertension. Indeed, in a primary care 
hypertensive population, 43 % of  patients with PA, diagnosed by a positive confirmation 
test, have aldosterone levels below 0.44 nmol/l. (31) Despite lowering of  the cut-off  
value of  aldosterone from 0.42 nmol/l to 0.40 nmol/l in our primary care population, 
it is likely that we have falsely excluded patients with hypertension from having PA. (30) 
Next to limitations in the screening test for PA, no confirmation test is currently 
considered to be the golden standard. (13) In the studies described in this thesis, we 
used the SLT as confirmation test for PA. Next to safety issues because of  volume 
overloading (2 L in 4 hours) in specific patient groups, (e.g. heart failure or severe 
therapy resistant hypertension), sensitivity and specificity of  the SLT are restricted. 
When compared to the fludrocortison suppression test, which is generally accepted as 
a reliable confirmation test for PA, sensitivity and specificity are 85-90 % and 92-84 % 
respectively. (32, 33) Importantly, these numbers have to be interpreted with caution, since 
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the fludrocortison suppression test itself  is not the golden standard. When compared 
to the finding of  significant lateralisation of  aldosterone production on AVS, in patients 
with a unilateral aldosterone producing adenoma (APA), sensitivity and specificity of  
the SLT are 83 and 75 % respectively. (34) In a recent study 29 % of  patients with PA had 
lateralisation on AVS despite a post-SLT aldosterone <0.139 nmol/l, which is similar to 
the cut-off  value we use to exclude PA in our centre. (35) Interestingly, these 12 patients 
all had potassium values between 2.7 and 3.5 mmol/l. Therefore, the authors suggest 
to avoid confirmation testing and perform AVS in all patients with a positive screening 
test for PA and hypokalemia. (35) This suggestion was adopted in the recently updated 
international guideline on the diagnosis of  PA (13), but has not yet been implemented in 
our local protocol. Major drawbacks of  avoiding the SLT and proceed to AVS quickly 
might be the costs and patients’ safety. 
It follows that diagnosis of  PA is still challenging. Therefore, it would be highly relevant 
to study novel biomarkers for the diagnosis of  PA. An attractive candidate is urinary 
prostasin, which is involved in epithelial sodium channel activation. (36, 37) In our centre, 
specific omics profiles for patients with PA are currently being investigated. Future 
studies are needed to validate their role in the identification of  PA. 
Using the current strategy of  diagnosis and treatment of  PA, patients with PA are at 
increased risk of  cardiovascular events compared to patients with EHT. (9) In this thesis, 
we reported for the first time that patients with PA have lower levels of  circulating 
adenosine than control patients with EHT and similar blood pressure levels. This finding 
might, at least in part, explain their higher risk of  cardiovascular events compared to 
patients with EHT. 
Indeed, endogenous adenosine induces powerful cardioprotective effects, including 
vasodilation and inhibition of  atherosclerosis, inflammation and fibrosis, and limitation 
of  IR injury. (15) The potential importance for this substance to impact on cardiovascular 
outcome is illustrated by studies reporting that genetic variants in the adenosine 
metabolism leading to increased endogenous adenosine formation are associated 
with improved cardiovascular survival in patients with coronary artery disease. (38) In 
addition, in patients with an acute MI, administration of  exogenous adenosine limits 
IR injury (39, 40), although not consistently, and might protect against the development 
of  heart failure (41). Although increasing adenosine concentrations can limit IR injury, 
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most studies report that prevention of  adenosine signalling does not further increase 
IR injury. (23, 42)
From these observations we can appreciate that a reduction in circulating adenosine levels 
might impair cardiovascular function, as our research group previously hypothesized in 
a study in patients with hyperhomocysteinemia in whom the risk of  cardiovascular 
events is increased. In these patients, adenosine-induced vasodilation was impaired 
due to an increased uptake of  adenosine into the intracellular compartment, limiting 
adenosine receptor stimulation. (43)
From our results it follows that modulation of  the adenosine metabolism might reduce 
the excess risk of  cardiovascular events in patients with PA. In chapter 3.2, we showed 
that treatment with MR antagonists does not increase extracellular adenosine formation 
in healthy humans in vivo. (44) It is therefore interesting to explore the effects of  drugs 
known to increase extracellular adenosine levels. Statins are known to upregulate the 
enzyme CD73 (21), which converts adenosine monophosphate to adenosine. We propose 
that these drugs are attractive candidates to lower the risk of  cardiovascular events in 
patients with PA. Also, dipyridamole, which is an ENT-blocker resulting in increased 
extracellular adenosine concentrations (45), could potentially serve this goal. 
Follow up studies would definitely benefit from measurements of  circulating adenosine 
levels before and after adrenalectomy. Also, future studies should focus on unravelling 
the metabolic changes driving lower adenosine levels, to pave the way towards novel 
pharmacological treatment of  PA. The circulating concentration of  adenosine is the 
sum of  adenosine production, cellular uptake, and intracellular degradation. Activity 
of  the enzyme CD73 did not differ between the patients with PA and EHT. Therefore, 
increased cellular uptake and degradation of  adenosine most probably explains the 
lower adenosine concentration, comparable to patients with hyperhomocysteinemia. (43) 
As mentioned before, endogenous adenosine has multiple effects that potentially protect 
against cardiovascular disease, including limitation of  atherosclerosis, inhibition of  
thrombocyte aggregation, inhibition of  inflammation and fibrosis, vasodilatation, and 
limiting ischemia-reperfusion injury. (15, 20) In our study, we investigated the susceptibility 
to forearm IR. The significant reduction in circulating adenosine levels but unaffected 
susceptibility to IR injury in patients with PA compared to patients with EHT can have 
several potential explanations. First, the beneficial effect of  adenosine on IR injury 
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is controversial, at least in humans in vivo. Whilst administration of  adenosine before 
reperfusion diminished IS in patients with an anterior wall MI (39, 40), several preclinical 
studies (46-48) and clinical studies (49, 50) failed to show an effect of  exogenous adenosine 
on IR injury. In addition, even if  enhanced adenosine receptor stimulation might 
limit IR injury, this does not necessarily mean that a reduction in adenosine receptor 
stimulation would augment IR injury, particularly considering the fact that many 
endogenous substances regulate IR susceptibility. For example, adenosine receptor 
antagonists did not increase IS itself  in preclinical models of  IR-injury (14), although these 
antagonists did significantly prevent the beneficial effects of  ischemic pre- and post- 
conditioning. (23, 42)
Future studies in patients with PA should therefore not focus on IR injury, but on 
alternative determinants of  cardiovascular damage. An attractive topic to study is 
atherosclerosis for several reasons. First, patients with PA have an increased risk of  
atherosclerotic complications, including myocardial infarction and stroke, compared to 
patients with EHT. (9) Second, in animal models aldosterone increases atherosclerosis and 
promotes plaque formation via the MR. (51, 52) Third, adenosine has anti-atherosclerotic 
properties (20) and in genetic deletion models, inactivation of  the adenosine metabolism 
leads to progression of  atherosclerosis (53). We therefore propose that the reduced 
circulating adenosine levels in patients with PA may, at least in part, contribute to 
progression of  atherosclerosis. 
Another appealing mechanism of  the excess risk of  cardiovascular events in PA appeared 
to be overproduction of  the β-galactoside-binding lectin Gal-3. Aldosterone increases 
Gal-3 protein levels and expression in in vitro and in vivo studies (16-19) and in patients 
with heart failure, circulating Gal-3 is associated with extracellular matrix markers 
and with adverse long-term cardiovascular outcomes. (54, 55) Also in these patients, 
aldosterone levels are increased and treatment with MR antagonists improves mortality 
and morbidity. (10-12) Indeed, higher plasma Gal-3 concentrations in patients with PA 
compared to EHT were observed by an Asian group (the TAIPAI study group), and 
levels return to normal after adrenalectomy. (19, 56) In our study described in chapter 2.3 
however, we did not find differences in plasma Gal-3 concentrations between patients 
with PA, cured PA patients (post-adrenalectomy), and patients with EHT. (57)
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Despite limitations due to the retrospective character, our study benefits from major 
strengths. In comparison to the small cohort of  the TAIPAI study group (19, 56), we 
selected a large group of  patients. The patients in our cohort did not use treatment 
interfering in the renin-angiotensin-aldosterone system and we carefully corrected our 
results for potential confounders. Levels of  circulating Gal-3 were 10-fold lower in the 
cohort of  the Asian study group, which may be explained by a difference in analytical 
method or ethnic background of  the patients. (57)
In a subanalysis of  our study in chapter 2.3, we compared Gal-3 levels in patients with 
PA with and without LVH. The observation that the difference in cardiac damage is not 
reflected by differences in plasma Gal-3 concentrations, excludes a role of  plasma Gal-3 
in aldosterone-mediated target organ damage in humans in vivo. (57)
In contrast to the direct cardioprotective effects of  MR antagonists on IR injury and 
cardiac remodelling in preclinical models as described in our review in chapter 3.1 (8), we 
could not translate these findings to the human in vivo situation. (44, 58) Eplerenone did 
not protect against IR injury in human cardiac tissue (58), and we could not confirm a key 
role of  adenosine receptor signalling in the beneficial effect of  eplerenone. (44)
It has been recognized that many promising findings of  preclinical (cardiovascular) 
research cannot be confirmed in human studies. (59, 60) This so-called ‘translational 
failure’ in general can be explained by methodological shortcomings in animal studies, 
such as the lack of  a formal sample size calculation, selection bias due to the lack 
of  randomization, unblinding, and inadequate statistical analyses. (59, 60) Also, animals 
substantially differ from humans with regard to physiology and pathophysiology. 
Alarmingly, only 2 of  the 500 protective strategies regarding cerebral IR injury in animal 
models have been proven to be effective in humans. (59)
Another important difference between preclinical and clinical studies is the use of  
different end points. In chapter 2.2, we measured brachial FMD before and after upper 
arm ischemia, as a model for endothelial IR injury. In chapter 3.3, we used the recovery 
of  contractile function as a marker for IR-injury. (58) These models significantly differ 
from the studies in animals, in which histological infarct size is used as the primary 
endpoint. However, the protective effect of, amongst others, IP has been confirmed in 
the FMD and atrial trabeculae models. (22, 23, 61) 
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The effect of  early administration of  MR antagonists on IR injury and post-infarction 
LV remodeling in patients with an acute MI, independent of  the presence of  heart 
failure, is currently under investigation in the MINIMISE STEMI trial. (62) From our 
study described in chapter 3.3, we concluded that administration of  eplerenone just 
before the onset of  ischemia does not protect against IR injury in human atrial tissue 
ex vivo. One might argue that the presence of  the endogenous ligand aldosterone is 
required for the protective effect of  MR antagonists. However, MR antagonists also 
confer cardioprotection in adrenalectomized rats (63) and in ex vivo Langendorff  perfusion 
models (8), showing that the cardioprotective effect of  MR antagonists is independent 
from the presence of  aldosterone. The calculated concentration of  eplerenone in our 
human atrial tissue ex vivo model was approximately 6 times higher than the calculated 
(peak) plasma levels in healthy adults after a one week treatment of  eplerenone 50 mg 
bid. (44) In the MINIMISE STEMI trial, patients receive the parenterally available MR 
antagonist potassium canrenoate in a dosage of  200 mg, followed by spironolactone 
50 mg od during 3 months. (62) The dosage of  canrenoate is comparable and the 
maintenance dose of  spironolactone is slighty higher than the dosages used in the 
ALBATROSS trial, which failed to show a beneficial effect of  MR antagonism on major 
cardiovascular outcomes in patients admitted for MI. (64) Given these results and our own 
observations (58), we await the results of  the MINIMISE STEMI trial with interest and 
scepticism. 
Taken together, we showed that an active screening strategy for PA might not prevent 
the development of  cardiac damage in these patients, as reflected by our finding that 
LVH is already present at the time of  diagnosis of  hypertension. This does not exclude 
however, an important role for future studies aiming at improving the diagnostic 
strategy for PA. Currently, there is a delay in diagnosis of  PA of  approximately 8 
years (25), which leads to (progression of) cardiovascular damage in these patients.
Therefore, we aimed to unravel underlying mechanisms of  aldosterone-mediated 
cardiovascular damage, with the ultimate goal to develop novel treatment strategies 
in patients with PA. Our exciting finding of  reduced circulating adenosine levels in 
comparison to patients with EHT could potentially serve this goal. Future studies are 
needed to confirm our finding and to unravel the underlying pathway of  these reduced 
adenosine levels. Pharmacological modulation of  the adenosine metabolism could 
Summary and general discussion 
207
4
then be a way to improve mortality and morbidity in patients with PA and bilateral 
aldosterone overproduction, who cannot be surgically treated. These patients are 
continuously exposed to high aldosterone levels and its toxic effects on the cardiovascular 
system, that may not be prevented completely by treatment with MR antagonists. MR 
antagonists have been shown to protect against IR injury and post-infarction cardiac 
remodelling in preclinical models, but we could not translate an effect of  eplerenone on 
IR injury in human cardiac tissue. We are therefore reluctant to further study the effect 
of  MR antagonism on IR injury in humans in vivo. Furthermore, MR antagonists did 
not increase extracellular adenosine formation in healthy humans in vivo. Future studies 
are needed to unravel mechanisms -other than upregulation of  extracellular adenosine 
levels- of  the cardioprotective effect of  MR antagonists. 
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SAMENVATTING
Het hormoon aldosteron, dat in onze bijnierschors wordt geproduceerd, speelt een 
belangrijke rol in de bloeddrukregulatie. Overproductie van aldosteron, zoals bij 
patiënten met primair hyperaldosteronisme (PA), resulteert in hypertensie (hoge 
bloeddruk) en/of  hypokaliëmie (een laag kaliumgehalte in het bloed). Bij de meeste 
patiënten met hypertensie is de oorzaak hiervan overigens niet bekend. We spreken in 
dat geval van essentiële hypertensie (EHT). 
Naast de bekende negatieve gevolgen van hypertensie op hart- en vaatziekten (1, 2), wordt 
gesuggereerd dat aldosteron zelf  directe schadelijke effecten heeft op ons hart- en 
vaatstelsel: laboratorium- en dierexperimentele studies hebben aangetoond dat aldosteron 
zorgt voor meer schade door reactieve zuurstofverbindingen, bindweefselvorming, 
celdood en een toename in de infarctgrootte bij dieren met een hartinfarct (3-8). 
Behandeling met medicamenten die de werking van aldosteron blokkeren, zogenaamde 
mineralocorticoïd receptor (MR) antagonisten, verminderen op consequente wijze de 
infarctgrootte in deze diermodellen. (8) 
Patiënten met PA blijken een hoger risico op bezoemfibrilleren (een hartritmestoornis), 
hartfalen, het krijgen van een hartinfarct en het ontwikkelen van linkerventrikelhypertrofie 
(verdikte hartspier) te hebben dan patiënten met EHT en vergelijkbare 
bloeddrukken. (9) Behandeling met MR antagonisten vermindert de totale sterfte, sterfte 
door hart- en vaatziekten en het aantal ziekenhuisopnames voor hart- en vaatziekten bij 
patiënten met hartfalen. (10-12)
Om de behandeling van patiënten met PA te kunnen optimaliseren met als doel om 
hart- en vaatziekten bij deze patiënten te voorkomen, is het belangrijk om te begrijpen 
welke effecten aldosteron heeft op ons hart- en vaatstelsel en hoe MR antagonisten dit 
kunnen voorkomen. In dit proefschrift is gepoogd om de onderliggende schadelijke 
effecten van aldosteron alsmede de gunstige effecten van MR antagonisten op ons 
hart- en vaatstelsel te ontrafelen, met het uiteindelijke doel om diagnostiek naar en 
behandeling van PA te verbeteren. 
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In hoofdstuk 2.1 onderzochten we door middel van een actieve screeningsmethode of  
patiënten met PA al hart- en vaatschade hebben in de vroege fase van hun ziekte. Patiënten 
met een nieuw gediagnosticeerde hypertensie uit meer dan 50 huisartspraktijken werden 
gescreend op het hebben van PA. Screening op PA geschiedt door middel van het 
meten van aldosteron en renine in een bloedmonster. Vervolgens dient de diagnose te 
worden bevestigd. In het Radboudumc wordt hiervoor de zoutbelastingstest gebruikt, 
waarbij patiënten in 4 uur tijd 2 L fysiologisch zout via een infuus krijgen toegediend. 
Bij gezonde personen zorgt het toedienen van vocht voor een onderdrukking van de 
aanmaak van renine en aldosteron. Bij patiënten met PA blijft de aldosteronproductie 
echter verhoogd direct na de test. 
Van de 361 hypertensieve patiënten bij wie een aldosteron en renine in een bloedmonster 
werd bepaald, werd bij uiteindelijk 9 patiënten de diagnose PA gesteld door middel van 
een positieve zoutbelastingstest. (13) We vergeleken 6 verschillende markers voor hart- en 
vaatschade tussen 6 patiënten met PA en 24 patiënten met EHT. Wij vonden dat in 2 
van de patiënten met PA (33.3 %), vergeleken met geen enkele patiënt met EHT, reeds 
linkerventrikelhypertrofie aanwezig was. We vonden geen verschillen in de andere 5 
markers voor hart- en vaatschade tussen de patiënten met PA en patiënten met EHT, 
hetgeen verklaard kan worden door het kleine aantal proefpersonen. 
Echter, vanwege het significant vaker voorkomen van linkerventrikelhypertrofie hebben 
wij geconcludeerd dat bij patiënten met PA orgaanschade al aanwezig is in de vroege 
fase van hun ziekte. Het is daarom belangrijk om deze patiënten in een vroeg stadium 
op te sporen en ze tijdig te behandelen. 
De onderliggende mechanismen van de schadelijke effecten van aldosteron alsmede 
de gunstige effecten van MR antagonisten op ons hart- en vaatstelsel zijn nog niet 
volledig opgehelderd. De meeste voorgestelde mechanismen werden verkregen 
uit laboratorium- en dierexperimentele onderzoeken. Zo is van MR antagonisten 
aangetoond dat zij kunnen beschermen tegen ischemie-reperfusie (IR) schade. (8) IR 
schade is de schade die resteert na een periode van ischemie (zuurstofgebrek door een 
verminderde of  afwezige bloeddoorstroming) ondanks reperfusie (het herstellen van 
de bloeddoorstroming). In een elegante serie van dierexperimenten werd aangetoond 
dat het beschermende effect van MR antagonisten op IR schade afhankelijk is van 
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stimulatie van de adenonisinereceptor. (14) Adenosine is een bio-organische verbinding 
met krachtige beschermende effecten op hart- en bloedvaten. (15) 
In hoofdstuk 2.2 vertaalden we de bevindingen van deze dierexperimentele studie naar 
de mens. Onze hypothese was dat patiënten met PA lagere adenosineconcentraties in 
hun bloed hebben en (hierdoor) en verhoogde gevoeligheid voor IR dan patiënten met 
EHT. Dit zou, in ieder geval gedeeltelijk, het hoger risico op toekomstige hart- en 
vaatziekten bij deze patiënten kunnen verklaren. 
Het meten van adenosineconcentraties in het bloed is zeer gecompliceerd, omdat 
binnen een seconde de helft alweer wordt afgebroken. In het verleden is op de 
afdeling Farmacologie-Toxicologie echter een betrouwbare methode ontwikkeld om 
de adenosinevorming en –afbraak na bloedafname te voorkomen. Hiervoor wordt 
een speciale spuit gebruikt, waarbij het bloed aan het eind van de naald meteen 
gemixt wordt met een oplossing van blokkers van eiwitten die betrokken zijn in het 
adenosinemetabolisme. 
Voor het meten van IR schade bij de mens gebruikten we een alternatieve, maar veilige 
en betrouwbare methode, namelijk het meten van de mate van vaatverwijding in de 
armslagader, vóór en na 20 minuten durende ischemie en 20 minuten durende reperfusie. 
Ischemie van de bovenarm werd gecreëerd door met een volledig opgepompte 
bloeddrukband de bloedtoevoer naar de arm te onderbreken. 
Voor de selectie van de patiënten in deze studie gebruikten we strenge diagnostische 
criteria om PA te bevestigen dan wel uit te sluiten. We eindigden met 2 vergelijkbare 
groepen van 20 patiënten met PA en 20 patiënten met EHT. Er waren geen verschillen 
in man-vrouw verdeling, leeftijd, duur van hypertensie en de hoogte van de bloeddruk 
tussen de studiegroepen. De belangrijkste bevinding in onze studie was dat patiënten 
met PA significant lagere adenosineconcentraties in het bloed hebben dan patiënten met 
EHT, maar dat er geen verschil is in de gevoeligheid voor IR tussen beide studiegroepen. 
De verlaagde adenosineconcentraties bij patiënten met PA verschaft een nieuwe en 
spannende verklaring voor het verhoogd risico op hart- en vaatziekten bij deze groep 
patiënten, in vergelijking met patiënten met EHT. Medicamenten die op een gunstige 
manier het adenosinemetabolisme stimuleren, zouden mogelijkerwijs het risico op 
toekomstige hart- en vaatziekten bij patiënten met PA kunnen verlagen.
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We bestudeerden een ander onderliggend mechanisme van het verhoogd risico op hart- 
en vaatschade bij patiënten met PA in hoofdstuk 2.3. Aldosteron heeft in laboratorium- 
en dierexperimentele onderzoeken laten zien bindweefselvorming in bloedvaten en het 
hart te stimuleren en uit experimentele studies bleek dat dit effect werd bewerkstelligd 
via galectine-3 (Gal-3)-productie en -uitscheiding. (16-19) Naast bindweefselvorming is 
Gal-3 belangrijk in veel andere biologische processen in ons lichaam, zoals celgroei en 
celdood. 
Onze hypothese in hoofdstuk 2.3 luidde dat overproductie van aldosteron Gal-3-
uitscheiding stimuleert in verschillende celtypes van ons hart- en vaatstelsel en het 
immuunsysteem, leidend tot bindweefselvorming en slagaderverkalking in de vaatwand 
en het hart bij mensen. Bij 78 patiënten met PA, 56 patiënten met EHT en 39 patiënten 
die na bijnierverwijdering van PA genezen waren, hebben we Gal-3 concentraties in 
een bloedmonster gemeten. In deze goed gekarakteriseerde patiënten zagen wij geen 
verschillen in Gal-3 waarden tussen de 3 groepen. Ook na correctie voor mogelijke 
beïnvloedende variabelen bleken de Gal-3 concentraties niet hoger in patiënten met PA 
dan in de patiënten met EHT of  de van PA genezen patiënten. Hieruit concludeerden 
we dat het onaannemelijk is dat Gal-3 in het bloed bijdraagt aan het verhoogd risico op 
hart- en vaatziekten bij patiënten met PA ten opzichte van patiënten met EHT. 
Tenslotte hebben we onze aandacht in hoofdstuk 3 op de beschermende effecten van 
MR antagonisten op het hart- en bloedvaten gericht. In hoofdstuk 3.1 hebben wij een 
overzicht van de literatuur over de beschermende effecten van MR antagonisten op 
IR schade en remodellering van het hart na een hartinfarct gegeven. Laboratorium- 
en dierexperimentele studies hebben een gunstig effect van MR antagonisten op IR 
schade aangetoond wanneer zij werden toegediend net voor de fase van ischemie, 
of  net voordat gestart werd met reperfusie. (8) Deze beschermende effecten van MR 
antagonisten lijken derhalve te worden veroorzaakt door non-genomische (snelle) 
signaalroutes in de cel. Zoals hierboven reeds beschreven, is een van de voorgestelde 
onderliggende mechanismen van deze beschermende effecten op het hart door MR 
antagonisten stimulering van de adenosinereceptor. (14) 
In hoofdstuk 3.2 onderzochten we dit veronderstelde effect van MR antagonisten bij de 
mens. We onderzochten of  behandeling met de MR antagonist eplerenon bij gezonde 
vrijwilligers zorgt voor een toename in de adenosineconcentratie in het bloed. Om de 
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moeilijkheden van metingen van adenosineconcentraties in bloed te omzeilen, gebruikten 
we een indirecte manier om de hoeveelheid adenosine te evalueren. We gebruikten 
een van de effecten van adenosine als uitleesmaat voor de hoeveelheid gevormde 
adenosine in het bloed, namelijk de mate van vaatverwijding in de arm als respons op 
toediening van het medicijn dipyridamol in de onderarmsslagader. Om dit model van 
adenosinevorming te kunnen begrijpen, is het belangrijk om het adenosinemetabolisme 
van de mens te kennen: adenosine wordt gevormd uit de afbraak van adenosine 
monofosfaat door het enzym ecto-5’-nucleotidase, ook wel CD73 genaamd. Verdere 
afbraak van adenosine gebeurt in de cel. Als gevolg daarvan zal adenosine over het 
celmembraan via een transporter (de equilibratieve nucleoside transporter (ENT)) 
de cel in gaan. Stimulatie van adenosinereceptoren op het celmembraan induceert 
verschillende effecten, zoals vaatverwijding, remming van ontsteking en bescherming 
tegen IR schade. (15, 20) Dipyridamol verhoogt de adenosinedeconcentratie buiten de 
cel door de ENT te remmen (zodat adenosine niet de cel in kan gaan) en zorgt dus 
voor lokale vaatverwijding. (20) Derhalve weerspiegelt het vaatverwijdende effect van 
dipyridamol de adenosinevorming door het enzym CD73. (21) 
Uit onze in hoofdstuk 3.2 beschreven studie concludeerden we dat de MR antagonist 
eplerenon, in een dosering van tweemaal per dag 50 mg gedurende een week, geen 
invloed heeft op de adenosinevorming in gezonde mannelijke vrijwilligers. Het is 
daarom onwaarschijnlijk dat een verhoogde adenosinevorming bij mensen bijdraagt aan 
de beschermende effecten van MR antagonisten op het hart.
Echter, gezonde vrijwilligers verschillen substantieel van oudere patiënten met één of  
meerdere ziekten. Daarom onderzochten we onze hypothese opnieuw, maar dan in 
een experiment met menselijk hartweefsel, van patiënten die een open hartoperatie 
ondergingen. Van deze patiënten gebruikten we het rechter hartoor, dat verwijderd 
werd door de hartchirurg voor aansluiting van de hart-longmachine. Uit het hartoor 
van elke patiënt werden 2 afzonderlijke hartspiertjes vrijgemaakt en gefixeerd in een 
orgaanbad. We induceerden contractiliteit (samentrekking) van deze hartspiertjes door 
elektrische stimulatie en gebruikten het herstel van de contractiliteit na een periode van 
ischemie en reperfusie als betrouwbaar eindpunt voor IR schade. (22-24) Van elke patiënt 
werd één hartspiertje blootgesteld aan eplerenon en de andere aan het oplosmiddel. 
Zoals beschreven in hoofdstuk 3.3 zorgde eplerenon niet voor een vermindering van IR 
schade in menselijk hartspierweefsel. Onze resultaten conflicteren met de bevindingen 
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samengevat in hoofdstuk 3.1, waarin MR antagonisten IR schade beperken wanneer ze 
worden toegediend op het moment voor IR.
DISCUSSIE, KLINISCHE IMPLICATIES EN 
TOEKOMSTPERSPECTIEVEN
Ondanks het verhoogd risico op hart- en vaatziekten bij patiënten met PA, waardoor 
vroegtijdig diagnosticeren en behandeling noodzakelijk is, weten we dat er een vertraging 
van gemiddeld 8 jaar bestaat in het diagnosticeren van PA. (25) Waarschijnlijk komt dit 
door de afwezigheid van de typische hypokaliëmie in 37-56 % van de patiënten met 
PA (25), alsmede het gebrek aan aandacht voor PA onder artsen of  de aanname dat PA 
zeldzaam is en derhalve niet standaard onderzocht hoeft te worden. Integendeel, PA blijkt 
de meest voorkomende secundaire vorm van hypertensie. (26) In de huisartsenpraktijk 
komt PA bij 3-12 % van de patiënten met hypertensie voor, vergeleken met 1-30 % in 
ziekenhuizen. (27, 28) 
Door het systematisch screenen op PA in de huisartsenpraktijk in combinatie met 
uitgebreide evaluaties van markers van hart- en vaatschade en door ontrafeling van 
nieuwe onderliggende mechanismen die bijdragen aan het verhoogd risico op hart- en 
vaatziekten bij patiënten met PA, draagt dit proefschrift bij aan de verbetering van de 
diagnostische en therapeutische behandeling van deze patiënten in de toekomst. 
In hoofdstuk 2.1 lieten we zien dat patiënten met PA al linkerventrikelhypertrofie 
hebben in de vroege fase van hun ziekte, namelijk op het moment van vaststellen van 
hypertensie door de huisarts. Onze bevinding, hoewel deze met voorzichtigheid moet 
worden geïnterpreteerd vanwege de kleine aantallen, zou artsen moeten aanmoedigen 
om te zoeken naar PA om (verdere) hart- en vaatschade te beperken. (13) Als we 
echter kijken naar de adviezen in de huidige internationale richtlijn (13), zou in geen 
van de patiënten in onze studie een aldosteron en renine bepaald zijn, omdat deze 
patiënten geen aanwijzingen voor PA hadden, zoals therapieresistente hypertensie of  
hypokaliëmie. 
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Daarom zou men kunnen voorstellen om alle patiënten met een nieuw gediagnosticeerde 
hypertensie te screenen op PA. Het is beschreven dat screening op PA bij patiënten met 
hypertensie leidt tot een tienvoudige toename in het detecteren van PA en tevens een 
tienvoudige toename in het aantal bijnierverwijderingen. (29) Het screenen op PA in de 
huisartsenpraktijk is echter uitdagend gebleken: in een voorgaande studie waarin de 
prevalentie (het vóórkomen) van PA bij patiënten met een nieuw gediagnosticeerde 
hypertensie werd onderzocht, bleek de screening in minder dan 10 % van de 3748 
patiënten te zijn uitgevoerd. (30) Belangrijker nog: PA bleek nauwelijks voor te komen 
in de huisartsenpraktijk, namelijk maar bij 2.6 % (BI 1.4-4.9 %) van de patiënten 
met hypertensie, hetgeen gezondheidswinst en kosteneffectiviteit van een dergelijke 
screening op PA in twijfel trekt. 
We includeerden 6 patiënten met PA, die in de voorgaande studie werden 
gediagnosticeerd. (30) Door de veel lager dan verwachte prevalentie van PA had onze 
studie in hoofdstuk 2.1 niet genoeg kracht om verschillen in 5 van de 6 markers voor 
hart- en vaatschade tussen de patiënten met PA en patiënten met EHT aan te tonen. Een 
andere belangrijke beperking van onze studie was het gebruik van bloeddrukverlagende 
medicijnen tijdens de vaatmetingen, waardoor onze resultaten vertroebeld kunnen zijn. 
Een mogelijke verklaring voor het lage screeningspercentage alsmede de lage prevalentie 
van PA is de mogelijkheid dat PA een langzaam voortschrijdende ziekte is, met milde 
symptomen en milde bloedafwijkingen in de beginfase van de ziekte en het ontwikkelen 
van meer typische en ernstigere karakteristieken wanneer PA zich verder ontwikkelt. 
Mild verhoogde bloeddrukken en de afwezigheid van hypokaliëmie zou huisartsen 
ervan weerhouden kunnen hebben om aldosteron -en renineconcentraties te meten 
bij de patiënten met een nieuw gediagnosticeerde hypertensie. (30) Ook zou het zo 
kunnen zijn dat de waarde van de screeningstest voor PA beperkter is bij patiënten 
met een nieuw gediagnosticeerde hypertensie. Inderdaad is gebleken dat bij een groep 
patiënten met hypertensie in de huisartsenpraktijk 43 % van de patiënten met PA een 
lage aldosteronwaarde in het bloed had. (31) Ondanks het verlagen van de ondergrens 
van de afkapwaarde van aldosteron van 0.42 nmol/l naar 0.40 nmol/l, is het zeer goed 
mogelijk dat we bij patiënten met hypertensie de diagnose PA ten onrechte hebben 
uitgesloten. (30) 
Naast beperkingen van de screeningstest voor PA, is geen enkele bevestigingstest 
bestempeld als de gouden standaard. (13) In de studies in dit proefschrift hebben 
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we de zoutbelastingstest als bevestigingstest voor PA gebruikt. Het toedienen van 
het volume van 2 L kan uitdagend zijn, met name bij patiënten met hartfalen of  
therapieresistente hypertensie. Daarnaast heeft de zoutbelastingstest een beperkte 
sensitiviteit en specificiteit. Deze 2 termen beschrijven de waarde van een medische test. 
Sensitiviteit beschrijft het percentage terecht positieve uitslagen onder zieke patiënten 
en specificiteit beschrijft het percentage terecht negatieve uitslagen onder niet-zieke 
patiënten. Vergeleken met een fludrocortison suppressietest, hetgeen wordt beschouwd 
als een betrouwbare bevestigingstest voor PA, zijn de sensitiviteit en specificiteit van 
de zoutbelastingstest respectievelijk 85-90 % en 92-84 %. (32, 33) Uiteraard dienen deze 
getallen met voorzichtigheid te worden geïnterpreteerd, omdat de fludrocortison 
suppressietest zelf  ook geen gouden standaard is. Als we de zoutbelastingstest 
vergelijken met bijnieradersampling bij patiënten met een eenzijdige overproductie van 
aldosteron (dus in één van de beide bijnieren), dan zijn de sensitiviteit en specificiteit 
respectievelijk 83 en 75 %. (34) In een recente studie bleek 29 % van de patiënten met 
PA eenzijdige overproductie bij bijnieradersampling te hebben ondanks een aldosteron 
van <0.139 nmol/l na de zoutbelastingstest, hetgeen ook de afkapwaarde is om PA uit 
te sluiten in ons ziekenhuis. (35) Interessant genoeg bleek deze 29 % een kaliumwaarde 
in het bloed tussen 2.7 en 3.5 mmol/l te hebben (normaalwaarde: 3.5-5.0 mmol/L). 
Daarom suggereren de auteurs van de studie om bevestigingstesten over te slaan bij 
patiënten met een positieve screeningstest voor PA én hypokaliëmie. (35) Deze suggestie 
is overgenomen in de nieuwe versie van de internationale richtlijn over de diagnose en 
behandeling van PA (13), maar nog niet in ons lokale protocol. Nadelen van het overslaan 
van de bevestigingstest en dus meteen naar bijnieradersampling door te pakken zouden 
de kosten en patiëntveiligheid kunnen zijn. 
Het is duidelijk dat diagnostiek van PA nog altijd uitdagend is. Daarom zou het heel 
waardevol zijn om nieuwe biomarkers voor de diagnose van PA te vinden. Het eiwit 
prostasine in de urine, dat betrokken is in het openen van natriumzoutkanalen in onze 
cellen, is een aantrekkelijke kandidaat. (36, 37) In ons ziekenhuis worden momenteel 
specifieke profielen van markers voor patiënten met PA onderzocht. Uiteraard is hierin 
nog veel onderzoek nodig. 
Met de huidige diagnostische strategie en behandeling hebben patiënten met PA 
een verhoogd risico op hart- en vaatziekten vergeleken met patiënten met EHT en 
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vergelijkbare bloeddrukken. (9) In dit proefschrift hebben wij voor het eerst aangetoond 
dat patiënten met PA lagere adenosineconcentraties in hun bloed hebben dan patiënten 
met EHT en vergelijkbare bloeddrukken. Deze bevinding zou, in ieder geval gedeeltelijk, 
een verklaring kunnen zijn voor dit verhoogd risico bij patiënten met PA. 
Het is inderdaad zo dat het lichaamseigen adenosine krachtige beschermende effecten 
op het hart- en vaatstelsel heeft, zoals vaatverwijding en het beperken van IR schade, 
slagaderverkalking, ontsteking en bindweefselvorming. (15) De mogelijke gunstige 
invloed van adenosine op hart- en vaatziekten wordt geïllustreerd door onderzoeken 
die rapporteren dat genetische varianten in het adenosinemetabolisme die leiden 
tot een verhoogde adenosinevorming, geassocieerd zijn met een langere overleving 
bij patiënten met kransslagaderziekten. (38) Daarnaast beschermt het toedienen van 
adenosine bij patiënten met een acuut hartinfarct tegen IR schade (39, 40), hoewel dit 
niet consequent in de literatuur wordt beschreven. Toediening van adenosine zou 
mogelijk ook beschermen tegen het ontwikkelen van hartfalen. (41) Hoewel oplopende 
adenosineconcentraties IR schade kunnen beperken, beschrijven de meeste studies dat 
het voorkomen van adenosinesignallering IR schade niet verder vergroot. (23, 42)
Uit deze observaties kunnen we herleiden dat een afname in adenosinewaarden in het 
bloed een negatieve invloed op ons hart- en vaatstelsel heeft, zoals ook eerder door 
onze onderzoeksgroep werd voorgesteld bij patiënten met de stofwisselingsziekte 
hyperhomocysteïnemie, bij wie het risico op hart- en vaatziekten is vergroot. Bij deze 
patiënten bleek het vaatverwijdende effect van adenosine beperkt door een verhoogde 
opname van adenosine in de cel, waarbij stimulatie van de adenosinereceptor voorkomen 
werd. (43)
Uit onze resultaten zouden we kunnen opmaken dat beïnvloeding van het 
adenosinemetabolisme het verhoogd risico op hart- en vaatziekten bij patiënten met 
PA kan verlagen. In hoofdstuk 3.2 hebben we laten zien dat MR antagonisten de 
adenosinevorming buiten de cel niet verhogen bij gezonde vrijwilligers. (44) Het is daarom 
interessant om medicamenten te testen waarvan we weten dat ze adenosineconcentraties 
in het bloed wél verhogen. Van statines (cholesterolverlagers) is bekend zij dat het enzym 
CD73, dat adenosinemonofosfaat omzet in adenosine, stimuleren. (21) Een statine is dan 
ook een aantrekkelijke kandidaat om het risico op hart- en vaatziekten bij patiënten met 
PA te verlagen. Ook dipyridamol, dat een ENT-blokker is en leidt tot een toename van 
adenosineconcentraties buiten de cel (45), zou dit effect kunnen hebben. 
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Het zou absoluut interessant zijn om in toekomstig onderzoek bij patiënten met PA 
adenosineconcentraties in het bloed te meten voor en na bijnierverwijdering. Ook 
zou in toekomstig onderzoek de nadruk gelegd moeten worden op het ontrafelen van 
de oorzaak van de lagere adenosineconcentraties bij patiënten met PA, zodat nieuwe 
therapeutische opties beschikbaar kunnen komen. De adenosineconcentratie in het 
bloed is de som van adenosineproductie, opname van adenosine in de cel en afbraak 
van adenosine in de cel. In onze studie was geen verschil in activiteit van het enzym 
CD73 tussen patiënten met PA en patiënten met EHT, dus een verhoogde opname 
in de cel of  verhoogde afbraak van adenosine in de cel is de meest waarschijnlijke 
verklaring voor de verlaagde adenosineconcentraties bij patiënten met PA, net zoals bij 
patiënten met hyperhomocysteïnemie. (43) 
Zoals hierboven vermeld, heeft adenosine verschillende effecten die mogelijk 
bescherming bieden voor het ontwikkelen van hart- en vaatziekten, zoals beperken van 
slagaderverkalking, remming van bloedplaatjesklontering, remming van ontsteking en 
bindweefselvorming, vaatverwijding en beperking van IR schade. (15, 20) In ons onderzoek 
hebben we de gevoeligheid voor onderarms-IR onderzocht. Het feit dat deze niet 
verschilde tussen patiënten met PA en patiënten EHT, terwijl de adenosineconcentratie 
in het bloed wel significant lager was bij patiënten met PA, kan verklaard worden door 
verschillende zaken. Ten eerste is het gunstige effect van adenosine op IR schade 
controversieel, in ieder geval bij mensen. Terwijl toediening van adenosine vóór 
reperfusie (herstel van bloedtoevoer) de hartinfarctgrootte verminderde bij patiënten 
met een hartinfarct (39, 40), hebben verschillende dierexperimenten (46-48) en klinische 
onderzoeken (49, 50) geen effect van toediening van adenosine op IR schade kunnen 
constateren. En ook al zou stimulatie van de adenosinereceptor IR schade kunnen 
beperken, dan betekent dit nog niet meteen dat een afname in stimulatie van 
de adenosinereceptor IR schade vergroot, vooral vanwege het gegeven dat veel 
andere lichaamseigen stoffen de gevoeligheid voor IR reguleren. Als voorbeeld 
hebben adenosinereceptorantagonisten in diermodellen van IR schade laten zien de 
hartinfarctgrootte niet te vergroten (14), hoewel deze antagonisten wel de gunstige 
effecten van pre- en post-conditionering voorkomen. (23, 42) Pre- en postconditionering 
is het herhaaldelijk toebrengen van korte periodes van zuurstoftekort, respectievelijk 
voor of  na IR, om IR schade te voorkomen. 
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Toekomstige onderzoeken bij patiënten met PA zouden zich daarom niet moeten 
richten op IR schade, maar op alternatieve determinanten van hart- en vaatschade. 
Om verschillende redenen is slagaderverkalking een aantrekkelijk onderwerp 
om te bestuderen. Ten eerste hebben patiënten met PA een hoger risico op 
complicaties van slagaderverkalking dan patiënten met EHT, zoals een hartinfarct en 
beroerte. (9) Ten tweede is in diermodellen aangetoond dat aldosteron slagaderverkalking 
verergert en dat verkalkingen ontstaan via stimulatie van de MR. (51, 52) Ten derde heeft 
adenosine de eigenschap om slagaderverkalking tegen te gaan (20) en inactivatie van 
het adenosinemetabolisme leidt tot progressie van slagaderverkalking (53). Daarom 
suggereren we dat de verlaagde circulerende adenosinewaarden bij patiënten met PA 
zouden kunnen bijdragen aan de progressie van slagaderverkalking. 
Een andere aantrekkelijke verklaring voor het verhoogd risico op hart- en vaatziekten 
bij patiënten met PA leek overproductie van galectine-3 (Gal-3). Aldosteron 
verhoogt Gal-3 eiwitconcentraties en expressie in laboratoriumonderzoek en 
diermodellen (16-19) en bij patiënten met hartfalen is Gal-3 geassocieerd met slechte 
uitkomsten. (54, 55) Ook in deze patiënten zijn aldosteronconcentraties verhoogd en 
behandeling met MR antagonisten heeft een gunstig effect op de overleving en het 
aantal ziekenhuisopnames. (10-12) Inderdaad is in Aziatisch onderzoek gevonden dat 
Gal-3 concentraties verhoogd zijn in het bloed van patiënten met PA ten opzichte van 
patiënten met EHT. De verhoogde Gal-3 waarden bij deze patiënten met PA herstelden 
weer naar normaal na bijnierverwijdering. (19, 56) In onze studie beschreven in hoofdstuk 
2.3 echter, zagen wij geen verschillen in Gal-3 concentraties tussen patiënten met PA, 
genezen patiënten met PA (na bijnierverwijdering) en patiënten met EHT. (57)
Ondanks beperkingen van het achteraf  samenstellen van de groep patiënten, heeft onze 
studie sterke punten. Vergeleken met de kleine Aziatische studies (19, 56), selecteerden wij 
een groot cohort (groep van) patiënten. De patiënten in ons cohort gebruiken geen 
medicatie die invloed kon hebben op aldosteron- en reninewaarden en we corrigeerden 
onze resultaten met zorg voor mogelijke beïnvloedende factoren. De waarden van 
Gal-3 in bloed waren tien maal zo laag als in het Aziatische cohort, hetgeen verklaard 
kan worden door een verschil in analysemethode of  de etnische achtergrond van de 
patiënten. (57)
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In een analyse van een deel van onze studie beschreven in hoofdstuk 2.3 vergeleken 
we Gal-3 waarden binnen de groep van patiënten met PA mét en zónder 
linkerventrikelhypertrofie. Onze observatie dat een verschil in hartschade niet werd 
weerspiegeld door een verschil in Gal-3 concentraties, sluit een rol van plasma Gal-3 in 
de door aldosteron veroorzaakte orgaanschade uit bij mensen. (57)
In tegenstelling tot de direct beschermende effecten van MR antagonisten op IR schade 
en remodellering van het hart in dierexperimenteel onderzoek, zoals beschreven in 
ons overzicht in hoofdstuk 3.1 (8), konden we deze bevindingen niet vertalen naar de 
menselijke situatie. (44, 58) De MR antagonist eplerenon beschermde niet tegen IR schade 
in menselijk hartweefsel (58) en ook konden we geen sleutelrol van signalering van de 
adenosinereceptor in het beschermende effect van eplerenon aantonen. (44)
Het is bekend dat veel veelbelovende bevindingen van dierexperimenteel onderzoek 
niet kunnen worden vertaald naar onderzoek bij mensen. (59, 60) Dit zogenaamd ‘falen 
van vertaling’ kan in zijn algemeenheid worden verklaard door methodologische 
tekortkomingen bij dierstudies, zoals het ontbreken van een goede berekening van 
de steekproefgrootte, het ontbreken van randomisatie, het niet blinderen van het 
onderzoek en inadequate statistische analyses. (59, 60) Ook verschillen dieren fysiologisch 
en pathofysiologisch gezien substantieel van mensen. Alarmerend genoeg zijn slechts 
2 van de 500 beschermende strategieën bij IR schade van het brein bij dieren ook 
effectief  gebleken bij mensen. (59)
Een ander belangrijk verschil tussen laboratorium- en dierstudies en onderzoek 
bij mensen is het verschil in eindpunten. In hoofdstuk 2.2 hebben we de mate van 
vaatverwijding van de armslagader gemeten vóór en na ischemie van de bovenarm, als 
model voor IR schade. In hoofdstuk 3.3 gebruikten we het herstel van de contractiliteit 
(het samentrekken) van hartspierweefsel als maat voor IR schade. (58) Deze modellen 
verschillen substantieel van de dierexperimentele studies, waarin infarctgrootte werd 
gebruikt als uitkomstmaat. Het beschermende effect van bijvoorbeeld pre-conditionering 
is echter ook bevestigd in het model van vaatverwijding van de armslagader en het 
model met hartspiertjes. (22, 23, 61) 
Het effect van MR antagonisten op IR schade en remodellering van het hart bij 
patiënten met een acuut hartinfarct wordt momenteel onderzocht in de MINIMISE 
STEMI trial. (62) Uit onze studie in hoofdstuk 3.3 concludeerden we dat toediening van 
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eplerenon net voor een ischemische prikkel niet beschermt tegen IR schade in menselijk 
hartweefsel. Men zou kunnen beargumenteren dat de aanwezigheid van lichaamseigen 
aldosteron nodig is voor het beschermende effect van MR antagonisten. Echter bieden 
MR antagonisten ook bescherming bij ratten bij wie de bijnieren zijn verwijderd (63) 
en in hartmodellen waarin geen aldosteron aanwezig is (8), hetgeen betekent dat het 
beschermende effect van MR antagonisten onafhankelijk van de aanwezigheid van 
aldosteron is.
De berekende eplerenonconcentratie in ons hartweefselexperiment was 6 keer hoger 
dan de berekende eplerenonconcentratie in het bloed van gezonde vrijwilligers (na één 
week behandeling met eplerenon tweemaal daags 50 mg). (44) In de MINIMISE STEMI 
trial ontvangen patiënten de MR antagonist canrenoaat in een dosering van 200 mg via 
het infuus, gevolgd door de MR antagonist spironolacton in een dosering van eenmaal 
daags 50 mg gedurende 3 maanden. (62) De dosering canrenoaat is vergelijkbaar met de 
dosering die werd gebruikt in de ALBATROSS trial en de dosering spironolacton is iets 
hoger. In de ALBATROSS trial werd echter geen gunstig effect van MR antagonisten 
bij patiënten met een acuut hartinfarct op hart- en vaatschade gezien. (64) Vanwege deze 
bevindingen en onze eigen observaties (58) wachten wij met grote interesse en scepticisme 
op de resultaten van de MINIMISE STEMI trial. 
Samenvattend hebben wij aangetoond dat het actief  opsporen van PA het ontwikkelen 
van hart- en vaatschade niet voorkomt, omdat er al linkerventrikelhypertrofie aanwezig 
is op het moment dat deze patiënten zich voor het eerst met hypertensie bij de huisarts 
presenteren. Dit betekent echter niet dat studies die zich richten op de verbetering van 
het diagnostische proces van PA niet belangrijk zijn. Er is namelijk een gemiddelde 
vertraging in het diagnosticeren van PA van 8 jaar (25), hetgeen leidt tot (progressie van) 
hart- en vaatschade bij deze patiënten. 
Wij hebben daarom gepoogd onderliggende mechanismen van de schadelijke effecten 
van aldosteron op ons hart- en vaatstelsel te ontrafelen, met als uiteindelijk doel 
om nieuwe behandelingsstrategieën voor patiënten met PA te ontwikkelen. Onze 
spannende bevinding van de verlaagde adenosinewaarden bij patiënten met PA ten 
opzichte van patiënten met EHT zou dit doel wel eens kunnen dienen. Toekomstig 
onderzoek is nodig om onze bevinding te bevestigen en om de onderliggende route 
van deze verlaagde adenosineconcentratie op te helderen. Beïnvloeding van het 
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adenosinemetabolisme met medicatie zou de overleving en ziektelast van patiënten met 
PA en tweezijdige aldosteronoverproductie kunnen verbeteren, omdat deze patiënten 
niet kunnen worden behandeld door een bijnierverwijdering. Deze patiënten zijn dus 
continu blootgesteld aan hoge aldosteronconcentraties met schadelijke effecten op 
ons hart- en vaatstelsel, die mogelijk niet geheel voorkomen kunnen worden door 
behandeling met MR antagonisten. MR antagonisten hebben in laboratorium –en 
dierexperimentele studies aangetoond te beschermen tegen IR schade en remodellering 
van het hart na een hartinfarct, maar wij zagen geen effect van eplerenon op IR schade 
in menselijk hartweefsel. We zijn daarom terughoudend in het bestuderen van de 
effecten van MR antagonisten op IR schade bij mensen. Daarnaast verhoogden MR 
antagonisten de adenosinevorming niet bij gezonde vrijwilligers. Meer onderzoek is 
nodig om de mechanismen van het beschermende effect van MR antagonisten op ons 
hart- en vaatstelsel te ontrafelen. 
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